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1 INTRODUCTION 
1.1 Background to the Study 
Research and development (R&D) is the process of creation of new knowledge and 
know-how via a controlled process as opposed to relying on chance (Brockhoff 2003). 
The purpose of the controlled process is to increase processes’ efficiency and ability to 
innovate (Brockhoff 2003). Firms' survival and success, which are dependent on its 
ability to innovate, to create knowledge and to capitalize on inventions and know-how, 
is in essence directly linked to its R&D process (Dunk and Kilgore 2001). Firms' inter-
nal R&D capabilities are in many industries often viewed as critical determinants in its 
ability to get ahead in competition (Pisano 1990). Especially in technology driven in-
dustries there are significant positive returns to R&D investments through introduction 
of new or improved products and services (McEvily and Chakravarthy 1999). Techno-
logical lead and its transformation to innovative products as fruits of corporate R&D 
can be seen as a monopolistic advantage that helps enterprises to compete in today’s 
market (Lall 1980). Similarly Schumpeter (1942) noted how previous R&D investments 
on innovations are harvested through temporary monopolistic profits (Gassmann, Enkel, 
and Chesbrough 2010; Freeman 2003). This type of competitive advantage can be de-
rived from corporation's ability to link or integrate its subsidiary activities across geo-
graphic locations (Porter 1986, 1820). As the R&D function is central to the economic 
success of a company (Ghoshal and Bartlett 1988), its study and coordination needs to 
be on the top agenda for management and researchers alike (Cheng and Bolon 1993).  
 Historically research and development has been one of the core functions that 
needed to be kept in the home base or home country (Creamer 1976; De Meyer and Mi-
zushima 1989; Terpstra 1977). The shift to globally dispersed foreign-based R&D by 
multinational corporations has been one of the most significant changes in their opera-
tions and represents complete change to traditional thinking on the need to centralize 
core corporate functions to national headquarters. Already in the 1930s portion of R&D 
was conducted overseas by the largest European and US multinational corporations 
(Cantwell 1995). After this, globalization of R&D has progressed in three phases, with 
early expansion in the 1960s and 1970s. This was followed by a second expansion in 
the 1980s and 1990s with a more emphasis on strengthening overseas R&D. In the peri-
od from 1985 to well into the 1990s the proportion of foreign R&D to total R&D ex-
penditure increased steadily with some industry groups, such as chemical industry, 
pharmaceutical industry and machinery companies, allocating large percentages of their 
R&D budgets to foreign-based R&D (Cheng and Bolon 1993). This is a trend that has 
only intensified in the 21st century and shows no signs of subsiding with the third phase 
of global expansion ongoing according to study by Lewin and Peeters (2006). 
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 As globalization of R&D is intervened with the changes in global economy of 
the 21st century, emphasis has to be put to understand the globalization of R&D and 
identify its key determinants. Such research on the factors influencing globalization of 
R&D have to do with company's motivations and reasons behind decision to establish 
R&D subsidiaries across borders and related to the growth of R&D globalization. Alt-
hough some studies have reported individual or sets of influencing factors as explaining 
increased investment on R&D globalization, they have not been conclusive and the re-
search has thus far been fragmented. Studies (Kay 1979; Miller 1977; Vernon 1977, 41-
45; Dunning 1999, 61-79; Lall 1980, 102-122; Hirsch (1976), 25,70; Creamer 1976, 
35,5) have emphasized factors derived from rational-economic theory and relying on 
profit-maximization hypothesis, which have been argued not to be suitable in explaining 
R&D activity notwithstanding the relevance of rational-economic theory on global dis-
persion of manufacturing activity (Lall 1979). While some studies argue that access to 
vast skilled labor pools and centers of excellence to be the driving factors (Bardhan 
2006) other studies indicate the R&D cost differentials between countries to be the ma-
jor expected benefit (Norwood et al. 2006).  
 Contrary to the findings presented in above mentioned articles is another per-
spective offered by Ronstadt (1977). Ronstadt (1977) argued that globalization of R&D 
activities follows an evolutionary path from supportive role of sales and manufacturing 
to technology development which, later researchers have argued to be part of the inter-
nationalization process (Boutellier, Gassmann and Zedtwitz 1999a). This view has been 
shared also through a historical examination of pharmaceutical industry's development, 
which points how from the early offshoring of manufacturing decades ago the phenom-
enon has travelled up the value chain from manufacturing, through back office opera-
tions and services, to include research and development, now representing the whole 
gamut of value creation (Bardhan 2006). Buckley and Casson (1976, 53-54) argue that 
instead of evolutionary process the phenomenon is due to decreasing communications 
costs and development of educational capacities overseas, which relocates R&D work to 
places where costs of non-tradable production factors are cheapest. Similarly to how the 
key determinant behind globalization of R&D has eluded researchers, has the factors 
emerging from industry level studies been inconsistent with firm level studies (Hewitt 
1980; Hewitt 1983; Pearce 1989), complicating reporting of reliable results.  
Some studies have grouped factors influencing R&D globalization to frameworks 
such as Boddewyn's (1985) framework of conditions, motivations, or precipitating cir-
cumstances or Kuemmerle (1999) with his division of influencing factors as home-base-
augmenting (HBA) and home-base-exploiting (HBE). In their classification of compa-
ny's involvement in foreign R&D, von Zedtwitz and Gassmann (2002) presented factors 
as those related to access to markets and customers or those related to access to local 
science and technology while at the same time they notified the inherent difference of 
research in comparison to development and its effect on the R&D globalization process. 
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This type of classification based on multiple factors has been able to explain the phe-
nomenon a bit more and structure it as a question covering multiple variations of the 
same phenomenon. 
 The above mentioned classifications and the wider literature on globalization of 
R&D indicates that there exist multiple reasons for globalization of R&D and firms seek 
to capitalize on those factors that further their competitive position or organizational 
goals (Kuemmerle 1999a). Thus some R&D can be moved to offshore location follow-
ing an evolutionary process, some activities are shifted overseas to capitalize on coun-
tries' R&D cost differentials while other functions are located across borders to benefit 
from other influencing factors. As companies have different reasons and pursue differ-
ent benefits from the globalization of R&D (Kuemmerle 1999a), they also use different 
methods to capitalize on these influencing factors. One indication of this is that compa-
nies can be divided to types based on what they seek from the globalization of R&D and 
through what means (Gerybadze and Reger 1999; Ronstadt 1978).  
 This study proposes that the different ways to capitalize on the distinct benefits 
for globalization of R&D can thus also be seen in the light of its subconcepts as govern-
ance forms for dispersing R&D overseas as indicated by Boehe (2008). These govern-
ance forms for R&D globalization are: offshoring of R&D, offshore outsourcing of 
R&D and internationalization of R&D. The term off-shoring refers to the strategy of 
transferring activities across national borders using internal resources (Hätönen and 
Eriksson 2008). The practice of a firm entrusting to an external entity based in other 
countries the performance of an activity is commonly referred to as offshore outsourc-
ing (Varadarajan 2008). Internationalization has been viewed as a process of increasing 
involvement in international markets, through building on existing activities and the 
growing tendency of operations to span across national boundaries (Welch and Lu-
ostarinen 1988; Westhead et al. 2007; cf. Ronstadt 1978). The three above listed con-
cepts are innately separate, follow different motivations and require variant responses to 
the management of R&D. Further influencing the R&D globalization process is the sep-
aration to whether it is development activities or research activities that are to be global-
ized (von Zedtwitz and Gassmann 2002). Similarly as development varies from re-
search, the different development tasks can vary from one another and different research 
tasks such as basic research may differ from i.e. from applied research to the same de-
gree (Iansiti 1993; Lall 1979). Thus the actual R&D function to be globalized should be 
also taken into consideration. This is especially true for R&D in industries such as 
pharmaceutical industry, whose R&D process covers many fields of science, moves up 
the value chain and has very different requirements for its distinct parts (Cooke 2005). 
To corroborate or refute factors and their relations on the governance forms of global-
ized R&D an empirical study was conducted from the perspective of pharmaceutical 
industry managers in the case of People's Republic of China.  
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1.2 Research Gap 
In the early research scrutinizing globalization of R&D, three assumptions dominated 
the research (Cheng and Bolon 1993). One was the notion of R&D as a home-country-
based function, which safeguarding was paramount (Buckley and Casson 1985). Anoth-
er one was the dependency of firms' global competitiveness on its ability to innovate 
(Franko 1989). The third one, focused on technical and scientific development taking 
place in hosting countries and their competitiveness globally facilited by technology 
transfer on a international level (Quinn 1969; Robinson 1988). In this early research 
international business researchers have paid insufficient consideration on the manage-
ment of R&D in multinational firms as well as on the underlying reasons and mecha-
nisms for the process of R&D globalization (Cheng and Bolon 1993). the research find-
ings of past research on R&D globalization's management was allocated by Cheng and 
Bolon (1993) into five strains of research. These are research on: site selection for R&D 
unit, local autonomy granted to subsidiaries in the light of centraliza-
tion/decentralization of management, international coordination of multinational R&D, 
organizational structure for globalized R&D, as well as the human resource manage-
ment of geographically dispersed R&D units (Cheng and Bolon 1993).  
 The location of overseas R&D subsidiaries were found to be in countries where 
the parent company already had considerable presence whether in marketing or manu-
facturing, or even both, according to studies with a focus on site selection (Ronstadt 
1977; Behrman and Fischer 1980; De Meyer and Mizushima 1989) Concentration of 
advanced technology resources has also been argued to be an important site selection 
characteristic (Cheng and Bolon 1993). Government regulations in the target country 
were also reported to be reasons for location selection (Behrman and Fischer 1980; De 
Meyer and Mizushima 1989). This stream of research has also focused on the im-
portance of company's country of origin in site selection and tendency to globalize parts 
of its R&D process, with comparisons of European and US companies involvement in 
overseas R&D (De Meyer and Mizushima 1989) similarly as on the globalization of 
R&D by Japanese firms (Behrman and Fischer 1980; De Meyer and Mizushima 1989). 
Nevertheless in his study Ronstadt (1977) reported that different criteria on site selec-
tion were not behind overseas R&D investment decisions.  
Management of globalized R&D has also been studied from the point of centraliza-
tion/decentralization, which was used by Behrman and Fischer (1979) as division crite-
ria in separating companies into four groups. Other studies found this to be related to 
company's general approach on centralization, where time considerations on the com-
pletion of the project were shown to play a part alongside R&D unit's size (De Meyer 
and Mizushima 1989). These studies have also put forward a number of internal com-
pany related and external factors that affect this process although focusing on the man-
agement of dispersed R&D and not strictly on the factors influencing the decisions 
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whether and why to pursue a globalized R&D structure. Thus their contributions have to 
be taken into account as well when analyzing influencing factors presented in the litera-
ture on globalization of R&D, which are discussed in chapter 2 of this paper. 
Continuing from the early research and building on research concerning existing fac-
tors this research attempts to corroborate the findings already presented in the literature 
and scrutinize the phenomenon in the distinctive context of China and pharmaceutical 
industry. The research is grounded on the field of international business (Mudambi 
2007). Its context is the international pharmaceutical companies and the international 
distribution of their core activities. Its geographical focus is on the People's Republic of 
China (PRC), world's second largest economy. The field of corporate research and de-
velopment as well as pharmaceutical discovery is central to this study. It is also related 
to the study of innovations by having high technology products and value creation via 
globally disaggregated R&D value chain as its central focus (Kotabe and Mudambi 
2009). From the above mentioned standpoint this study attempts to diminish deficit are-
as on the subject of globalization of R&D in research to date. The following research 
gaps were identified: 
Majority of studies on globalization of R&D consist of macroeconomic surveys 
(Gerybazhe and Reger 1999). Sectoral studies focus on the IT-industry while there is 
insufficient research on the pharmaceutical industry especially more specific, pharma-
ceutical product discovery and development process related investigations, which would 
take into account the inherited differences of research and development and those be-
tween different stages of the drug discovery R&D process (cf. Iansiti 1993; Lall 1979)  
 Regarding the geographical focus of studies, most studies are concentrating on the 
US, Japan and Europe (Gerybazhe and Reger 1999), with increasing focus on India, 
South Korea and Taiwan while less emphasis has been placed on the study of sifting 
R&D activities to China, with contributions only from a few researchers (Gassman and 
Han 2004; von Zedtwitz 2004; Sun 2007). 
Many of the frequently cited studies in the past research are buil on an old paradigm 
of the multinational enterprises' management and control (Buckley and Casson 1985; 
Bartlett and Ghoshal 1989; 1990; Hedlund 1993), which do not take into account the 
networked nature of today’s pharmaceutical development and emphasis on sourcing or 
dispersion of value activities and R&D diversity in drug discovery (Su 1994; Chen and 
Hung 2010) based on the new paradigm (Gerybazhe and Reger 1999). Also as stated, 
there seems to be a gap in literature covering the subject on the suitability of different 
parts of drug discovery in regards to globalization of R&D. 
Majority of studies (Boehe 2008; Grossman and Hansberg 2006;2008; Zheng and 
Xiong 2008; Håkanson, Hu 2007; Bardhan 2006; Lewin and Peeters 2006; Norwood 
2006; Bardhan and Jaffee 2005; Markuse 2005; Gassman and Han  2004; Grossman and 
Helpman 2003; von Zedtwitz and Gassman 2002; Davis 2000; Gassman and Zedtwitz 
1999; Gerybazhe and Reeger 1999; Florida 1997; Reddy 1997; Hendry 1995; Beck-
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mann and Fischer 1994; Quinn and Hilmer 1994; Clark and Wheelwright 1994; Nobel 
1993a,b; Kogut and Chang 1991; Howels 1990b; Kuemmerle 1990; Boddewyn 1985; 
Bucley and Casson 1976) in the field of R&D globalization handle pull factors that at-
tract R&D investment to certain locations. While many of these studies are macro eco-
nomically and academically important, majority of them contribute very little to the 
managerial aspects. Similarly management studies such as De Boer et al. (1998) along 
with Gassmann and Han (2004), which deal with the day to day cultural, institutional 
and language barriers for a successful management in geographically and culturally 
distant locations that are insightfully helpful in preparing managers for these problems, 
contribute again little to operational arrangement and beneficial corporate structures. 
Thus these studies hardly connect to the findings on R&D globalization factors, alt-
hough some studies provide analysis of established companies based on factor frame-
works, but these studies do not fully answer to the problems arising from the establish-
ment of R&D globalization and adoption of suitable governance form. Therefore a gap 
in literature seems to exist in how the benefits of these literature derived factors could 
be most efficiently capitalized depending on the governance forms as depicted by Boehe 
(2008). 
1.3 Definition of Key Concepts 
Jargons and acronyms replete the field of sourcing and distribution of business activi-
ties, with even widely used terms "outsourcing" and "offshoring" being poorly defined 
or inaccurately used by managers and academics alike (Oshri et al. 2009). An explana-
tion to this conceptual disarray could be found on the interdisciplinary background of 
global R&D management, which spans disciples such as, management, international 
business, engineering and natural sciences. To analyse the current literature on R&D 
globalization and the influencing factors associated with it as well as the different strat-
egies of shifting operations beyond borders to different geographical locations to pursue 
this globalization, a number of key concepts have to be defined. First of all the term 
sourcing has to be explained, as by its scope and definition almost any firm is involved 
in some sort of sourcing arrangement. It is defined by Oshri et al. (2009, 2) as: 
 
"Sourcing is the act through which work is contracted or delegated to an external entity 
that could be physically located anywhere. Sourcing encompasses various in-sourcing 
and outsourcing arrangements such as offshore outsourcing, captive offshoring, near 
shoring and on shoring." 
 
The act of shifting organizational activities to another country other than that of the 
corporation's home country can essentially be divided into offshore outsourcing, off-
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shoring and internationalization based on the factors affecting the decision, which as a 
whole has been termed as the globalization of organizational activities in this paper. 
Thus globalization of R&D is an umbrella term that covers R&D offshore outsourcing, 
R&D offshoring and R&D internationalization, which are micro economic concepts. 
The macro economical concept Globalization of R&D is used in literature to illustrate 
the phenomenon on a country or industry level (Niosi 1997; Serapio and Dalton 1999; 
Li and Zhong 2003; von Zedtwitz et al. 2004; Sun et al. 2007; Florida 1997). Globaliza-
tion of R&D has been discussed extensively in different fields of literature, such as 
studies in international business journals (Di Minin and Bianchi 2011; Zhang et al. 
2007; Florida and Kenney 1994; Sun et al. 2007; von Zedtwitz 2005; Pearce 2005; Red-
dy 1997; Nieto and Rodríguez 2011; Hotz-Hart 2000; Mendez 2003; Song and Shin 
2008; Sun and Wen 2007;) and in papers from top journals concentrating on innovation 
studies, policy and management (Serapio and Dalton 1999; Florida 1997; Gerybadze, 
and Reger 1999; Dunning 1994; von Zedtwitz and Gassmann 2002; Kuemmerle 1999; 
Carlsson 2006; Athukorala and Kohpaiboon 2010; Petrella 1992; Uzunidis and Boutilli-
er 2012; Dunning and Lundan 2009; Feinberg and Gupta 2004), as well as in journals 
dealing with technology or R&D management (Manuel et al. 2000; Casson and Singh 
1993; Bardhan 2006; Reddy and Sigurdson 1997; Moncada-Paternò-Castello et al. 
2011) along with governmental and institutional publications (Lundin et al. 2007; Foray 
2006; Reddy 2002; Golnam et al. 2007; Barr and Tessler 1996; Åkerblom and Luhtala 
2006). Various authors have used terms such as geographical decentralization of R&D 
(Di Minin and Bianchi 2011; Buckley and Casson 1998; Cheng and Bolon 1993; Cas-
son and Singh 1993; von Zedtwich et al. 2004; Håkanson and Nobel 1993; Fischer and 
Behrman 1979; Nieto and Rodríguez 2011; Contractor and Sagafi-Nejad 1981) or dis-
persion of R&D (Lamin and Livanis 2013; Phene and Almeida 2008; Adler and Hashai 
2007; Kuemmerle 1999; Rugman and Verbeke 2003;) to illustrate the same phenome-
non, for simplicity in this paper the author has used globalization of R&D to cover all 
these three terms. 
In this paper as an actual arrangement of operations, internationalization of R&D and 
offshoring of R&D includes the in-house execution of R&D activities. The abroad con-
tracting out of R&D activities and centers is termed offshore outsourcing. Before con-
ceptually separating these three terms the author states that in this paper the following 
definitions are used. R&D internationalization has been viewed as a process of increas-
ing involvement in international markets, through building on existing activities and the 
growing tendency of operations to span across national boundaries (Welch and Lu-
ostarinen 1988; Westhead et al. 2007; cf. Ronstadt 1978). The term offshoring charac-
terizes a strategy of transferring activities across national borders using internal re-
sources (Hätönen and Eriksson 2008). The practice of a firm entrusting to an external 
entity based in other countries the performance of an activity is commonly referred to as 
offshore outsourcing (Varadarajan 2008). 
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A clear distinction should be made between offshoring of R&D and be the general 
internationalization of R&D, due to the different logical underpinnings of these con-
cepts (Boehe 2008). Companies generally acknowledge that their international expan-
sion is a continuum of small steps to be taken in order for a gradual adaptation into the 
host country’s unique market environment to happen (Ronstadt 1978). Several drivers 
have been suggested as the logic behind R&D internationalization, such as market-
drivers (market size, strategic clients or lead markets), as well as technology –drivers 
(production facilities or science, world centers of excellence) in cutting-edge research 
(Boutellier, Gassmann and Zedtwitz 1999). This is a striking contrast to the logic given 
by the transaction cost economics respectively for offshoring, which has been stated to 
be motivated by labor and technology considerations and other factors, such as cost 
considerations (Norwood et al. 2006).  
General understanding of offshoring (Boehe 2008) is stated as shifting value-chain 
activities abroad from the home country. Another common usage of the term is the relo-
cation of organizational activities to an in-house subsidiary, also titled captive offshor-
ing (Boehe 2008). This is nevertheless challenged by Norwood et al. (2006, 35), who 
makes the case that:   
 
“There is no clear, universally accepted definition of what constitutes offshoring “ 
 
They (Norwood et al. 2006, 8) nevertheless say for the underlying reason for offshor-
ing to always be the same by stating that:  
 
“Virtually all of the studies examining business offshoring decisions and their antici-
pated benefits identify cost savings as the leading expected benefit.”  
 
The above mentioned are loose definitions, which are more clearly elaborated by a 
strict and broad definition of the concept (Boehe 2008). The value of the loose defini-
tion has to do with the promising reduction in cost that comes from moving organiza-
tional activities to a location with favourable business conditions.  
The strict definition requires a shutting down of a home location and the consequent 
overseas transfer of existing economic activities (Hertveldt et al. 2005, 9; Boehe 2008). 
A broad definition of offshoring forfeits the closing down of a home location require-
ment. This is due to three scenarios, the home site may take on other activities or the  
home site's abandonment may only happen after a time (Boehe 2008). A third scenario 
is that a company may decide instead of expanding in its home country to establish 
business in an offshore location instead (Hertveldt et al., 2005,9). A specialized case of 
offshoring is nearshoring, which is the relocation of organizational activities to a neigh-
boring country and onshoring that refers to moving operations to another inhouse facili-
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ty within the original country (Oshri et al. 2009). In this paper nearshoring is included to 
the broader definition of offshoring and due to the international business standpoint of 
this study onshoring isn't considered. 
Similarly it is also worth noting that offshoring is conceptually distinct from out-
sourcing. Outsourcing is defined as the intent of shifting value chain activities to an 
external generally legally independent entity, which can be located at home or abroad 
(Boehe 2008). A more functionalistic definition by Oshri et al. (2009, 4) states out-
sourcing as follow: 
 
"Outsourcing is defined as contracting with third service provider for the management 
of completion of a certain amount of work, for a specified length of time, cost, and level 
of service." 
 
Very often outsourcing relationships are short-term, arms-length relationships be-
tween a contractor also known as customer and the service provider also known as a 
supplier. This interaction generally involves passing of designs, prototypes or test speci-
fications by the contractor to the supplier, which in accordance to the contract provides 
the contractor with components, products or test results.  
However, offshoring may be combined with outsourcing, which is termed offshore 
outsourcing and refers to a situation when an activity is carried out by another organiza-
tion in another country (Boehe 2008). Where in offshoring the functions are performed 
in a foreign country by a foreign wholly owned subsidiary, offshore outsourcing in con-
trast refers to a situation where an external organization performs business functions on 
behest of the company in a country other than the one where the products or services are 
actually developed or manufactured. Here worth noting is that a cooperative agreement 
or joint product development implies longer term relationship and is considered in this 
paper as offshoring if and as it usually involves direct investment. For this kind of net-
worked business model where both partners work in an integrated manner is a grey area 
between offshoring and offshore outsourcing, as it often involves intense long-term, 
rather than short-term interaction, focused on jointly creating new knowledge, new 
technology or a new product (Ford et al. 2003). 
 As stated the globalization of R&D can be arranged by means of internal (captive or 
in-house) or external (outsourcing) delivery models (Oshri et al. 2009, 4) and R&D off-
shore outsourcing and R&D offshoring follow different logic than R&D internationali-
zation (Boutellier, Gassmann and Zedtwitz 1999). Thusly R&D offshore outsourcing 
can be contrasted with both the internationalization of R&D and offshoring of R&D as 
rationales behind overseas sourcing of R&D operations to support firms domestic and 
global organization. Similarly, as these concepts are distinguishable from each other. In 
this paper the broader definition of offshoring and offshore outsourcing are adopted to 
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represent those geographically dispersed R&D operations that are not part and not mo-
tivated by the same reasons as the general internationalization of firms R&D. 
Characteristics of all of above mentioned three strategies of going beyond borders 
can also be scrutinized in the light of the "traditional view" or "traditional paradigm" of 
R&D globalization versus the "new paradigm of transnational innovation" and the un-
derlining factors driving these two views. In the worldview of "traditional paradigm" 
technological and scientific knowledge base and product concepts are derived from a 
single dominant home location; the fruits of which are then later reproduced in periph-
eral locations (Gerybadze and Reger 1999). This process of primary flows of infor-
mation and knowledge from the central locations to the periphery leads to one-way 
technology transfer, outward learning and exploitation of knowledge with a very little 
knowledge based added value in the peripheral locations (Gerybadze and Reger 1999). 
As this is how the world looked like in the 1970s, a period in history that was character-
ized by US superiority in almost all fields of science and technology.  
The new paradigm is a striking contrast to this with an focus on market and technol-
ogy interaction in all locations, multiple centers of knowledge at differing geographical 
locations around the globe that participate in knowledge sharing through inward and 
outward learning in opposition to one way information transfer combined with a global 
integration of number of actors along the value chain through cross-functional learning 
(Gerybadze and Reger 1999). The view is illustrated by the fact that in all major fields 
of science and technology two or three centers of excellence exist today with an intense 
competition and frequent changes in order among them (Cooper 2005).  
When analyzing the globalization of R&D, the widely used abbreviation R&D has to 
be defined as well as the distinction between what is considered R in relation to D. In  
the 2008 OECD Factbook, the phrase research and development (R&D) is depicted as:  
 
"creative work undertaken on a systematic basis in order to increase the stock of 
knowledge, including knowledge of man, culture and society, and the use of this stock of 
knowledge to devise new applications" (OECD 2008).  
 
This OECD definition of R&D is the one used in this study to indicate the whole 
R&D process. A more general compressed definition of R&D refers to the process of 
development of either: new knowledge, products or services to an entity such as a com-
pany. A common definition of research is the process of discovering scientific 
knowledge, which has the potential to further the development of commercially viable 
manufacturing processes and products by acting as a technology platform (von Zedtwitz 
and Gassmann 2002), a definition of research used in this paper as a clarification. Dif-
ferent concepts and definitions exist also on product development processes. One of 
them, supported by operations researchers seems to agree that its heart constitutes the 
design-build-test cycle (Clark and Fujimoto 1991; Wheelwright and Clark 1994). Inte-
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gral part of this cycle is the building of either virtual or more often physical prototypes 
from a new product design at the design stage. Various testing is then performed for the 
prototypes, after which the test results are fed back to supplement the design stage. The 
cycle may be repeated until a satisfactory results are obtained or until the new product 
design is abandoned. Another generally accepted but a looser definition characterizes 
development as the process of applying a technological platform to the creation of new 
commercially viable production processes and products (Medcof 1997). The author has 
chosen to use this looser definition of development in this paper, as it is based on con-
forming ideology with the definition of research adopted by the author. 
1.4 Purpose of Research 
A motivation for this research comes from the phenomenon presented in numerous 
industry white papers and in the academic literature on the need to increase productivity 
and enhance profitability of the industry by geographically dispersing pharmaceutical 
R&D. A notable development in the industry is the need for pharmaceutical companies 
to limit their R&D costs and increase the productivity of R&D due to declining reve-
nues from the expiration of the 25 most significant drug patents (DeRuiter and Holston 
2012). This research attempts to show how companies can capitalize on advantages that 
are derived from the influencing factors depending, which governance form they em-
ploy and what portion of drug discovery processes R&D they plan on conducting in 
China. The purpose of this research is to identify factors influencing the globalization of 
pharmaceutical R&D in PRC and how these factors affect the different governance 
forms on a continuum of pharmaceutical drug discovery. This research attempts to ful-
fill the above mentioned purpose by answering to the following research question:  
 
"How to determine the appropriate governance forms for globalization of pharma-
ceutical R&D for international pharmaceutical companies in the context of PRC based 
on the influencing factors?" 
 
 The research question is divided into the following subquestions with the objective 
that when the subquestions are answered they will provide a complete and coherent an-
swer to the main research question: 
 
“What are the different factors influencing the internationalization of pharmaceuti-
cal R&D to PRC?” 
 
  “What are the different factors influencing the offshore outsourcing of pharmaceu-
tical R&D to PRC?” 
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“What are the different factors influencing the offshoring of pharmaceutical R&D to 
PRC?” 
 
“How does the continuum formed of pharmaceutical drug discovery's stages influ-
ence the globalization of pharmaceutical R&D in the context of PRC?” 
 
In order to answer the above mentioned research question an empirical qualitative re-
search was conducted in China. The research is based on 8 qualitative expert theme in-
terviews with local pharmaceutical directors and managers conducted in 2011-2012, 
utilizing theme interview method with few standardized guiding open ended questions 
and validating findings using a semi-structured research questionnaire. The research is 
confined to the R&D operations conducted in China by International Pharmaceutical 
companies, their R&D departments/subsidiaries or their contract research organizations 
(CRO). The international pharmaceutical industry, with  2009 market size of $808 bil-
lion USD today is dominated by 12 large MNCs that form the Big Pharma as depicted 
by fortune 500 report (CNN, Fortune 500 2009). The Big Pharma is further augmented 
by over 30 large and close to a 100 medium sized companies (IMAP 2011). The indus-
try is formed with the addition of over a thousand biotech companies since the 1990s, of 
which an over 100 have become essential parts (Cockburn 2004). Many of the smaller 
and medium sized pharma and biotech companies are service providers such as contract 
research organizations (CRO), contract manufacturers (CMO), ingredient manufacturers 
or active pharmaceutical ingredient (AIP) developers and producers (Su 1994; Chen and 
Hung 2010).  
This study is further limited to only those pharmaceutical companies that have aver-
age R&D intensity on the company level or at minimum on the business level equal or 
higher than 10% as indicated by the University of Tottenhaim's Database on Interna-
tional R&D Investment Statistics (INTERIS) and ISI Database on International Re-
search and Innovation Activities (ISI-DORIA). Choosing this company inclusion crite-
ria in the research enables the scrutiny of R&D as independent from other functions of 
the company (Cantwell, 1994, 8) and is a criteria used in other studies on the field, 
which validates comparisons (Gerybadze and Reger 1999; Meyer-Krahmer and Reger 
1999).  
Concerning the globalization of R&D activities interesting path of research has fo-
cused on the role of communication and knowledge sharing on the success of globalized 
decentralized R&D (Leifer and Triscari 1987). This research do not dwell on the need 
of large transnational firms to establish efficient internal communications or mecha-
nisms of knowledge sharing except from the point of whether it is a factor affecting the 
decision to whether move R&D and why to move R&D to foreign countries.  
Similarly some research on globalization of R&D has focused on the location deci-
sions and criteria for site selection. These are not considered in this research except for 
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the specific location factors related to PRC on account they are included as a factor in-
fluencing the decision whether to move R&D and why to move R&D to foreign coun-
tries (Gassman and Han 2004; von Zedtwitz 2004).  
The structure of this paper includes an introductory first chapter, which consist of the 
background to the R&D globalization phenomenon, an illustration of the early research 
on R&D globalization, while compiling it to influencing factors handled by present re-
search. Furthermore the first chapter defines some key concepts, states the purpose of 
this study and the research problem. In the second chapter the history of R&D globali-
zation and its characteristics are chronicled followed by a more contemporary literature 
review of the research on the influencing factors on R&D globalization to date. The 
chapter is continued with a recount of the most influential factor frameworks presented 
in the literature, together with analysis on their theoretical contributions and a compari-
son of the frameworks. The chapter is completed with a presentation of the field of 
study and how the intrigues of pharmaceutical industry and the specific environment of 
People's Republic of China impact the influencing factors identified in the literature, 
along with a description of the pharmaceutical drug discovery process and the chapter 
findings are summarized in an initial framework. The third and next chapter acquaints 
the reader with the methodology and methods used in this study while the fourth chapter 
presents the results and findings of the empirical research. The fifth and last chapter 
presents the author's conclusions, together with their theoretical and managerial implica-
tions. 
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2 LITERATURE ON GLOBALIZATION OF R&D 
2.1 History of R&D Globalization 
There is both academic research emphasis as well as interest from the business commu-
nity and governmental decision-makers towards globalization of R&D (Gerybadze and 
Reger 1999). As it is not a new phenomenon and a one that represents the most signifi-
cant change in traditional corporate thinking it is surprising that the research on it re-
mains fragmented and theoretical contributions are still lacking. As reported in a study 
by Cantwell (1995), already in the 1930s the largest European and US multinational 
corporations had shifted about 7% of their R&D to overseas. In 1960s and 1970s was a 
period of strong global dispersion of corporate activities, which let to companies setting 
up factories and sales operations in foreign countries. These operations were already in 
the mid-1960s accompanied by significant foreign R&D conducted by MNCs according 
to US tariff commission's 1973 report (Lall 1979). In 1980s this trend intensified as 
these foreign subsidiaries started being supported by design and development geared 
towards adapting products and processes to local requirements (Gerybadze and Reger 
1999). A significant part has also played the convergence of IP protection for example 
with the adoption of The Patent Cooperation Treaty of 1978, which enables the usage of 
uniform format patent application applicable in all of the participating countries 
(Boddewyn 1985).  
As the globalization of R&D became a stronger trend in the 1980s, its significance 
continued to grow in the 1990s, with large multinational firms augmenting the disper-
sion of innovation activities globally (Patel and Pavitt 1992; Cantwell 1994, 15-23; No-
naka and Takeuchi 1995, 197-210; Roberts 1995a,b). De Meyer and Mizushima (1989) 
also reported that heavy investment by Japanese firms in manufacturing facilities over-
seas was by the process of globalization subsequently leading to development of "pe-
ripheral activities" that supplemented manufacturing facilities, firstly activities such as 
process and product engineering, followed by more complex R&D operations.  In the 
mid-1980s and well into 1990s corporations strengthened their foreign R&D activities. 
This trend of multinational companies extending their R&D competences on to a global 
scale was influenced by the emergence of coherent national innovation systems and 
increasingly sophisticated markets in the receiving countries of Organization for Eco-
nomic Co-operation and Development (OECD). The implications for R&D manage-
ment where that gradually the foreign R&D centers, previously occupied with the ex-
ploitation and adaptation of centrally developed home country-based technologies, be-
came integral parts of the R&D network by being involved in exploration and advanced 
development (Gerybadze and Reger 1999).  
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A survey by Lewin and Peeters (2006), depicting the major functions to be global-
ized of 90 companies from the 650 US Forbes Global 2000 companies, found major 
increases (81% growth rate) in the future plans for offshoring of research and develop-
ment that indicates for the third global expansion of R&D globalization to be ongoing. 
R&D internationalization and offshoring in some ways resemblances the offshoring 
of manufacturing, in that it has potentially high capital requirements but at the same 
time it bears some similarity to services offshoring; which usually is not at all capital 
intensive but has high requirements on the white collar job market and affects multitude 
of different white collar occupations simultaneously (Bardhan 2006). This is in contrast 
to the low skill uniform blue collar labor requirements of manufacturing. Manufacturing 
has traditionally shifted purely to countries that offer low-cost production opportunities 
such as the East Asia, while services have traditionally favored the English speaking, 
institutionally compatible old British colonies of the Commonwealth of Countries such 
as India and Bangladesh (Bardhan and Kroll 2003). Globalization of R&D has tradi-
tionally progressed according to the changes in cutting edge scientific development and 
networks offered in different parts of the world (Cooke 2005). Intensification of global 
competition has forced companies to seek spending cuts at all cost centers leading R&D 
globalization to the search of equal portions of low cost and availability of vast skilled 
scientific talent pools in China, India, Russia along with many of the former Eastern 
European socialist countries (Bardhan and Jaffee 2005).  
 Furthermore some research states that MNCs increasingly off-shore product devel-
opment activities completely according to a simple formula of the difference between 
incurred coordination costs and savings on operational costs. Buckley and Casson 
(1976, 53-54) state that all R&D work should be located to regions where costs of non-
tradable production factors were cheapest and educational capacities most developed in 
the absence of communications costs. They show how the increase of R&D capabilities 
in the low and medium cost emerging countries, together with innovations in ICT lead-
ing to decreasing coordination and communications costs, enhance the probability that 
R&D work is shifted or dispersed from high cost to medium or low cost countries (Bu-
cley and Casson 1976, 53-54).  
 
2.2 Factors influencing Globalization of R&D 
From the history of R&D globalization it is evident that many factors influence this 
phenomenon. Gerybadze and Reger (1999) suggested in their empirical study conducted 
between 1994 and 1997 for a number of reasons to be behind this development in glob-
alization of R&D. Such reasons as: the effect of national innovation systems, fiscal con-
solidation of R&D, changes in the management of R&D, design of systems for commu-
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nication and knowledge sharing, network externalities in advanced markets and manu-
facturing systems, technology and options seeking activities in R&D as well as desire 
for inward learning that requires presence in most technologically and scientifically 
sophisticated locations. Similarly in their paper they illustrated a change that started in 
the 1990s with R&D management being rethought in major multinational companies 
that were undergoing managerial changes in R&D. These managerial changes resulted 
from the increasing problems of coordination related to building-up of regionally dis-
tributed intra-corporate R&D structures and their embedding into worldwide R&D co-
operations and strategic alliances (Gerybadze and Reger 1999). 
The preliminary findings by Gerybadze and Reger (1999) suggest that factors related 
to Globalization of R&D have to be seen as those impacting on the macroeconomic lev-
el and those that are micro economic factors impacting on the firm level. Macroeconom-
ic factors are those such as the effects of national innovation systems, availability of 
labor, fiscal consolidation of R&D and cross country cost differentials together with the 
changes in the world economy and growing importance of some markets in the develop-
ing countries (Granstad, Håkanson and Sjölander 1993). Another set of macroeconomic 
factors are those presented by Boddewyn (1985) as conditional factors, which can be 
seen as basic requirements for setting up any R&D operations in a country. Such factors 
are for example the necessary infrastructure in the country, starting from the supply of 
electricity and clean water to all the way to the structure of country's tertiary education. 
Similarly according to Boddewyn (1985) the legal framework in the country creates a 
basic condition for a company, whether it can shift so high value activities, products or 
technologies to a given country. According to Granstad et al. (1993) micro economic 
factors in turn are those that affect decision making mostly on the level of individual 
companies, such as managerial changes and inducements from high-end markets or 
production environments as well as individual financial incentives or strategic alliances 
with expertise centers or research groups and professors. In the following sub chapters 
both the micro- and macroeconomic factors derived from the literature are divided ac-
cording to their operational focus to R&D as: labour factors, financial factors, market 
consideration factors and risk factors, which are then summarized in table 1 together 












Table 1. Influencing factors on globalization of R&D from literature with their authors 
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2.2.1 Availability of labor and centers of excellence 
Gerybadze and Reger (1999) point on the growing sophistication of national innovation 
systems in OECD countries during the 1980s and 1990s as facilitators of polycentric 
learning environments that lead to multinational corporations to extent their R&D net-
works to many new non-typical R&D locations outside US and Western Europe. By 
spawning a leading center of excellence in a relevant field of science and technology a 
national innovation system forces multinational corporations (MNC) to source talent 
and know-how outside their home base in order to stay competitive. Gassmann and Han 
(2004) highlight that the difficulty of attracting best international talent to overseas des-
tinations, forces companies to establish R&D facilities to locations where highest exper-
tise and facilities are available. Beckmann and Fischer (1994) add that private facilities 
as well as public institutions, such as research centers and universities, function as local 
sources of engineerial and natural science knowledge along with technical spill-over. 
Together these public and private actors form local pockets of innovation, which are 
geographically as well as academically defined expertise areas, characterized by high 
know-how potential. Also as the core of informal expertise network, they facilitate shar-
ing and processing of knowledge and information in the early phases (Beckmann and 
Fischer 1994). 
In general, it can be said that such local pockets-of-innovation are spawned with the 
formation of excellence centers or science parks, which attract investors by providing 
space, advanced infrastructure, and sorely needed high-tech facilities along with finan-
cial incentives (Gassmann and Han 2004). Gassmann and Han (2004) affirm that gener-
ally companies have been attracted to shift overseas parts of their R&D operations to 
regions characterized by a high rate of new technology output or centers of excellence in 
hopes of greater advantageous spill-over potentials. Shifting R&D overseas to target 
country may also be beneficial for acquiring applicable sciences & technologies such as 
those related to safety measures and standards (Beckmann and Fischer 1994). 
In the future the role of publicly financed research will expand brought upon by sci-
entific advancement that increases potentially relevant research fields (Leifer and Tris-
cari 1987). Thus the importance placed on centers of excellence formed by universities 
and research centers will continue to expand. Worth to note that cost considerations and 
financing play a part in steering particular research or technologies to defined areas as in 
recent years the costs of basic R&D have risen sharply simultaneously when public fi-
nancing for R&D has stagnated or even decreased, especially in Western countries 
(Beckmann and Fischer 1994). The case is further weakened by the inability of many 
companies to afford cutting edge R&D by themselves and then thus forced to locate and 
depend on the resources in places where they are available (Beckmann and Fischer 
1994). 
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Gerybadze and Reger (1999) also list organizational innovations that are accelerating 
the change in R&D globalization, such as the development of new management solu-
tions that allow for rapid flexible networking of institutionally or regionally scattered 
centers of competencies through R&D co-operations and strategic alliances (Sydow 
1992; Gerlach 1993; Gerybadze 1995). These new solutions include novel arrangements 
for distributing R&D activities and competencies from the mother company for its sup-
pliers and to various outside stakeholders such as universities, private research institutes 
and even to customers (Gerybadze and Reger 1999).  
On the same note the blurring of basic and applied research as well as research in re-
lations to development has led companies into adapting new mixed forms between basic 
and applied R&D that required decisive changes in the corporations' management 
(Iansiti 1993; Leifer and Triscari 1987). All these changes have resulted, especially in 
R&D intensive sectors, in wide outsourcing arrangements across the whole spectrum of 
value creation operations. 
Another implication of this managerial change is presented in multiple studies and 
has to do with R&D-specific location factors e.g., the desire to access a local talent pool 
(Teece 1976; Ronstadt 1977; Mansfield, Teece and Romeo 1979; Lall 1980; Kogut and 
Zander 1993). A system for global technology procurement, which has enabled the dis-
tribution of R&D and facilitated learning from geographically distant knowledge cen-
ters, has been enacted in most MNCs to respond to these changes (Gerybadze and Reger 
1999). Availability of labor for skilled R&D occupations is critical for the adoption and 
flourishing of offshore outsourcing, offshoring and internationalization of R&D. Ac-
cording to Bardhan (2006) a global labor market that comprises the whole length of 
R&D labor pool formed of scientists, engineers and other academic and high-tech pro-
fessions is the effectively result of technological progress and politico-economic chang-
es. Nevertheless, other considerations than labor costs and educated labor supply market 
are also of outmost importance. Such crucial features Bardhan (2006) says are geo-
graphical distribution and clustering of talented labor, tradition for commitment by 
R&D labor as knowledge assets, labor market mobility and labor laws, contractual labor 
provisions and practices and the practical and legal framework of intellectual property 
protection. Because the expertise of the personnel is paramount to R&D operation's suc-
cess, great importance has to be put into the recruitment process and suitability testing 
as well as the continued training of employees (Beckmann and Fischer 1994).  
Another push factor for R&D globalization has been scarcity of R&D resources for 
high-tech companies operating in small markets (Gassmann and von Zedtwitz 1999). 
Beckmann and Fischer (1994) also state that first and foremost importance for the suc-
cess of the R&D mission is the availability of advanced R&D labor pool and the exper-
tise of the personnel. They see that in the Western world, especially in smaller countries 
there is a scarcity of engineers and researchers. Shifting operations overseas, when it 
may be cheaper to transfer a project abroad instead of increasing the capacity back 
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home, may alleviate these resource capacity shortages at home (Beckmann and Fischer 
1994).  Even companies operating in large markets with abundant domestic R&D base 
have been forced to shift their R&D overseas in search of technological and scientific 
know-how on a global scale by increased competition within and outside their industries 
(Gassmann and Han 2004). 
Related to the aforementioned capacity arguments, another factor which may save 
time and increase product development capacity termed asynchronous parallel devel-
opment model describes how a project can be carried out at different locations simulta-
neously if separated into several independent components by an MNC with several 
R&D or product engineering units; just as they do with component production and final 
assembly activities (Boehe 2008). When limiting a function to one particular location or 
a facility, it decreases the amount and variety of competencies that could be employed 
for that function (Beckmann and Fischer 1994). By dividing the function to multiple 
locations different competencies can be accessed and synchronous although partly par-
allel work can be achieved (Beckmann and Fischer 1994).  
The picture painted of the phenomenon in the academic literature on R&D globaliza-
tion by the above mentioned authors shows the importance of national innovation sys-
tems and local high-technology clusters in the formation of centers of excellence. These 
actors function first and foremost on the macroeconomic level promoting a certain 
country or a region but also on the individual company level through the centers of ex-
cellence and the business relations, academic expertise as well as technology and infra-
structure incentives they provide. Importance of centers of excellence is most evident 
for companies dependent on cutting edge research. Identically the aforementioned ac-
tors also supply firms with the resource paramount to their success – human capital. 
Availability of labor has been shown as make or break factor in decisions to establish 
intra corporate subsidiaries to a country while off less importance in outsourcing, affect-
ing on micro level but dependent on macro policies, such as higher education and labor 
laws. 
2.2.2 Cross country cost differentials and financial incentives  
Another set of studies indicate for a key factor behind globalization of R&D and es-
pecially the offshoring of R&D to be the need to cut down costs that was cited by 93% 
of respondents as a major strategic driver in a survey by Lewin and Peeters (2006). 
Even though not exclusively handling R&D the survey’s results are applicable, as the 
soaring cost of R&D are closing on the borderline of the financeability of innovation.  
Gerybadze and Reger (1999) report that fiscal consolidation is a result of the increasing 
costs of R&D that has many companies against the barrier of the financeability of R&D 
while at the same time keeping up with the "R&D arms race", a high tech competition 
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phenomenon extensively illustrated by von Braun (1995). A manifestation of the fiscal 
consolidation is both the weakening of central research as spending on fundamental 
research is limited and a stronger business-unit focus as the research is geared towards 
application orientation (Roussel et al. 1991).  
As a symptom of the increasing costs, cross country R&D cost differences have at-
tracted considerable attention. In fact, the cost argument has been suggested to be the 
major factor by preliminary empirical evidence from some studies (Buckley and Casson 
1976; Norwood et al. 2006). These studies include for example, a research on US phar-
maceutical companies carrying out some R&D in Denmark by Davis (2000), who found 
the main reason to be taking advantage of positive cost differentials and another by 
Reddy (1997), who also argue cost differentials to be the primary force. Nevertheless, 
financial benefits can be reaped through other means than purely through cost reduction, 
for example with financial incentives offered to high-tech companies by excellence cen-
ters or science parks, including three year complete tax levy following company's estab-
lishment, with a subsequent 50% discount for the next three years, and a 15% tax rate 
discount from the seventh year onwards, along with other tax incentives (Gassmann and 
Han 2004). Clearly R&D globalization is then a flexible way for evading home coun-
try’s regulations and profiting from host country’s policies preferential to FDI (Gross-
man and Helpman 2003; Hu 2007). 
Contrary to studies by Lewin and Peeters (2006), Buckley and Casson (1976), Nor-
wood et al. (2006), Davis (2000) and Reddy (1997), a great number of publications on 
globalization of R&D have reached the conclusion that cost is not the major factor, such 
as report by Gassmann and von Zedtwitz (1998) on the importance of long term strate-
gic goals and not short term ROI considerations. According to Granstrand, Håkanson 
and Sjölander (1993), these direct cost advantages rarely influence the internationaliza-
tion of R&D, but other efficiency factors such as costs of coordination and transfer, and 
critical laboratory size do have an impact on international R&D organization. However, 
costs can apply to industries that experience strong cost competition in relation with 
high R&D requirements and costs (Cheng and Bolon 1993). In more detail, majority of 
costs are comprised of personnel cost differences, which on average account for two 
thirds of costs. Thereby developing countries may appear as attractive cost centers, alt-
hough infrastructure costs may erode these gains, which Beckmann and Fischer (1994) 
pointed out. They say that the state of infrastructure in a country can lack to such an 
extent that setting up any facilities or operations is impossible or it can be a source of 
extensive costs. Even though the per capita costs of employees would be beneficially 
low, the overall costs of R&D in a developing country can be surprisingly high and effi-
ciency so lacking due to inhospitable infrastructure that only a fraction of cost ad-
vantages can be realized (Beckmann and Fischer 1994).  
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2.2.3 Access to markets, local adaptation and requirements  
Another set of objectives for R&D globalization include the need to react to differential 
and varied environments of product requirements, markets and institutions more agilely 
(Grossman and Hansberg 2006; 2008). Similarly, market size and growth as well as the 
opportunity for inward learning from these lead markets has been reported to be major 
drivers in R&D globalization.  
Gerybadze and Reger (1999) state that inducements from high-end markets and pro-
duction environments are building blocks of the corporate R&D; capitalizing on these 
externalities requires R&D to take place in several of these leading locations in the 
world. Deriving from this, some researchers have stated that conducting R&D offshore 
increases the amount of local knowledge the firm can obtain (Howells 1990; Kogut and 
Chang 1991; Florida 1997), which may be achieved by organizational learning and ca-
pability building in the host country. Beckmann and Fischer (1994) argue that an over-
seas R&D department becomes interesting to the whole R&D structure of the company 
only when both the amount and sophistication of local lead users as well as the innova-
tiveness and the number of new product introductions by local companies reaches a 
sufficient level.  
Studies by Teece (1976), Ronstadt (1977), Mansfield et al. (1979), Lall (1980) and 
Kogut and Zander (1993) emphasize market characteristics, size and attractiveness of 
foreign markets. Market potential, i.e. market size and growth, is especially paramount 
in regards to company's interest in placing R&D opposed to lower value operations to 
that specific country and spending resources for the required product adaptation 
(Beckmann and Fischer 1994). Shifting R&D overseas to a target country may also be 
beneficial for quickly approaching fragmented markets (Markusen 2005; Zeng and 
Xiong 2008). Building on this Bardhan (2006) says that, gaining country intelligence 
and initial access for future market penetration can best be achieved through R&D 
globalization. Country intelligence and knowledge for initial access for future market 
penetration can potentially benefit a company also in more indirect ways: cultivation of 
unrelated business and government contacts, spillover gains to other business activities 
and opening up of third country markets access from locationally advantageous position 
(Bardhan 2006). 
Beckmann and Fischer (1994) say that reacting to market environments can be based 
on market adaptation by carrying out research and designing to the market in question. 
Further research suggests that conducting R&D in an offshore location is integral in 
facilitating product adaptation to local markets (Howells 1990; Håkanson and Nobel 
1993a,b). Competition increases the need to decrease time-to-market, with local R&D 
potentially speeding up product development. Decreasing time-to-market can reduce the 
costs of launching late or the costs of doing it wrong. This results in a competitive edge, 
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by either beating the competition in introducing a new product much sooner than others 
or by introducing a better product at the same time (Clark and Wheelwright 1994). 
Studies by Teece (1976), Ronstadt (1977), Mansfield et al. (1979), Lall (1980) and 
Kogut and Zander (1993) also illustrate the need to adapt product variants to country-
specific situations. Beckmann and Fischer (1994) explain how country's development 
and economic conditions may put pressure on the structure and content of the product 
and thus require product adaptation. Their study suggests also that the amount of prod-
uct adaptation needed to modify the existing product into meeting the local needs also 
plays a factor here (Beckmann and Fischer 1994). Local requirements may also play a 
part as product's applicability to local legal requirements and standards have to be veri-
fied, which usually requires at least minor adjustments (Beckmann and Fischer 1994). 
To be competitive, products have to correspond to market and even to individual cus-
tomer needs and requirements. The local adaptation of a product is especially para-
mount when introducing a novelty product to the market. The scale of required modifi-
cations depends on the variability of customer needs, local manufacturing competencies 
and legal requirements. Socio cultural values, differences and requirements may require 
product adaptation even inside geographically relatively small areas (Beckmann and 
Fischer 1994). 
One of the main reasons for constructing technical research abroad is the difficulties 
in receiving permits from local institutions. From the author's perspective, decisive is 
not the permits themselves, which are often readily given in the Western world but the 
long time and the risks involved in them overseas. Alas, the permit times can total sev-
eral years and the process requires wide open disclosure and cooperation with stake-
holders. In addition, immediate costs will be increased due to delays in market entry and 
multiplied by high demand. (Beckmann and Fischer 1994) However, Beckmann and 
Fischer (1994) highlight that the important permit categories are safety measures and 
standards.  
Beckmann and Fischer (1994) report that when a new company is establishing its 
first R&D laboratories and does not have previous local presence nor a recognizable 
brand, what they will be lacking is attractiveness as an employer and trust from poten-
tial customers, which decreases available capacity. A solution to this is the gradual 
building of operations in a country from the least value associated operations to the 
most value creative ones. Thus previously off-shored production has also been found by 
Kuemmerle (1999) to be a pull factor, as on site R&D facilities are needed to provide 
technical support. When considering capacity arguments, Boehe (2008) says that thriv-
ing for an synchronous round-the-clock dispersed development model through global-
ized R&D function is another push factor, which may also contribute to shortening de-
velopment times. These gains come from the possibility that work can be continued 
globally round-the-clock by different people, thus critically cutting delivery times. 
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The market potential is closely associated with the tendency for products adaptation 
to markets with decreasing time-to-market, as well as with the company's interest on the 
overseas R&D department as a source for inward learning and local knowledge. The 
direct effect of market size, attractiveness and growth is whether market entry to a par-
ticular market is considered strategically significant, which warrants local presence and 
seeking public approval. Another factor closely associated with market interest are local 
and legal requirements that facilitate technology acceptance in the country, which on 
extreme may require local content in production or development.  
2.2.4 Risk factors in globalization of R&D  
In their survey of 90 companies from the 650 US Forbes Global 2000 companies Lewin 
and Peeters (2006) present a number of risk factors of offshoring, those especially relat-
ed to offshoring R&D are as follow: poor quality, loss of control, lack of data security, 
weakening employee morale, operational inefficiency, infrastructure instability in host 
country, intellectual property loss and political instability in host country.  
When it comes to outsourcing the main risk factor is that the provider may attempt to 
surpass the customer if the customer's core competence is not kept away and is not a 
real barrier to entry in to the marketplace (Quinn and Hilmer 1994). Lewin and Peeters 
(2006) state, that in outsourcing another risk factor is associated with a potential de-
crease in cross-functional learning and knowledge sharing. Outsourcing has been ar-
gued to also decrease the overall learning ability of the organization on the organiza-
tional areas from where the activity is outsourced as it increases insecurity, reduces will-
ingness to question and experiment thus reducing innovativeness as well as decreases 
motivation of the workforce (Hendry 1995). Concerning internationalization of R&D a 
major risk factor worth mentioning is political and infrastructure instability, which may 
turn a long span strategic investment decision and gradual build up into utterly flawed 
(Beckmann and Fischer 1994). 
Instead of outright risks some factors can be seen as basic conditions required for 
any R&D work as presented by Boddewyn (1985). These include infrastructure consid-
erations such as the supply of electricity and clean water, road network and port facili-
ties extending all the way to the structure of country's institutions, such as tertiary edu-
cation. Similar basic condition for R&D work is the legal framework in the country. A 
basic requirement for the establishment and retention of a company’s R&D department 





2.3 Analysis on Influencing Factor Frameworks 
Factors influencing industrial R&D on an international scale are numerous and varied 
but can conveniently be classified into groups that better illustrate their implication 
(Granstrand, Håkanson and Sjölander 1993 ). Different approaches have been used to 
classify motivations for R&D internationalization (Granstrand, Håkanson and Sjölander 
1993; Dunning and Narula 1995; OECD 1998; Gassmann and Han 2004). In this chap-
ter, the author presents and describes such prominent classifications presented in table 




 Table 2. Table illustrates the different categorizations presented in the literature, the 
factors associated with them and their relations 
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2.3.1 Conditional factors and decision framework 
One such classification approach by Boddewyn (1985) lays out the basic conditions for 
R&D in any given country in a world as well as describes the decision process from the 
basic conditions to the underlying motivations all the way to the precipitating circum-
stances that ignite the spark for R&D globalization. Boddewyn (1985) presents three 
categories that explain how differing theories of foreign investment can be organized. 
His framework is based on Aristotle’s' ideas of condition-motivation-precipitating cir-
cumstances. The same framework can be used to organize influencing factors in global-
ization of R&D when factors are divided into those dealing with conditions, motivations 
or precipitating circumstances. These can be both internal as well as external factors 
from the firm's perspective and dwell on the rational, economic viability and structural 
factors when conducting R&D overseas. Similarly, some of these factors can be macro-
economic while others are microeconomic affecting on individual firm level, when oth-
ers affect on both micro- and macroeconomic levels. 
From the conditions part of the framework three factors are of particular importance:  
 Improved information and communication technologies play a significant 
role enabling viable conditions for global R&D network. 
 Improvement in infrastructures necessary for R&D facilities in many newly 
developed and developing countries through social, economic, and technolog-
ical development.  
 Convergence in international patenting standards and practices offers more 
uniformed, reliable protection for intellectual property (IP) rights.  
Expected benefits from the globalization of R&D are categorized as motivations, 
which Boddewyn sees as increases in positive organizational outcomes or as decreases 
in negative organizational outcomes: 
 Benefits can be derived with sourcing of top scientific talent, participating in 
centers of excellence or tapping into a large skill pool that exists in other 
parts of the world.  
 By locating R&D laboratories to different locations globally a varied flow of 
new ideas, products, and processes can be acquired (Ronstadt 1977; Terpstra 
1977). 
 Distributing R&D activities internationally allows the capitalization of loca-
tion-specific advantages by allocating work and/or responsibilities depending 
on the expertise, knowledge, and external resources of each R&D subsidiary. 
 By employing dispersed local R&D facilities local needs related to time, rel-
evance and taste could be better catered (Mansfield et al. 1979; Robinson 
1988).  
 Government incentives, such as direct R&D grants, tax write-offs, and inter-
est-free loans lure companies to shift their R&D overseas (Robinson 1988). 
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Situations inside and outside the company that provide motivations for shifting R&D 
overseas are called precipitating circumstances, which Boddewyn perceive as including 
the following: 
 Wide involvement in overseas production and global marketing often require 
technical support and local adaptation, which are usually dependent on per-
manent on-site R&D facilities (De Meyer and Mizushima 1989; Pearce 1989; 
Mansfield et al. 1979).  
 Success of competitors in global R&D may encourage others in the industry 
to shift R&D overseas as well. 
 Shortage of scientists and engineers in many fields in the U.S. (NSF 1990b) 
and the rest of the Western world (Håkanson and Zander 1988) has been ar-
gued to play a part. This shortage of talent has led many companies to look 
for available talent from their foreign subsidiaries.  
 The technological advancement of many non-Western countries in various 
fields and the increasing number of U.S. patents granted to non-Western 
MNCs (Glismann and Horn 1988). 
 Host governments pressuring MNCs to establish R&D facilities as a condi-
tion for market entry (Behrman and Fischer 1980; Robinson 1988).  
The importance of Boddewyn's framework is firstly that it clearly lays out the basic 
conditions for R&D, namely sufficient ICT, viable infrastructure and reliable intellectu-
al property protection and rule of law. Although slightly outdated in regard to many 
developing or even underdeveloped countries today, in the case that these conditions are 
fulfilled, the location can be considered as a potential R&D location.  
Furthermore Boddewyn's framework presents the decision process and the most im-
portant motivations for globalization of R&D. These motivations being: availability of 
R&D resources such as advanced labor force and cutting edge-technology and science, 
accessing local proprietary technology or benefiting from technology spill-over, finan-
cial incentives and tax deductions, knowledge acquisition through inward learning. Alt-
hough Boddewyn (1985) do not mention the importance of market size and growth as a 
motivation, he nevertheless lists local adaptation of products that fit the host market as 
an important motivation and market size as a precipitating circumstance.  
The last part of the framework explains the decision to take action regarding geo-
graphical globalization of R&D activities. Albeit companies might have sufficient moti-
vations for R&D globalization or more than one motivations, Boddewyn (1985) pre-
sents, how it takes a change in either the operational, competitive, legal environment or 
supply of advanced R&D resources to commence R&D globalization in a company. 
Despite that his framework does not touch upon the mode of R&D globalization, the 
author sees it as the thought experiment on whether a company should consider R&D 
globalization. 
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2.3.2 Firm specific capabilities in home or foreign market 
For his part, Kuemmerle (1999) divided reasons for globalization of R&D into two cat-
egories of R&D globalization: home-base-exploiting (HBE) and home-base-augmenting 
(HBA). This framework's purpose is to help managers to structure their planning pro-
cesses and better utilize the advantages present. He saw firms as entities seeking to ex-
ploit specific capabilities present in their organization in a foreign environment or build-
ing new firm-specific advantages from resources present in the foreign environment.  
Reasons for home-base-exploiting (HBE) R&D operations were listed as follows: at-
tractiveness of the target country's market, share of population with tertiary education, 
regulatory reasons and manufacturing or marketing reason (Kuemmerle 1998). He nev-
ertheless point out that, according to his research, companies will establish their interna-
tional sales and manufacturing presence before investing in HBE R&D sites abroad. 
When interpreting the reasons, it also became evident that the share of population with 
tertiary education might be applicable to both HBA and HBE investment.  
According to him, causes for home-base-augmenting (HBA) R&D operations are: 
private and public investment to R&D and the spill over gains from that investment, one 
country's stock of knowledge and the centers of excellence this knowledge base and the 
national science structure generates. A proxy for this measurement was the level of sci-
entific achievement in the country. The quality of the human resource pool and thus the 
availability of talented labor was also identified as a reason for HBA R&D. 
The basic idea behind Kuemmerle's concept is that, after the decision for R&D glob-
alization is seen as beneficial to a company, the firm has to determine, whether it wants 
to continue catering to its home market, utilizing resources available in the offshore 
location by thus furthering its competitive position and introducing new products, or 
whether it wants to access the host market by capitalizing on the existing capabilities at 
home. Be that as it may, Kuemmerle (1998) talks about the own capabilities of a com-
pany, whether they are those already present in the home market or those that are going 
to be acquired from the host market. Thus he provides the basic distinction between 
offshoring R&D and the internationalization process that guides the firm to a new mar-
ket, but decisively leaves out offshore outsourcing of R&D.  
2.3.3 Role of macroeconomic factors 
Another classification approach differentiates between demand-oriented and supply-
oriented drivers for R&D internationalization (Granstrand, Håkanson and Sjölander 
1993). It can be conceived as a more detailed distinction between the watershed drawn 
by Kuemmerle (1998) that also takes into account the micro- and macroeconomic dis-
tribution. The classification proposed by Granstrand, Håkanson and Sjölander (1993) 
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illustrates the different factors in a more concrete way and takes into consideration the 
scenario for offshore outsourcing, when neither labor nor science nor markets are de-
termining factors in R&D globalization to the host country. 
The demand-oriented factors induce companies to locate R&D abroad in order to 
better serve foreign host markets (Granstrand, Håkanson and Sjölander 1993). Such 
factors according to Granstrand, Håkanson and Sjölander (1993) are special needs of the 
local country/market, which require modifications of the firm’s products i.e. local adap-
tation and host country restrictions, such as local content requirements, tolls, import 
quotas, and fulfillment of standards.  
The supply-oriented factors in the other hand are those dependent on the host market 
characteristics. These factors thus illustrate many of the local advantages, such as favor-
able access to skilled technical expertise i.e. availability of labor, which can be available 
perhaps at a lower cost than elsewhere, a factor that also has been already reported in 
literature as cross country cost differentials. Similarly, as a factor they point to the ac-
cess to sophisticated foreign scientific infrastructure (e.g., new regional technological 
competence centers such as universities and other research establishments) i.e. centers 
of excellence.  
Granstrand et al. (1992) in an older study have mentioned another related group of 
motivations, which are the environmental motivation factors. They say that the notion 
of "national systems of innovation" can foster a suitable environment for R&D, which is 
supported by views on that national institutional structures, policy environments, indus-
trial organizations, traditions, etc. can impact economic performance.  
Nevertheless, Granstrand, Håkanson and Sjölander (1993) indicate that the estab-
lishment of foreign manufacturing subsidiaries often happen, first through exports then 
later through a sales subsidiary. Manufacturing then forces companies to enact technical 
support activities, which tend to evolve over time into proper development projects 
(Granstrand, Håkanson and Sjölander 1993). Thus they show how company's operations 
evolve once it has attained a certain position in the local market and then the induce-
ments to set up local adaptive R&D become pressing, highlighting the case for market 
dependent R&D internationalization. What their classification shows us, is that factors 
have an influence either on macro or micro level, while some function on both levels. 
This segregation between macro and micro levels presents some factors as more envi-
ronmental than motivational. They also provide a clearer distinction between factors 
that favor home market augmenting through supply driven offshoring and the ones that 
speak on the behalf of demand driven home-country exploiting through internationaliza-
tion.  
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2.3.4 External, efficiency and socio-cultural drivers in global competition 
Beckmann and Fischer (1994) present a more refined classification scheme, where 
they identified five categories of R&D globalization drivers: input-oriented, output-
oriented, external, efficiency-oriented and political/social-cultural. This classification is 
based on the work by Granstrand, Håkanson and Sjölander (1993), as the underlining 
idea for the input-oriented and output-oriented categories correspond with their supply- 
and demand-oriented view of. The three other categories presented by Beckmann and 
Fischer (1994), which are external, efficiency-oriented and political/socio-cultural fac-
tors, further illustrate the case on differing motivations for R&D globalization. From 
their work can also be distinguished some conditional factors, similar to those reported 
by Boddewyn (1985), which are technical development and infrastructure constrains. 
These factors, even though divided to input-oriented or efficiency-oriented by Beck-
mann and Fischer (1994), differ from the others in their category and have properties 
corresponding to conditional factors. Thusly Beckmann and Fischer (1994) present five 
principal classes of drivers for R&D entry into host country.  
The first class encompasses drivers related to personnel, know-how and infrastruc-
ture. Input-oriented factors consist of availability of labor, centers of excellence, local 
presence and the conditionality of sufficient infrastructure. Availability of labor, which 
is a factor of first and foremost importance for the success of the R&D mission, is am-
plified by a scarcity of engineers and researchers in the West. Difficulty of attracting 
advanced labor overseas guides companies to centers of excellence, such as public insti-
tutions, research centers and universities as well as private facilities. These centers of 
excellence form local pockets of innovation and provide knowhow and infrastructure. 
Local presence and a recognizable brand increase company's attractiveness as an em-
ployer and facilitate operations in the target country.  
According to Beckmann and Fischer (1994), output drivers are product-oriented fac-
tors, which include the following: local lead users, proximity and access to markets, 
inward learning, supplier and distributor collaborations and brand or local image of the 
company. Market potential i.e. market size and growth is especially paramount in re-
gards to company's interest in placing R&D to a specific country and spending re-
sources for the required product adaptation. Thus their study suggests that in order to be 
competitive, products have to correspond to market and even individual customer needs 
and requirements, especially when introducing a novelty product to the market. The 
scale of required modifications depends on the variability of customer needs and the 
amount of product adaptation needed to modify the existing product into meeting local 
market needs is an output driver (Beckmann and Fischer 1994).  
External factors are government incentives or subventions such as overall tax optimi-
zation schemes, grants, subsidies and other financial incentives available in the host 
country. R&D locations can be highly dependent on the overall tax optimization of a 
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concern. Locally produced R&D may also entitle the company for price incentives. 
From the public perspective, external factors are clearly macro economical tools, but 
financial incentives such as pure cash can be a major factor influencing decision on the 
micro level especially in small companies. This classification to such external drivers is 
a fresh look, not covered by Granstrand, Håkanson and Sjölander (1993) although pre-
sented by Boddewyn (1985), another shared similarity on par with the conditional fac-
tors discussed. In later work Gassmann and von Zedtwitz (1998) also report these exter-
nal factors as part of their classification. 
Efficiency drivers, for instance the potential to build a global 24-hour laboratory, co-
ordination costs and critical laboratory size, play a role as well. Other efficiency drivers 
for example are direct cost advantages extensively discussed in academic literature, 
such as but not limited to the labor costs. (Beckmann and Fischer 1994) However, pre-
vious studies have demonstrated that direct cost advantages rarely have an influence. 
However, in these same studies other cost considerations, such as coordination and 
transfer as well as critical laboratory size. Beckmann and Fischer (1994) state neverthe-
less that acquiring sufficient critical mass in laboratory size can be dependent on direct 
cost advantages. More specifically, R&D unit size has been anticipated on an industry 
dependent way to have an effect on the R&D globalization. Low personnel amount 
combined with restricted resources and standardized costs can create a suboptimal tech-
nical and financial workload. Depending on the facility size, regards to resources and 
personnel, a detrimental over optimal situation can also be created. Cost of coordination 
is a centralization force and negative to any attempt in decentralizing these higher value 
operations, without the huge development in information and communication technolo-
gy (ICT). If the unit's size and functions expand, the communication and coordination 
together with administrative costs become overly proportional to the R&D function, 
which leads to loss of customer focus and flexibility. (Beckmann and Fischer 1994) 
Political and socio-cultural drivers also seem to have a considerable impact in locat-
ing R&D abroad, such factors include: legal requirements, local content rules, technolo-
gy acceptance and public approval. Legal requirements contain safety measures, stand-
ards and other permits from local institutions. When product's applicability to local re-
quirements and standards has to be verified, the legal or socio-cultural framework is 
very important, as the process takes a long time and requires wide open disclosure and 
cooperation with stakeholders. Furthermore, according to Beckmann and Fischer (1994) 
these requirements can be a source of substantial costs. Sometimes product can even be 
subject to local development or production requirements. Local content requirement 
puts pressure on companies to shift their R&D, either as a government requirement or 
due to encouragement from subsidies and free import duties. In typical agreements the 
amount of locally produced value is required to be increased annually. In extreme cases, 
local content requirement may mean government ownership. Beckmann and Fischer 
(1994) note that socio-cultural values, differences and requirements as well as country's 
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development and economic conditions may also provide requirements for product adap-
tation. The local acceptance of a technology or research field as well as the public image 
of a company is important to the continuation of operations in a certain country. Fur-
thermore, funding for research in public institutions is dependent on general opinion.  
Beckmann and Fischer (1994) show how external, efficiency and socio-cultural driv-
ers can become the most important factors even though company's underlying motiva-
tions would be in line with either the input-driven or output-driven factors. This is espe-
cially true in cases where infrastructure or legal considerations prevent any longer term 
involvement in the country even when market, labor or technology motivations would 
exist. Furthermore the external, efficiency and socio-cultural drivers can be the only 
factors that are of interest, when neither market nor advanced R&D resources considera-
tions are present and when the only motivations are cost considerations, financial incen-
tives, legal requirements or political considerations such as trade barriers. These cases 
thus illustrate the legitimacy for offshore outsourcing of R&D in relation to R&D off-
shoring and internationalization of R&D. 
2.3.5 Legal market requirements and stature of cost considerations 
Following the above classification scheme used by Beckmann and Fischer (1994), 
Gassmann and von Zedtwitz (1998) divided factors affecting globalization of R&D 
emerging from their own study, into five corresponding categories: quality of the input 
at the foreign site, quality of expected output, external drivers on R&D globalization 
and factors dealing with the general operating efficiency as well as political and socio-
cultural issues.  
Among the input-oriented factors they list: improvement in information and commu-
nication networks, insufficient home personnel, prevalence of local pocket-of-
innovation, local infrastructure suitability, amount of qualified personnel abroad, ac-
cessing local scientific community and tapping into informal networks (Gassmann and 
von Zedtwitz 1998).  
Similarly, they have grouped factors into output-oriented category: national and legal 
conditions, country-specific cost advantages, local economic and natural advantages, 
improvement of local image, adaptation to local production processes, customer-specific 
development, closeness to lead users, local values as well as market and customer prox-
imity (Gassmann and von Zedtwitz 1998).  
Concerning the external drivers for R&D internationalization, Gassmann and von 
Zedwitz (1998) list acquisition of parent company or a merger, historic reasons, peer 
pressure, tax optimization. Their efficiency-oriented factors are those from management 
literature: improving flexibility through new organization, mass depression in home 
country and reduction of development failure risk. In addition, efficiency-oriented fac-
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tors include also those from rational economic: local critical mass, making use of many 
time zones, lower R&D personnel costs and reduction of development cycle times. Fur-
thermore their efficiency-oriented factors include those from logistic theories, such as: 
closeness to production, marketing, distribution and overcoming logistic barriers.  
In the other hand, political socio-cultural factors are those that have to do with inter-
national relations, political situation and trade regulations: improvement of international 
patenting laws, overcoming protectionist barriers, local social and peaceful labor rela-
tions, local content, home country legal restrictions, low acceptance and subsidies. 
Gassmann and von Zedtwitz (1998) noted that direct cost advantages, such as labor 
costs rarely influence the internationalization of R&D as suggested in their later work 
and other academic literature, although controversially discuss cost in many context and 
present cost considerations. Since they nevertheless list this as both an efficiency-
oriented and an output-oriented R&D globalization factor derived from their research 
and interviews, its significance has to be evident in some cases of R&D globalization. 
What Gassmann and von Zedtwitz (1998) discovered concerning internationalization 
of R&D, is that in some industries national and legal requirements can be as important 
as market considerations. Alas, they also brought into discussion the historical perspec-
tive of a company's involvement in international business as well as the potential effect 
of mergers and acquisitions along with customs and trade barriers. Furthermore, they 
based direct and consequential cost considerations as both an efficiency-oriented and an 
output-oriented R&D globalization factor indicating that on top of R&D offshoring and 
R&D offshore outsourcing, cost factor plays a part also in internationalization of R&D.  
2.3.6 Inherent difference of research and development 
Research activities have been shown to have distinguishable different characteristics 
than development activities (Abetti 1985; Allen 1980; Cleland and King 1983; Cleland 
and Kocaoglu 1981; Cooper 1983; Tornatzky 1983; Twiss 1980; Withey et al. 1983). 
The inherent differences of research and development can be erroneously disregarded 
with the usage of the term R&D. The necessities of science entail different managerial 
problems than those of engineering and development (von Zedtwitz and Gassmann 
2002, 571). Research has been described as technology expansion, usually noted to con-
cern the expansion of scientific knowledge and assessment of its feasibility (Leifer and 
Triscari 1987). Thus technology expansion through research has to do with the in-
ventive process and the expansion of technology base (Leifer and Triscari 1987). De-
velopment contrary has to do with the intent on creation of a new or modified product, 
process or service through the application of technology base to its operational require-
ments (Leifer and Triscari 1987). A generally understood relationship of the R&D tasks 
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is that development is more structured and less varied, whereas research is theoretically 
oriented and widely varied (Leifer and Triscari 1987).  
The objective of research is thus the generation or expansion of knowledge, concept 
testing, creation of prototypes, new component testing, etc. (Leifer and Triscari 1987). It 
is suggested that research or technology expansion process is a set of uncertain and un-
predictable activities taken to reduce technological uncertainty, which tend to proceed in 
an unpredicted non-planned series of phases (Leifer and Triscari 1987).  
The aim of development is geared towards the physical output of new products or 
processes (Allen 1980; Johne 1984). Satisfying operational or customer needs and ful-
filling cost and scheduling constrains are generally considered as the objectives of the 
development process (Leifer and Triscari 1987). Development process is usually a less 
uncertain, more controlled and focused phase aiming for a compromise of the needs of 
the different organizational players and desired objectives (Leifer and Triscari 1987).  
Descriptions attached to research and development on the counts of technology re-
quirements and task complexity is that technology associated with research is more non-
routine than the technology needed for development on a technology requirement con-
tinuum from nonroutine to routine (Perrow 1967; Van de Ven and Delbecq 1976). 
Products utilizing a significant new technology require technological research input pri-
or to product development, and although closely intertwined these processes typically 
require technology transfer between them (Eldred and McGrath 1997a,b).   
As R&D work progresses to being an operational reality that is near production ap-
proval, internal and external special interest groups become more involved and funds 
are required. At this point, external influence on the R&D project grows and the project 
requires more maintainability from higher management. Focusing on the distinction 
between R and D, Leifer and Triscari (1987) therefore argue that development is synon-
ymous with higher amounts of environmental uncertainty compared to research (Leifer 
and Triscari 1987). This result is directly in contradiction with their findings on in-
creased communication requirements for research.  
Another watershed between R and D has to do with interdependency of the project, 
as in the extent to how the project is interrelated to other parts of the organization to 
make its contribution (Leifer and Triscari 1987). Development projects are seen as re-
quiring more coordination, approval and input from other functional parts of the organi-
zation (Leifer and Triscari 1987).This would suggest that on development projects, due 
to higher risks, organizational interrelatedness and lesser knowledge sharing, there is a 
need for more centralization and formalization in the form of location requirements, 
control and management participation than what is associated with research projects. 
Leifer’s and Triscari’s (1987) work reveals that, when analyzing R&D, it is para-
mount that research activities are scrutinized independently as research. Identically de-
velopment should be considered independent from other similar activities. Iansiti (1993) 
goes even further by showing that different research tasks may vary greatly in their con-
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text, requirements and contributions. An example of this is the inherent difference of 
basic research from applied research (Lall 1979). Where the former attempts to explain 
a novelty concept, finding or a theory, the later is geared towards the refinement of the 
former or its applications (Lall 1979). Equivalently Iansiti (1993) explains the continu-
um of different development activities and how those requirements presented for in-
stance by Leifer and Triscari (1987), can differ for distinct research tasks. Thus we 
should also take into account that dissimilar research tasks or dissimilar development 
tasks can differ in nature as much as development varies from research (Iansiti 1993). 
2.3.7 Market and technology in regards to company size and structure of R&D 
As described above the term R&D is not homogenous and, as fundamental differences 
exist for research compared to development (Leifer and Triscari 1987), they are also 
subject to different location drivers. Von Zedtwitz and Gassmann (2002) provided em-
pirical evidence for separation compared to integration of the R&D function. Von Zed-
witz and Gassmann (2002) determine access to local markets and customers as well as 
access to local science and technology as being the principal factors behind locating 
R&D globally. In the light of these two factors, they describe four different trends, 
which aim to capture locations specific advantages separately to both research as well as 
development. Thusly, depending on whether research or development is concentrated 
domestically or decentralized over different countries, they propose four generic re-
search and development globalization types: “national treasure”, “market driven”, 
“technology driven” and “global”.  
When both research and development is concentrated domestically at company's 
home base, this organization of R&D is titled “national treasure” model and is based on 
capitalizing on efficiency advantages of centralization. The model is characterized by 
little internationally dispersed R&D, focus on domestic market, a dominant position in 
design or technology with company's products requiring very little adaptation to foreign 
markets. Thus core R&D function is kept where it is easiest to control. Another im-
portant feature of R&D retention in home country is the ease of achieving minimum 
critical mass, which is the minimum amount of money or number of people required to 
start or sustain an operation or business process (Patel & Pavitt, 1992). In this model 
foreign manufacturing sites and sales organizations are still an important source of in-
formation on new market needs and customer satisfaction (von Zedtwitz and Gassmann, 
2002).  
When, in the other hand, research is more globally dispersed than development activ-
ities, with a deficiency of scientific personnel and talent in the home country as well as 
necessity of access to foreign centers of excellence, the preferential archetype conveyed 
by von Zedtwitz and Gassmann (2002) is the technology-driven model. Research thus 
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attempts to leverage industry spillover, location and market as well as academic compe-
tencies that are available in the chosen region. While development is retained central-
ized by the scale effects from establishment of technology platforms and from the avail-
ability of unique specialized testing equipment, synergy effects from ease of communi-
cation or knowledge sharing (Buckley and Casson 1976; Leifer and Triscari 1987), as 
well as due to efficiency and cost advantages, tendency for strong managerial oversight 
and central control as reported by Leifer and Triscari (1987) and nursing of commercial-
ly valuable assets. Leifer and Triscari (1987) indicate that these effects tend to be less 
associated with research and thus the location specific advantages possibly outweigh the 
centralization forces.  
Market driven model emphasizes domestic research but advocates dispersed devel-
opment. Companies chiefly following the call of the market, are focusing on business 
development, which is centered on customer demands and not led by scientific explora-
tion (von Zedtwitz and Gassmann 2002). According to von Zedtwitz and Gassmann 
(2002), critical mass for research is attained with smaller contributions by keeping it 
home as it is of low significance and the benefits of internal research are constantly put 
into question. The focus is on product development and new business creation with re-
gional market requirements such as codes, standards and customer behavior crucial. 
Highest level of R&D responsible for breakthrough innovations is kept in home loca-
tion, manufacturing R&D responsible for incremental improvements is dispersed ac-
cording to manufacturing sites and field engineering, chiefly associated with local adap-
tation and fulfilment of customer requirements, is handled independently from each 
market area (von Zedtwitz and Gassmann 2002).  
The fourth trend conveyed by von Zedtwitz and Gassmann (2002) is titled global 
R&D and has to do with dispersed research and dispersed development. The corner-
stone of R&D strategy for these companies is the global coordination or R&D through 
integrated R&D networks. Availability of high-quality scientific input such as centers of 
excellence is the dominant location decision criteria for research and development is 
market driven and conforms to local demands, standards and codes. The strategy is for 
the added significantly higher cost of management of R&D of global research to be off-
set by greater innovation. The advantage is that knowledge is readily transferred both 
ways and cross-functionally (citation) thus locally developed science can be utilized or 
adapted quickly worldwide and single development centers may take responsibility of 
the global launch of a product. 
The four different trends explained by von Zedtwitz and Gassmann (2002) illustrate 
how companies engaged in development have different interests and requirements than 
companies engaged in research. Furthermore by categorizing companies to either mar-
ket seeking firms that are in the process of internationalizing their R&D operations or 
into technology, science and R&D resources seeking firms who are offshoring their 
R&D efforts to a more suitable operational environment. Von Zedtwitz and Gassmann 
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(2002) formulate the governance form (Boehe 2008) for companies engaging either in 
offshoring of research or in the internationalization of R&D. Besides, the national treas-
ure model shows how the minimal amount of geographically dispersed R&D can be 
bolstered with R&D offshore outsourcing that is centered on decreasing cost or gaining 
specific capabilities from outside the company. When looking as a continuum and taken 
into their extremes, these four trends can also distinguish between different company 
sizes, from privately owned family companies seeking to expand all the way to MNCs. 
2.3.8 R&D globalization in the context of Peoples Republic of China 
In another classification by Gassmann and Han (2004), again based on the framework of 
Beckmann and Fischer (1994), but not exclusively conforming to their scheme, they 
present classification within the Chinese context. In this classification they merged out-
put and efficiency-oriented motivation factors into performance-oriented motivation 
factors while combining the external and political/social-cultural into business-
ecological motivation factors (Gassmann and Han 2004). 
According to this classification, the performance-oriented motivation factors consist 
of three factors. The first factor they point is comprehensively covered in literature as 
local adaptation or product adaptation to markets. This type of customer and market-
specific development lures companies into establishing R&D operations to host mar-
kets, where products are locally develop specifically for that market. Based on the inter-
views they have conducted, adapting products to the host market is widely seen as basic 
necessity. Secondly, they cite cost advantages as a factor, as the cost of equal size R&D 
facilities in China is roughly only one tenth of that in the West (Li and Zhong 2003). 
Further they have divided cost advantages firstly into cross-country cost differentials, as 
lower wages attract R&D, secondly adapting over-engineered product to Chinese cus-
tomer's lesser requirements. Besides, it's related to preferential policies or financial in-
centives enacted to encourage establishment of foreign R&D, such as corporate tax ex-
emption or duty free importation of R&D equipment. Short R&D cycle time and adap-
tation to local manufacturing processes are clear benefits of localized manufacturing 
R&D. Local manufacturing R&D can also assist in improving the quality,  offerings, 
reduce costs, or increase capabilities of the manufacturing operation (Ambrecht 2002).  
Amongst the input-oriented motivations, the huge potential human resources are of 
great importance for establishing R&D in China. Thus input oriented motivations in-
clude the availability of qualified personnel: firstly those educated in Chinese Universi-
ties and secondly the highly skilled overseas Chinese students returning to China. These 
returning Chinese form a uniquely qualified additional human resources pool, which 
bring experience and knowledge from around the globe. Another side of the input ori-
ented factors are the benefits that can be gained from informal networks and tapping 
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local information sources. Gassmann and Han (2004) also list the High Technology 
Development Zones (HTDZ), which host a large number of universities and scientific 
institutions as well as start-up firms, foreign-capital firms and large-scale local firms as 
an important input factor. These HTDZs are another factor that has already been report-
ed in the literature and previously has been described as centers of excellence.  
Business-ecological motivation factors, which combine those described as external 
and political/social-cultural factors, have to do with the macroeconomic conditions, 
trends and policies of the host country. Governmental policy is the first reported factor 
in this category, which is nevertheless related to two other factors that are availability of 
labor and financial incentives. These governmental policies help to attract highly edu-
cated returning Chinese students and professionals back from overseas and provide fi-
nancial motivations for R&D investment (von Zedtwitz 2004). Another factor is the 
continuing economic growth and the overwhelming market size, which has strategic 
importance (Gassmann and Han 2004). Another macro economical factor they list is the 
possible mid- and long-term competitive advantages of the market, which great lots of 
peer pressure inside an industry. Together these two factors make up the reported mar-
ket dependent justification for the added costs of internationalization of R&D in hopes 
of future market gains. 
What the classification by Gassman and Han (2004) offers, is the relevance of major-
ity of factors in the Chinese context, the magnitude of these factors along with the 
unique ascendancy of the Chinese government. Engineering man-hour costs in China 
are only one tenth of that in the triad region (Li and Zhong 2003). In 2002, 2.5 million 
students graduated from the country’s 3000 universities and colleges including 66,000 
M.A.’s and 14,000 PhD's, ranking third; USA (40,000) and Germany (30,000) (MOE 
PRC 2003a). In addition to the domestic graduates, more than 580,000 Chinese students 
studied abroad between 1978 and 2002, with 150,000 returning (MOE PRC 2003b). 
Chinese policy makers attract R&D to special economic High Technology Development 
Zones (HTDZ), which have resulted in 276 international R&D alliances between 1995 
and 2000, along with lion’s share of global FDI in 2012 (18%) 253 billion USD. Given 
the power of Chinese government, they pursue ‘technology for market’ policy, playing 




2.4 Field of Study 
2.4.1 The new paradigm of innovation and higher value activities in China 
Historically Western companies have seen China as an industrial base and brought 
technologies to China only for the purposes of implementing them in local manufactur-
ing joint ventures. Recently as a part of the new paradigm companies have started to 
view China as a potential destination for research and development. Kuemmerle (1999) 
points that it seems likely that populous Asian countries, such as India and China will 
increasingly attract HBE-type facilities. In addition to the large market these countries 
posses, they are also a home to a number of elite institutions of technical and scientific 
learning, which preselect the top qualified human resources, providing to multinational 
firms an easy access to advanced labor and top talent (Kuemmerle 1999). 
To endorse the new paradigm, China has risen to rank as the third most R&D inten-
sive country in the world, according to a (2003) OECD report. In 2001 total R&D 
spending by USA totalled US$282 billion, while that from Japan was US$104 billion, 
while China's R&D spending reached nearly US$60 billion, third behind US and Japan, 
but  ahead of Germany's US$56 billion. Similarly in 2011, China surpassed United 
States and Japan by becoming the world's top patent filer, with its continued drive for  
innovation and improvement on its track record of intellectual property rights. As stated 
by a Thomson Reuters report, published patent applications from China are on track to 
total nearly 500,000 in 2015, a considerably more than the close to 400,000 from the 
United States or that of Japan amounting close to 300,000 (Thomson Reuters 2011). 
Data from Thomson Reuters Derwent World Patents Index shows that there is an 16.7 
percent average annual increase in China's patent office's published patent applications, 
which have risen from 171,000 in 2006 to nearly 314,000 in 2010, (Thomson Reuters, 
patents 2011). 
In his 2004 article von Zedtwitz identified 199 distinct foreign R&D centres estab-
lished or being formed in China in early 2004, almost a quarter of the foreign R&D la-
boratories in USA. This has happened according to von Zedtwitz (2004) in a relative 
short period of time and during a time of global economic uncertainty and degreased 
R&D spending. Taking into consideration the huge numbers of college graduates and 
the continued demand by foreign companies it is expected that this development will 
continue as depicted by Gassman and Han (2004).  
Von Zedtwitz (2004) also reports on the locations of foreign R&D labs in China, 
with an overwhelming majority, 89% of all foreign R&D laboratories, are concentrated 
along a relative short strip of land between Beijing and Shanghai. He further reports that 
American companies tend to be located in Beijing while European firms go to Shang-
hai. Gassman and Han (2004) tell how Schindler in the late nineties established an R&D 
centre in Shanghai based on its market's sophistication and growth, a reputation that 
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Shanghai continues to enjoy among technology intensive companies. Beijing also tends 
to be the preferred R&D site for companies in the telecommunications and electronics 
industry, while Shanghai host mainly food, pharmaceutical and engineering companies. 
(von Zedtwitz 2004). Industry white papers also note that Shanghai has a strong medical 
science tradition and is today the centre of one of China's most powerful clusters of 
medical research players. Numerous international pharmaceutical groups and well-
reputed universities operate out of Shanghai. 
2.4.2 Gobalization of pharmaceutical R&D: the industry and China 
Differences among industries are significant for R&D globalization (Macher and 
Mowery 2008). The normal supply and demand market environment for pharmaceuti-
cals along with healthcare marketplace is distorted due to their intrinsic characteristics 
(Depret and Hamdouch 2000; Hamdouch and Depret 2001). The interests of pharma-
ceutical companies, public, patients and the healthcare system due frequently overlap 
but not always. This is reflected in the conflict between a continuous need for new vac-
cinations and medicines against increased regulatory control, price bargaining pressure 
from governmental healthcare institutions, greater amount of akternatives in drugs 
and/or treatment options, while the complexity and thus risks of modern drug molecules 
are substantially greater (Hamdouch and He 2009). 
Pharmaceutical industry has continuously shown high-levels of open innovation with 
distant partners (OECD, 2008). High R&D investment intensity on pharmaceutical sec-
tor is seem to be closely linked to its competitive advantage which nevertheless is de-
pendent on more systematic and dynamic factors (Hamdouch and He 2009). Neverthe-
less, severe financial problems can arise when annual R&D cost considerably exceeds 
the yearly cash flow or a company has R&D intensity equivalent to 10% of turnover. In 
many research intensive sectors technological development has leas to a "R&D arms 
race" (von Braun 1995). The research-intensive pharmaceutical firms are an rare excep-
tions to this as their shareholders see long term investment as industry characteristic and 
except high values from extremely high R&D investment ratios (Gerybadze and Reger 
1999). This market truce has been shaken right along with the declining returns of in-
vestment in the pharma sector (Paul et al. 2010).  
Productivity in pharmaceutical R&D has been declining for an extended period of 
time and many complex reasons has been attributed as its cause (Paul et al. 2010). The 
trend does not seem to subside as more than US$209 billion in annual drug sales at risk 
due to key patent expirations in 2010-2014. The patent expirations are estimated to re-
sult in $113 billion of sales being lost to generic substitution (Paul et al. 2010). Causes 
for increased costs in the pharmaceutical industry can be divided into external causes, 
such as growing regulatory conservatism and lack of international regulatory harmoni-
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sation, and internal causes of R&D, such as lack of managerial oversight on cost-
containment and a culture of suboptimal use of resources (Ruffolo 2006). The pharma-
ceutical industry is one of the most regulated industries in the world, and this is the 
source of external causes for decline in R&D productivity. The quality standard upheld 
from the pharmaceutical industry continues to increase, with questionable benefit to 
public safety or patient health with clear relations to government. 
Cheap labor has been the main drivers of manufacturing in China. Now that the Chi-
nese wage costs are rising sharply, the yuan currency is gaining against the U.S. dollar, 
and transport costs are increasing, the advantages traditionally associated with PRC 
against the U.S. and other traditional countries for conducting R&D have narrowed a bit 
in recent years (Thomson Reuters, manufacturing 2011). The Fiscal consolidation on 
the pharmaceutical industry reported by von Braun (1995), Gerybadze and Reger (1999) 
and Paul et al. (2010) requires a stable cost situation, without wage increases.  
Alas, the Chinese government as well as local or regional governments have recently 
been offsetting these rising costs by providing generous subsidies for the establishment 
of foreign R&D activities, thus renewing tpartly he cost advantage's for doing R&D in 
China. These incentives include grants given to foreign R&D centres in China that can 
import certain equipment duty free. Chinese government and more clearly the local mu-
nicipal governments attract R&D investment by providing advanced R&D infrastruc-
ture, togehter with space, high-tech facilities and financial incentives (Gassman and Han 
2004). Such financal incentives include up to three year tax levies for the establishment 
of a R&D centre. This is supplemented with  a 50% tax discount for additional three 
years from the third year onwards. The incentive can further be continued from the sev-
enth year onwards with a 15% discount, along with other tax incentives (Gassman and 
Han 2004). Direct government subsidies, price incentives and tax exemptions play a 
major role in the pharmaceutical industry (Beckmann and Fischer 1994). This case is 
highlighted in China with its Twelfth Five-Year Guideline that is centred on China's 
push for more technology intensive sectors that includes a special mention on pharma-
ceuticals and biotechnology (Xinhua 2010; KPMG China 2011). 
2.5 Pharmaceutical Drug Discovery 
Pharmaceutical product development pipeline covers the overwhelming majority of 
pharmaceutical industry's research and development spending and activities. The devel-
opment pipeline is a generic reference to the different parts of pharmaceutical drug dis-
covery process. The purpose of drug discovery is to advance a product candidate 
through progressively later stages of R&D to clinical phases and eventually commer-
cialization (Moos 2001). Its ultimate goal is the development of novel or improved high 
quality pharmaceutical products in a cost-effectively, with a continued support for prod-
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ucts throughout their life cycle (Gad 2005, 1). The process is fairly vested due to regula-
tions, quality control issues (Gad 2005, 337, 343, 346), tradition and tendency for best 
recognized procedures (Gad 2005, 560). Its different parts are in general as depicted in 
figure 2: prediscovery, discovery, pharmaceutical formulation and analysis, scale-up 
and process development, pre-clinical trials and toxicology as well as early- and late 
stage clinical trials (Gad 2005, 2). 
2.5.1 Prediscovery 
The prediscovery stage has all to do with understanding the true pathogenesis of the 
disease as before any discovery for potential new medicine can be done the underlying 
causes of the condition has to be unraveled (Gad 2005, 22; Cayen 2010,  8). In modern 
prediscovery stage this has to do with understanding how the genes that encode proteins 
are altered if applicable, how that or other factors alone or together with a genetic altera-
tion affects the proteins they encode, how those proteins interact with each other in liv-
ing cells, how those cells affect the tissue they comprise and finally, which physiologi-
cal conditions result to the patient from the affected tissue (Matsoukas and Mavro-
moustakos 2002, Ⅴ, 229, 236, 241, 251, 258, 267, 272, 279, 294). Thus the genetic, 
proteomic, cytological, histological and anatomical knowledge derived from the patient 
forms the basis of finding a new treatment (Cayen 2010, 3, 5). After sufficient under-
standing of the underlying causes of the disease is established the prediscovery stage 
continues with target identification and target validation. 
Target identification requires selection of a target molecule for a potential medicine 
from the chemical cascade of molecular interactions involved in the disease, i.e. choos-
ing a biochemical mechanism involved in a disease condition (Gad 2005, 15, 33; Cayen 
2010, 8). A critical feature for the molecule from a chemical pathway involved in the 
disease that is selected as a target for a medicine is that it has to potentially interact with 
and be affected by a drug molecule (Gad 2005, 33–34; Cayen 2010, 5, 8). This is either 
by making the molecule more active or less active, or changing its activity all together 
in the chemical cascade (Cayen 2010, 5, 8). Generally a target is a single molecule, such 
as a gene or protein, incrementally involved in a particular disease Cayen 2010, 8–9; 
Vallance and Levick 2007). Target molecule is often responsible either for a molecular 
imbalance by causing an important protein from being produced, by leading to overpro-
duction of proteins or has altered function due to erroneous protein splicing or folding. 
The purpose of target validation is to conform that the target molecule is actually in-
volved in the disease and that its function can be affected with a drug molecule whose 
pharmacokinetic properties and bioavailability are sufficient (Gad 2005, 3, 34). The 
target's relevance in the disease is studied through utilization of the disease's animal 
models and experiments in living cells (Gad 2005, 3). Target identification is governed 
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by the early project portfolio management that attempts to strike a balance between the 
requirements of the disease, the potential to turn the target into a medicine compound 
and business considerations (Gad 2005, 3, 47). Target identification has seen a steady 
increase in importance (Shayne 2005, 1). 
The underlying hypotheses of the prediscovery stage on toxicology and clinical ef-
fectiveness form the basis for the future success of the resulting clinical trials and drug 
launch and is thus extremely important that the best scientific knowledge in the world is 
behind any decisions to pursue drug discovery on certain type of disease or its certain 
affecting cause (Gad 2005, 2–3). All drugs on the market today are estimated to target 
only 500 biomolecules, and although major pharmaceutical companies change their 
target portfolio they still all focus on the same major classes of targets (Bleicher et al. 
2003). With all the companies focusing on a limited number of targets (Gad 2005, 14; 
Harvey 2001) there is a competition for brainpower in the form of best scientific minds 
and experts on these household targets (Lewin, et al. 2009). Furthermore the number of 
highly advanced centers of excellence is particularly limited in the pharmaceutical in-
dustry (Kuemmerle 1999). Thus prediscovery stage R&D can be seen as dependent on 
centers of excellence and a global network of R&D cooperation with renowned special-
ist. These specialists and the centers of excellence are usually dependant on public fi-
nancing, thus their focus and research in general is shaped by the national innovation 
system in the country. Reception of a grant is a recognition of the importance of the 
research and the researchers but also a way to shape direction of the research (Benner 
and Sandström, 2000). Successful research organizations in the academic field are those 
groups which can attract funding, prestige and recognition (Benner and Sandström, 
2000). Thus the influencing factors most strongly associated with prediscovery are the 
effect of national innovation systems, centers of excellence and financial incentives 
such as research grants.  
2.5.2 Discovery  
The next stage of drug development is discovery (Gad 2005, 1). Its objective is to find a 
promising molecule, called a lead compound that may act on the target and thus alter the 
course of the disease (Gad 2005, 3, 12, 22). Until recently, majority of the lead com-
pounds were found in nature from sources such as bacteria in soil, mold and plants (Gad 
2005, 12, 14, 560). Although nature still provides useful substances (Newmann et al. 
2000) thanks to scientific advances molecules can now be synthesized de novo from 
elements and computer modeling can be used to predict the different reactions of the 
molecule. High-throughput screening is the most utilized way in finding lead com-
pounds (Gad 2005, 560). Through robotics and advanced computing it allows testing of 
hundreds of thousands of molecules with suitable properties, called hit-molecules (Gad 
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2005, 50–52), against the target molecule to yield a number of lead molecules that 
would have pharmaceutical potential (Gad 2005, 560).  
The first part of discovery stage is hit-to-lead where molecules or libraries of mole-
cules are selected for high-throughput screening because they posses’ properties needed 
in a new drug or have properties already found in a known drug molecule (Gad 2005, 
560–561, ). To yield a lead compound these hit-molecules are tested against the target 
to select those with a confirmable effect on the target molecule (Gad 2005, 33–34, 36). 
Compounds selected from the hit-to-lead part go through early safety tests in lead dis-
covery that provide an initial assessment of the absorption, distribution, metabolism, 
excretion and toxicological properties of the lead compound (Gad 2005, 458–459).  
In lead prioritization part of discovery the properties of various lead compounds are 
compared in order to select a lead compound or lead compounds with the greatest po-
tential to be developed into effective and safe medicines (Gad 2005, 43, 45). This is 
often combined with the lead optimization part where the lead compounds selected from 
the initial screening are altered by changing their structure for the purpose of making 
them more effective and safe (Gad 2005, 47, 459). Making and testing hundreds of dif-
ferent variations called analogues of each original selected lead compound achieves this 
(Gad 2005, 44, 53–54). Already at this early stage the lead compounds will be consid-
ered through the nature of its formula and the inactive ingredients needed, its delivery 
mechanism as well as its potential for large-scale manufacturing in conjunction with its 
effectiveness and safety resulting in an active pharmaceutical ingredient (API) (Gad 
2005, 55).  
The discovery stage has seen a massive growth in screening compound numbers in 
past 15–20 years with a corresponding increase in costs without any increase in success-
fully launched new medicines (Bleicher et al. 2003). The early discovery phase is the 
most labor intensive part of drug discovery, with fairly standardized procedures (Paul et 
al. 2010) and thus a good target for offshoring R&D due to savings on labor cost and 
availability of large R&D labor pool if stringent quality requirements can be met. The 
influencing factors that play the greatest part in discovery are: cross-country cost differ-
entials and availability of labor, although with some basic infrastructure requirements. 
2.5.3 Preclinical 
Preclinical stage is preceded by characterization of the molecule, pharmaceutical for-
mulation and process development (Gad 2005, 458). Each of the selected APIs or drug 
candidates is then extensively characterized to determine the molecule’s shape, size, 
stability, strengths and weaknesses (Gad 2005, 48–55), preferred functional conditions, 
toxicity, bioactivity, bioavailability and underlying mechanism of action (Gad 2005, 55, 
459). Candidate molecules are then formulated from chemicals into a medicinal format 
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such as a capsule, aerosol or injection together with the development of chemicals man-
ufacturing process to reproduce the medical format on a commercial scale (Gad 2005, 
469–481,).  
The main goal of preclinical stage is to determine APIs ultimate safety profile 
through toxicology testing and prepare an Investigative New Drug (IND) application 
(Gad 2005, 2–3, 56, 459). Preclinical toxicology testing is a critical feature of the drug 
and thus thoroughly scrutinized by regulatory entities (Gad 2005, 55–56, 458–459). The 
main parts of preclinical toxicology testing are: acute toxicology studies that investigate 
the effect of one or more dose over a period of up to 24 hours to determine toxic dose 
levels, repeated dose studies that are looking into the effect of prolonged exposure to the 
drug, genetic toxicity studies assess the likelihood of compound being mutagenic or 
carcinogenic, reproductive toxicity studies evaluate drug's effect on fertility, embryonic 
and post-natal development, whereas toxicokinetic studies examine the effects of toxic 
doses and address drug’s clinical safety margins (Gad 2005, 56–57, 468–469, 476–477, 
478–481; reference56). Numerous guidelines such as those from FDA and ICH govern 
toxicology studies, which are required for filing an IND application (Gad 2005, 56). 
The application includes preclinical trials results and a characterization of API's (Gad 
2005, 56, 459). The influencing factors chiefly involved in preclinical stage are: local 
science and technology, new technology output, local requirements, socio-cultural val-
ues, local technology acceptance and quality control risks. 
2.5.4 Clinical trials 
Clinical trials are planned to an extent during preclinical phase studies, which should be 
designed to support the clinical trials (Cayen 2010, 423, 425). Generally clinical trials 
are designed to be held in three phases or in four phases when there is a requirement for 
aftermarket approval trials or licensing (Kerr et al. 2008, 9). Phase I clinical trials titled 
human pharmacology studies are the first instance where a drug can be tested on a hu-
man being; they can be begun after IND filing if the study is not but on hold (Cayen 
2010,  423–424; Kerr et al. 2008, 9–10). Phase I trials are closely monitored small-scale 
studies whose main goal is to discover if the drug is safe for humans but also to evaluate 
whether it causes side-effects and whether it has the desired effect (Cayen 2010, 423, 
429, 441–443; Kerr et al. 2008, 10–12). They are used to evaluate pharmacokinetic pa-
rameters and tolerance in healthy adult volunteers, through single dose studies, dose 
escalation studies and short-term repeated dose studies (Cayen 2010, 427–438, 446–
448).  
Phase II clinical trials, known as therapeutic exploratory studies, are also small-scale 
trials but their purpose is to evaluate drug's preliminary efficacy and side-effect profile 
in 100 to 250 patients with the disease or condition under study (Cayen 2010,  449–450, 
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Kerr et al. 2008, 9–10). Phase II trials include further safety and pharmacology studies 
on top of those done in vivo, on living cells and in vitro, on the glass during preclinical 
stage (Cayen 2010, 450–451). Phase II clinical trials are done in preparation to larger 
phase III trials and are concerned with the short-term side effects and risks associated 
with the drug, whether the mechanism of action is the intended and does the drug have a 
positive impact on the condition (Kerr et al. 2008, 9–10, 13–14).  
Therapeutic confirmatory trials or phase III clinical trials are large-scale clinical tri-
als with 1,000–5,000 patients that test the safety and efficacy of the treatment in large 
patient population (Kerr et al. 2008, 10–11, 14–15). Results of the phase III are key in 
determining the overall safety of the drug and whether it can be given approval (Kerr et 
al. 2008, 10–11, 14–15). Preparations to applying for the Biologics License Application 
(BLA) or the New Drug Application (NDA) are started already when phase III trials are 
still held but applying requires them to be concluded. Phase III trials are the costliest 
and longest stage in pharmaceutical drug discovery and development, making up the 
bulk of the cost. Phase III trials usually involve a number of sites all over the world, 
presenting a monumental challenge to managing and coordinating all the sites.  
Phase IV clinical trials are usually also large studies, which may be conducted after a 
medical intervention has been licensed for use and are sometimes required as a condi-
tion of licensing a new treatment (Kerr et al. 2008, 16). Phase IV trials may aim to de-
fine the treatment efficacy in a broad patient population, together with factors such as 
quality of life and the frequency of acute side-effects (Kerr et al. 2008, 16). They are 
also used to affirm new indications as well as to assess the cost effectiveness and impli-
cations of the intervention while comparing treatments' clinical advantages against ei-
ther the standard of care or an investigational medicine (Kerr et al. 2008, 16). 
Interest in participation on clinical trials from patients in Western world is low and 
many patients make for bad test subjects as they use a number of medications that com-
plicate the trials, hence today pharmaceutical companies involve patients from a number 
of countries to participate in their trials (Shah 2003). Clinical trials are often held in 
developing countries where oversight is lax and the number of patients is vast (Shah 
2003). The case in China is nowadays different with strict guidelines on the ethical 
codes of conduct for test but the potential number of patients is still truly vast. For the 
conduct of the trial, it is a huge benefit when one or few hospitals have access to a suffi-
cient number of patients for the conduct of the trial with a fraction of medical costs. The 
case is made complicated by government regulations, such as those applied by the Chi-
nese government and Chinese State Food and Drug Administration CFDA (CFDA 
2012; China Pharmacopoeia Committee 2005), which may force companies to conduct 
R&D, such as the replication of studies for pharmaceutical registration (Boddewyn 
1985). Market access, local and market requirements, customer information as well as 
the local advantage of sizeable patient pool and operating efficiency are factors influ-
encing clinical phase drug discovery with greatest risk stemming from inadequate 
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healthcare, hospital or other infrastructure as well as governmental decision making in 
intellectual property protection and market approval. 
2.5.5 Pharmaceutical R&D value chain 
Outsourcing some activities has always been a common practice in the pharmaceutical 
industry (Crossley 2004). At first roughly about 50 years ago, outsourcing consisted 
mostly of marketing (Crossley 2004). This was followed after 10 years by parts of for-
mulation such as medicinal chemistry and toxicology testing when in another 10 years 
most of the development processes and registration duties were outsourced (Crossley 
2004). Discovery stage and especially hit to lead and lead optimization were the only 
parts hardly touched by outsourcing but it has become a more common practice as well 
after some years (Hätönen and Eriksson 2008; Crossley 2004). This process has many 
similarities to that of the internationalization of R&D in general (Ronstadt 1977). Also 
those parts of drug development that were first outsourced in the country of origin are 
also the same parts that seem to have been targets for the different organizational forms 
of globalization of R&D activities and much for the same reasons (Crossley 2004).  
 
Figure 1. Different phases of drug development, their position in the value chain and 
relevant forms of sourcing agreements  
Thus it is the drug development stage to be globalized itself that is one of the im-
portant factors in the decision. The span of R&D globalization in general, value chain 
activities of drug discovery and relevant sourcing agreements are presented in figure 1. 
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2.6 Initial Framework  
This research is based on the conceptual understanding on the globalization of R&D 
derived from a review of contemporary literary on the subject. The general globalization 
of R&D activities has been researched from the point of view of centralization versus 
decentralization, in-house execution versus outsourcing as well as through its dispersion 
globally. This literature review is presented in detail in chapter 2. The literature review 
granted the author some assumptions on R&D globalization, which are depicted in the 
initial framework in figure 2.  
Many factors affecting the R&D globalization process have been identified but none 
of them can sufficiently alone explain why companies partake in this global globaliza-
tion of R&D.  It is assumed in this research that firms pursue globalization of pharma-
ceutical R&D because they attempt to benefit from a single or a number of influencing 
factors related to the geographical globalization of R&D activities, as firms seek to ex-
ploit firm-specific capabilities in foreign environments (Kuemmerle 1999).  
These factors affect together on a macroeconomic level, such as in a case of a coun-
try or an industry. A similar assumption is that on a firm level some influencing factors 
on R&D globalization are important to some firms when others seek other gains. As 
companies evaluate different options on exploiting these factors (Dunning 1958; Dun-
ning 1995; Hymer 1976), it follows that pharmaceutical R&D globalization in a firm 
may be pursued through different forms of R&D globalization. These R&D globaliza-
tion governance forms are: R&D offshore outsourcing, R&D offshoring or R&D inter-
nationalization. Academic literature on globalization of R&D activities explains how 
the concepts of R&D offshore outsourcing, R&D offshoring and the evolutionary inter-
nationalization of R&D process differ from each other. Based on these differences, the 
influencing factors on globalization of R&D have been associated with the different 
governance forms of overseas R&D globalization (Boehe 2008). Further assumption is 
that depending on what factors are of interest to the firm it should employ an R&D 
globalization mode suitable for the factors it wants to profit from. Depending on the 
firm's current situation and its future needs, it might prefer one of these three govern-
ance forms over the other two (Kuemmerle 1999). 
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Figure 2. Initial framework on the distribution of influencing factors according to R&D 
globalization governance form and pharmaceutical drug discovery. 
First decisions a company faces is whether to set up its own overseas subsidiary or 
engaging in some form of sourcing arrangements (Kuemmerle 1999). Offshore out-
sourcing and offshoring, although differently motivated, are both driven by cost reduc-
tion to some degree (Bardhan 2006). Nevertheless, as an only motivation, cross country 
cost differentials is only a clumsy way for cost cutting (Bardhan 2006). While cost is an 
important influencing factor, offshore outsourcing and offshoring are driven by other 
factors as well. R&D offshore outsourcing attempts to shift early stage financial risk 
associated with R&D by accessing external talent whose need is sporadic as a cost re-
duction (Bardhan 2006). Nevertheless it is chiefly a way to ensure access to best talent 
and knowhow of researchers from diverse disciplines (Sen and Rubinstein 1989). Rivoli 
and Salorio (1996) show that the decision between in-house R&D and contractual 
agreements should not be based only on the direct benefits but evaluate the long term 
potentials. Other factors encourage firms to choose R&D offshoring to own subsidiaries 
or research centers instead of offshore outsourcing (Ito et al. 2007). Factors affecting 
R&D offshoring have to do with government incentives (Hu 2007), previously off-
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shored production (De Meyer and Mizushima 1989; Pearce 1989) and knowledge seek-
ing activities (Ito et al. 2007). Knowledge is seen here in the form of regional require-
ments and on the need for product adaptation together with local market knowledge and 
country intelligence, which all affect firm’s inclination to offshore R&D to its own 
overseas subsidiaries (Bardhan 2006). Internationalization of R&D activities follows an 
evolutionary path (Ronstadt 1977). It has been portrayed as a gradual exploitation of 
location specific advantages in technology intensive companies (von Zedtwitz and 
Gassmann 2004). Access to markets and access to local science and technology have 
been proposed as the major driving forces behind this development (von Zedtwitz and 
Gassmann 2002). Nevertheless, these driving forces are actually a combination of many 
influencing factors previously identified in literature, which individually or together 
provide motivation for firms to engage in internationalization of R&D. Although cost 
considerations play a role in R&D internationalization as well, the value generating fac-
tors appear to be driving the internationalization more than static cost considerations 
(von Zedtwitz and Gassmann 2002).  
Depending on the tasks, the same factor affects firm’s decision to globalize R&D dif-
ferently (Ito et al. 2007). Separation of R&D to whether it is development or research 
that is globalized has been shown to affect the process (von Zedtwitz and Gassmann 
2002). Different development tasks can vary from other development tasks (Iansiti 
1993). Similarly, different research tasks may alternate such as basic research from ap-
plied research (Iansiti 1993). These can differ in nature as much as development varies 
from research (Iansiti 1993). Furthermore, depending on a firm and its strategic goals, a 
number of factors affect in a company specific way influencing the R&D globalization 
process (Kuemmerle 1999). Thus, the actual R&D function to be globalized, should be 
also taken into consideration as an influencing factor. It is argued in this paper that in 
the case of pharmaceutical R&D this separation can be viewed as separated on the lines 
of different stages of pharmaceutical product development. Thus this research assumes 
that the globalization of pharmaceutical R&D is dependent on the financial, scientific, 





3.1 Research Approach  
From the conceptual understanding derived from the academic literature on globaliza-
tion of R&D could be understood that the phenomenon had received lot of both aca-
demic as well as industry attention and was extensively studied. Nevertheless a huge 
ideological difference could be observed on whether this process was driven by pure-
ly/partly by cost considerations or whether other influencing factors such as access to 
key growth market, large talent pool, sourcing of top talent, centers of excellence, glob-
al and asynchronous R&D organization, availability of flexible, cost effective, sophisti-
cated CROs' and favourable investment environment were more important driving forc-
es. Similarly a rift existed in whether this was a process of internationalization of R&D 
driven by changes in the world’s economic landscape, which puts accessing markets in 
the emerging countries as the most important strategic goal, together with accessing 
technological excellence and knowledge in these locations or is this an extension of the 
off-shoring and offshore outsourcing practices already prevalent in other business func-
tions. 
Many researchers had already described different motivations as factors affecting 
R&D globalization and some researchers have made an effort to outline the characteris-
tics of foreign R&D activities in China (Xue and Wang 2001; Li and Zhong 2003). This 
research is conducted to explore the R&D globalization governance forms for pharma-
ceutical companies in China and on, which factors they can capitalize when undertaking 
such an endeavour. The empirical analysis takes into account all three governance forms 
of R&D globalization. Thus the author attempted to design a study that would clarify 
the issue in the case of pharmaceutical industry on the conditions of PRC by disclosing 
the prevalent industry opinions and understanding. 
To answer the gap left in literature there was a need to use the process of deduction, 
which is a method by which researcher attains reasoned confirmation of existing theo-
ries, to dismiss/conclude on the understanding of the phenomenon in existing literature 
(Burney 2008). By contrast induction is used to arrive to conclusions from an observed 
phenomenon by testing hypotheses and through pattern-recognition (Burney 2008). To 
reach an understanding of the phenomenon and to offer in the context of China a coun-
try spesific and pharmaceutical industry specific framework, the author used a mixture 
of deduction-induction method. The findings already presented in the existing academic 
literature were affirmed based on the empirical research through the process of deduc-
tion, which bestowed reasonable confirmation of existing theories. A new framework 
was proposed by the author through the process of induction based on he observed phe-
nomenon by testing hypotheses and via pattern-recognition. This research was ap-
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proached through critical rationalism realizing that the researcher has made hypotheses 
based on conceptual understanding derived from academic literature and holding theo-
ries presented in the literature as premise against the real world (Popper 1972). And thus 
leading to research conclusions that precognitions and hypotheses presented have either 
gained corroboration or are refuted and knowledge is accumulated by conjectures and 
refutations (Popper 1972). 
3.2 Research Method  
As the research on the phenomenon was based on opinions and understandings, it had to 
be seen as resulting from choices made by humans or groups of people based on analy-
sis of individuals or groups of individuals and in that case to be subjective. In this way it 
was presumed that people value same things as well as different things in dissimilar 
ways. Here the author take into account the questions of reality and constructed reality 
as a social sciences problem "what is real" by analyzing also the potential bias of these 
individuals or groups of individuals. Thus qualitative research approach, that emphasiz-
es subjective view, was needed to gain a deep understanding of the phenomenon as seen 
and understood by those who shaped it. 
Qualitative research is always research of the human world in its social context as 
opposed to quantitative research that can be applied to both to the human world as well 
as to natural sciences, and which is suitable to any- and everything that can be measured 
and quantified. Qualitative research by its definition is a research approach, which 
thrives to scientifically answer questions by using predefined rules and steps to solve it 
together with collecting evidence leading to findings and conclusions not determined in 
advance and yielding results applicable beyond the borders of the research settings 
(Mack, Woodsong, MacQueen, Guest and Namey 2005, 1). 
Taking into account this papers exploratory nature, the research is based chiefly on 
interviews with pharmaceutical managers, directors and other professionals with previ-
ous experience in China, together with knowledge freely available from Internet sites 
and official Chinese publications. In the early stages of research, the qualitative  inter-
view method is widely considered to be appropriate in navigate unclear boundaries be-
tween and the context and the phenomenon. This is especially true in cases where con-
temporary events are examined in the research question, and when only a minuscule 
amount or no control is expected over behavioural events. 
Qualitative study in this paper generally relies on in-depth expert interviews as the 
primary data source and validating results with secondary data such as company press 
releases and internet research. In 2012, eight interviews have been conducted for this 
study with senior pharmaceutical managers and other similar professionals working on 
pharmaceutical R&D activities in China. The eight interviews conducted represented 
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knowledge from seven (Pfizer, Johnsson&Johnsson, GlaxoSmithKline, Merck, Bayer, 
Eli Lilly, Novartis) of the twelve major pharmaceutical companies of the world. All the 
companies that the interviewees worked or had worked in china were based in Western 
countries, and each had a significant and traceable history in China.  
3.3 Research Settings 
The basic unit to be analyzed in this research is comprised of the understanding of the 
phenomenon by key personnel working in International pharmaceutical companies that 
have average R&D intensity on the company level or at minimum on the business level 
equal or higher than 10%. Choosing this company inclusion criteria in the research ena-
bles the scrutiny of R&D as independent from other functions of the company and is a 
criteria used in other studies on the field (Gerybadze and Reger 1999), which validates 
comparisons. The basic unit of research is further divided into their understanding of the 
phenomenon on the level of individual phases of pharmaceutical drug development of 
the above-mentioned companies. The key personnel selected for the interviews were at 
least in middle management positions to ensure sufficient knowledge of the subject. 
Preferably the interviewees were selected as those associated with management of re-
search and development, strategic management or from management of sales and mar-
keting if sufficiently knowledgeable on the subject of pharmaceutical R&D. 
The geographical area for this research is chosen based on literary findings, which 
indicate that the locations of foreign R&D labs in China, with an overwhelming majori-
ty 89% of all foreign R&D laboratories, are concentrated along a relative short strip of 
land between Beijing and Shanghai (von Zedtwitz 2004). Von Zedtwitz (2004) also 
reports that Shanghai hosts the majority of companies in the food, pharmaceutical and 
engineering industries, while Beijing tends to be the preferred R&D site for companies 
in telecommunications and electronics industries but also hosts pharmaceutical firms. 
The research was conducted by the author between September 2011 and May 2012 in 
China, with majority of the study and interviews taking place in Shanghai notwithstand-
ing an almost two month research trip to Beijing, were three interviews were agreed and 
executed. Part of the research in Beijing included a pharmaceutical conference and a 
social event, which both the author attended. The author also collected information on 
the pharmaceutical industry in China during a shorter research excursion to Hainan, 
where one interview was conducted. While in Shanghai the author participated in two 
conferences or seminars and on a university lead event. The research was conducted 
solely with the resources and networks of the author, notwithstanding substantial assis-
tance from Chinese and foreign friends or acquaintances, as well as invitations and in-
troductions from the heads of Finnpro in Shanghai and the Fudan Nordic centre. 
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3.4 Data Collection 
In this study, the author has generally relied on in-depth expert interviews as the prima-
ry data source. In addition, secondary data has also been collected to complement the 
primary data. The secondary data includes official Chinese publications, company press 
releases, and information available over the internet. Data derived in such a way affects 
the characteristic of knowledge acquired by scientifically analyzing the underlining 
phenomenon through explaining and predicting it via actions in social reality by search-
ing for regularities and causal relationships among the factors of the phenomenon, as is 
described by the positivistic nature of knowledge (Pitkäranta 2010). 
The reason behind selecting ‘interviews’ as the primary data collection method is 
that interviews are an established and often used way of gathering research material and 
conducting qualitative research (Eskola and Suoranta 1998, 65–72). The purpose of an 
interview is through an interviewer initiated and guided discussion, to determine the 
opinions and impressions of the interviewee on a subject (Eskola and Suoranta 1998, 
70–77). The idea of an interview is beautiful in its simplicity and sense; when the author 
want to know something about a person: what he is thinking, what are his motives, ect., 
why don't the author ask him directly (Eskola and Suoranta 1998, 65–72). The clearest 
definition of an interview is a situation where the interviewer asks questions from the 
interviewee although this definition has greatly been expanded to more coincide an ac-
tual conversation (Eskola and Suoranta 1998, 65–72). 
In addition, an interview is an interaction, where in both parties affect each other. 
The interview situation is affected by both the interviewer and the interviewee as well as 
physical, social and communication related factors (Eskola and Suoranta 1998, 70–77). 
The situation is abnormal in a sense that it is usually: premeditated, interviewer initiated 
and guided, interviewer generally has to motivate the interviewee, the role of the inter-
viewer is known to himself and picked up by the interviewee, in addition the interview-
ee has to be able to trust that his personal information and answers are handled confi-
dentially (Eskola and Suoranta 1998, 70-77). 
Qualitative research's purpose is the conceptual understanding of the world, in which 
both theoretical concepts and their empirical equivalents are needed (Eskola and Su-
oranta 1998, 75). Theoretical concepts are forged into empirically measurable units 
throught the process of operationalization (Lehtinen 1991, 17). Thus each concept has 
two definitions, a theoretical one that binds and explains its relationship to other theo-
ries as well as an operationalistic one that brings an measurable definition to the theoret-
ical framework and connects it to the reality (Harisalo et al. 2002).  
The methodological basis for operationalization is the idea of transferability evident 
in positivistic philosophy of science. Another basis is the test of semantic empiricism 
that purposes that words and sentences always share the same meaning regardless of 
user, context, time or place (Eskola and Suoranta 1998, 75–76) Operationalization is 
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based on natural science theory and its use in quantitative studies and humanities has 
been criticized extensively and the discussion is ongoing, here it is applied on the basis 
of socialistic constructiveness that states all scientific concepts and theories to be over-
time agreed treaties (Eskola and Suoranta 1998, 77). The author has used the process of 
operationalization to account for this discussion and enhance the transferability of this 








The Operationalized Questions 
How to determine 
the appropriate 
governance forms 




cal companies in 
the context of PRC 
based on the influ-
encing factors? 
What are the different 








What is the return from sales and 
incentives to cost generated from 
market entry and adaptation. 
What are the different 
factors influencing the 
offshoring of pharma-
ceutical R&D to PRC? 
The influence of 
centres of excel-
lence. 
What is the value generated for the 
end product? 
The influence of 
local science and 
technology. 
What is the value of local science and 
technology? 
What are the different 
factors influencing the 
offshore outsourcing of 
pharmaceutical R&D 
to PRC?" 
The influence of 
labour pool. 
What is the value of R&D labour 
supply surplus? 
The influence of 
cost and incen-
tives. 
What is the amount of cost savings 
and operational efficiency to initial 
investment? 
The influence of 
risks and minimal 
conditions. 
What is the cost of infrastructure, IP 
protection, training and the potential 
impact of risks?  
How do the different 
phases of pharmaceuti-
cal product develop-
ment process influence 
the dispersion of 
pharmaceutical R&D 












Which factors have an influence on 
preclinical phase 
The requirements 
for clinical trials. 
Which factors have an influence on 
clinical phase 
Table 3. Operationalization of the main research question, as well as the subquestions of 
this study together with the different forms of R&D globalization and 
their relationship to influencing factors 
The main research question, as well as the subquestions of this research are opera-
tionalized in table 3, with the purpose of clarifying the relationship of influencing fac-
tors presented in literature on globalization of R&D to different patterns of globally 
dispersing R&D activities. In the next section, following the guideline provided by Hart 
(1991), the interview process of this study is described in a detailed manner. 
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3.4.1 Selection of the Interviewees 
All the interviews were gained through social contacts and networks, called "quanxi" in 
Chinese, either in professional context or through friends and acquaintances. It is be-
lieved that the validity of data gathered for this research is enhanced further as a person-
al contact existed between the interviewer and the interviewee. This is because the in-
terviewee would have a higher motivation to be frank and communicate his views and 
perceptions accurately and truthfully. The interviewees, who all work in the pharmaceu-
tical industry or in related professions, were selected because of their expertise in the 
industry, especially in the context of China and represent knowledge from seven (Pfizer, 
Johnsson&Johnsson, GlaxoSmithKline, Merck, Bayer, Eli Lilly, Novartis) of the twelve 
major pharmaceutical companies. 
All the interviewees work in at least managerial or specialist level positions, they 
were selected to have different operational positions and diverse knowledge from phar-
maceutical R&D and the different parts of product development pipeline. The list of the 
interviewees and the associated relevant information are illustrated in Table 4. Follow-
ing the table, detailed description of each of the interviewees are provided. 
Table 4. List of interviewees for this study and their associated details 
 
Name of the 
interviewee 




Dr. Tang Pfizer Senior director 
Extensive R&D, 
Pharma & China 
13.01.2012 
63 min 
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Dr. Max Von 
Zedtwitz 
















Dr. Boxiong Tang (唐伯雄) is a senior director of Emerging Markets Outcomes Re-
search team at Pfizer (辉瑞公司新兴市场高级总监), responsible for outcomes research 
in specialty care products and Asia region. He has over 18 years’ experience in medi-
cine, health services and outcomes research. He received his M.D. in preventive medi-
cine, Ph.D. in health services research and a M.P.H. in the major of international health. 
Prior to Pfizer, Dr. Tang was the director of Health Economics and Clinical Outcomes 
Research in Johnson & Johnson and GlaxoSmithKline, where he was responsible for 
health outcomes research in biologics and oncology. Dr. Tang has published many 
manuscripts in the peer review journals and presentations in the international scientific 
congresses. Dr. Tang was selected to be interviewed due to his extensive knowledge on 
pharmaceutical R&D and specialization on the Asia region and on China especially. He 
has worked with a number of Chinese academics, researchers and companies in the 
pharmaceutical field and is privy to many decisions in the above-mentioned companies 
in regards to moving operations and conducting R&D in PRC. For his views on moving 
R&D to PRC and on the influencing factors there is a potential for bias in the sense of 
China as his home country, from his long stay in the United States where he has studied 
and worked for a number of years, a bias in opinion may also exist due to his other affil-
iations to Chinese companies such as CROs. 
Donald W. Wyatt is the founder of The Wyatt group. He has extensive experience 
in intellectual property, has served as a researcher in Merck, a large pharmaceutical 
company, an attorney in a law firm, patent counsel at a Fortune 500 company and as 
Vice-President of Legal Affairs and Corporate Secretary at a biopharmaceutical compa-
ny. He has acted as lecturer in Fudan university, one of China's top universities. Mr. 
Wyatt was selected to be interviewed due to his extensive understanding on conducting 
manufacturing and R&D operations in China. He has a lot of hands on experience on 
the realities of conducting operations in China in regards to infrastructure, working cul-
ture, educational system. From his legal and consultative work for major pharmaceutical 
clients he has detailed knowledge on moving operations such as R&D to PRC and many 
of the influencing factors behind the decisions. For his views on moving R&D to PRC 
and on the influencing factors there is a potential for bias from his early experiences on 
doing business in China, potential for bias also exist from his long work history in the 
United States on the time of US hegemony in pharmaceutical R&D. A bias in opinion 
may also exist due to his affiliations to clients in China or other business interests. He 
may also have been restricted on sharing some information that would be considered 
confidential. 
Lisa A. Kilday is a registered Patent Attorney and the Principal of Patent Protocol, a 
law and consulting firm focusing on the procurement and protection of intellectual 
property.  Mrs. Kilday has over fifteen-years of experience in intellectual property. She 
was an associate in the international law firm of McDermott Will & Emery LLP based 
in the Washington, D.C. office.  As a member of the Intellectual Property, Media & 
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Technology Department, she focused her practice on patent prosecution and counseling. 
Prior to joining McDermott Will & Emery, Mrs. Kilday was a patent law clerk and In-
tellectual Property Law associate with a D.C. law firm specializing in the preparation 
and prosecution of electrical, electromechanical, and chemical applications. Mrs. Kilday 
was selected to be interviewed due to his extensive understanding on the intellectual 
property in southeast-Asia and especially on the acute understanding of the level of bio-
pharmaceutical research in China. She has had many clients from the pharmaceutical 
industry. She may also have been restricted on sharing some information that would be 
considered confidential. 
Freesia Chen is a Supply Chain Manager at GSK China on Vaccines. She has 
worked in China in the pharmaceutical industry for almost ten years. She has worked 
first for Eli Lily with prescription medicines and other pharmaceutical products. After 
that she has then worked for Novartis in vaccinations business until last year when she 
started working in GlaxoSmithKline as a Supply Chain Manager on Vaccines. Mrs. 
Chen was selected to be interviewed due to his varied knowledge working for three ma-
jor pharmaceutical companies in China as well as his specialization on vaccinations, an 
important pharmaceutical product category. Mrs. Chen has extensive, local knowledge 
based on his work experience as a local in China's pharmaceutical sector. 
Rogers is a Clinical Trial posting specialist at Bayer China. He is a Chinese national 
and has been educated in a Chinese university. He has worked more than 5 years in his 
current post and has other work experience in the pharmaceutical and healthcare indus-
try. Rogers has extensive, local knowledge based on his work experience as a local in 
China's pharmaceutical sector. 
Nick works at Johnson & Jonhson China marketing department being responsible for 
medical products of Johnson China Marketing. He is Chinese national and has been 
educated in a Beijing medical university. Based on his medical studies he has fairly 
good understanding of medical research and the pharmaceutical industry. He has less 
than 10 years of work experience in Johnson &Johnson and comparable companies. 
Nick has extensive, local knowledge based on his work experience as a local in China's 
pharmaceutical sector. 
Dr. Zheng Li is the General Manager and Head of Lundbeck Research China. He 
received a PhD in Neuroscience and Behaviour from the University of Massachusetts, 
Amherst. He has worked as a Research Fellow and Postdoc for the University of Michi-
gan after which he started working as a Senior Scientist at Parke-Davis Pharmaceutical 
Research for half a decade and as a Principal Scientist at Pfizer for almost a decade. 
From Pfizer Mr. Li transferred to Lundbeck Research USA where he worked as a prin-
cipal Scientist/Team Leader until 2011 when he was appointed as the General Manager 
of Lundbeck Research China. As a General Manager of Lundbeck Research China Mr 
Li has build relationships with leading academic institutions in China and assisted in 
establishing contacts with contract research organizations throughout China. Dr. Tang 
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was selected to be interviewed due to his extensive knowledge on pharmaceutical R&D, 
specialization on China and on the outsourcing to Chinese contract research organiza-
tions especially. A potential for bias may exist from his recent promotion to manage the 
outsourcing of certain Lundbeck functions to Chinese contract research organizations. 
His many years of working in the US for major pharmaceutical companies may also 
affect his view of the influencing factors in globalization of R&D to China. 
Dr. Max Von Zedtwitz is a leading academic in the field of global R&D manage-
ment and reverse innovation. He is a professor of international business and innovation 
in Tongji University (China), University of St. Gallen (Switzerland), Grenoble School 
of Management (France), Chalmers University of Technology (Sweden) and Nyenrode 
Business School (Netherlands). He is an independent advisor and consultant on innova-
tion and China as well as director of GLORAD, the Research Center for Global R&D 
Management and Reverse Innovation. Previously he has acted as a former President, 
AsiaCompete Int'l Ltd. (Shanghai), former Vice President, PRTM Management Con-
sultants (Shanghai) Ltd. In his past academic career he has acted as a former Professor 
of Innovation, Technology Management, and Strategy at IMD, Tsinghua University, 
and Peking University. Dr. Max Von Zedtwitz was selected to be interviewed due to his 
extensive knowledge on R&D globalization, specialization on China and expertise on 
hight technology sector including pharmaceuticals. Potential for bias may come from 
his academic outlook on the subject, this can materialize itself through prepared pre-
formulated answers based on academic knowledge instead of based on day-to-day 
events. 
In addition to the above interviewees, the author initially considered collecting pri-
mary data from other potential persons. However, the plan was abandoned due to prac-
tical reasons. The potential interviewees included the owner of pharmaceutical CMO 
Company located in Tianjin whose company specialized in producing pharmaceutical 
bulk ingredients for export to US and Europe, a researcher in China's state cancer re-
search centre and a manager of a small western pharmaceutical company contract manu-
facturing OCT-medicines for bottom of the pyramid (POB) -market in southeast-Asia. 
Further two interviews were planned and proposed but could not be achieved because of 
time and place constrains, who are as below: 
Dr. Karen Atkin is vice president of AstraZeneca R&D in China, she joined Astra-
Zeneca 13 years ago. In this role, she leads the company’s Chinese R&D organisation, 
with a focus on achieving a step change in speed, quality and customer focus in the de-
livery of both new products and medical affairs. Karin Akins has reshaped AstraZene-
ca’s business model to add new capabilities and tap into external collaborations and 
partnerships.I was supposed to also analyze her lecture "The Power of Partnering: How 
to creatively expand the innovation network". The interview and analysis of the lecture 
could not be organized because of illness related cancellation of her lecture. 
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Dr. Jeremy Teo leads the Pharmaceutical R&D sub-practice for McKinsey in Asia.  
He has worked in R&D in the US, Europe and Asia, hosts a regular Quarterly Heads of 
Pharmaceutical R&D Roundtable in China and is a regular speaker and panelist at in-
dustry conferences. Dr Teo is a Physician by training with clinical training at the Na-
tional University of Singapore and Yale School of Medicine. He also holds a Masters in 
Molecular Immunology from Harvard University and an MBA from INSEAD. Analysis 
of his lecture on "Pharmaceutical R&D in China - Reality or Myth?" was also proposed 
but could not be achieved due to cancellation of the lecture for a business trip. 
3.4.2 Arranging the Appointments for Interviews 
All interview appointments were gained through personal contacts or via introductions 
from friends or acquaintaces together with the utilization of networks by the heads of 
Finnpro Shanghai and Fudan Nordic centre. The first contact to all interviewees was 
made through face to face meeting in a conference, seminar or a social event, unless it 
was the result of an introduction by a friend or aquaintance, in which case the first con-
versation was through en email, skype or a phone. After getting to know one another a 
more formal interview was scheduled in the interviewee’s office or in a public place, 
such as a cafeteria, restaurant or hotel lobby according to interviewee’s wishes. In cases 
where the first contact was a face to face meeting in a conference, seminar or a social 
event and conducting the interview straight away fitted both the interviewee and the 
interviewer part or the entire interview was conducted then and there in places, such as a 
restaurant or conference space or hotel lobby. When arranging the time interviewees 
where informed that the simplistic interview takes about 25 minutes. In one of the inter-
views this time was exceeded due to a bathroom break and after the scheduled time was 
exceeded in another interview, the requested time was extended to 40 minutes. However 
in few interviews with interviewees who possessed extraordinary amount of in-depth 
knowledge on the subject even this time was exceeded. The following examples are 
given to illustrate the importance of social networks, personal contacts and conferences 
as venues for such meetings, as well as to illustrate the relaxed nature of these inter-
views.  
An interview with a senior pharmaceutical director was held in a hotel lobby in 
Shanghai. The interview took place after a conference on R&D and innovation in China 
that was scheduled to be centred on the pharmaceutical industry. The author unknow-
ingly met the interviewee in question on the Shanghai metro. Unaware of each other’s 
destinations the author and the interviewee met again in the conference, where they 
chose adjacent seats and conversed on the conference topic and other topics of mutual 
interest. During the conference break, the author described his research topic and pro-
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posed an interview, which was readily accepted by the interviewee, who proposed that it 
would be conducted in the lobby over refreshments. 
Another interview was arranged in Beijing over a phone with a pharmaceutical man-
ager through an introduction from a long time Chinese friend. The actual interview time 
was arranged via email and it took place in the interviewee's office. The interviewee and 
interviewer had much in common and the actual interview was preceded by a lengthy 
conversation on mutual friends and acquaintances. 
3.4.3 Handling the Interviews 
The interview types can be divided in multitude of ways, and many categorizations exist 
(Rubin and Rubin 1995, 56). Simplistic classification and the one used by the author 
can be achieved by taking into account the degree of structuring on the questions and 
the extent the interviewer is parsing the situation (Eskola and Suoranta 1998, 77). A 
semi-structured interview is a one where the questions are the same for each interviewee 
and asked in the same sequence but is void of structured answers and encourages free 
expression (Eskola and Suoranta 1998, 77). In a theme interview the subject matter and 
themes are predetermined but this method lacks the structured prewritten questions, 
sequence and answers. In this interview type the interviewer makes sure that all prede-
termined themes are covered but their extent and sequence are varied from each inter-
view. In this method the interviewer has a framework of themes but not a readymade 
list of questions (Pitkäranta 2010). 
The interview method used by the author is a mixture of the two above mentioned 
where the author had predetermined an theme and a list of questions, the theme was 
introduced to each interviewee but questions where not asked in the same sequence and 
the extent of each question varied from an interviewee to interviewee and additional non 
predetermined questions were asked to facilitate conversation and deepen the interaction 
on a theme when necessary (Pitkäranta 2010). This mixture of methods and flexibility 
of the situation increased the trust between parties as well as facilitated deeper 
knowledge transfer and enabled the interviewer to increase the reliability of the data. 
To combine the advantages of unstructured and semi-structured interview methods, 
the interviews were started with introduction of theme, then open-ended questions, with 
the option of further unprepared questions followed by a structured questionnaire proto-
col (Pitkäranta 2010). The interviews were started by introducing the theme and asking 
formal open ended questions regarding the companies’ motivations and goals on their 
R&D activities in China, together with what organizational structures and forms of en-
try they utilized.  
67 
3.4.4 Timing the Interviews 
As reported on deep interviews there is a problem related to time constrains and in all 
the interviews conducted by the author the slated time frame of the interview was ex-
ceeded. In these cases the interviewee where asked if he would want to continue and the 
interview extended. The interviewees where not deliberately lead astray over the re-
quired time and the interview times provided would have been sufficient for the intend-
ed questions (Eskola and Suoranta 1998), but the extra time required for the unprepared 
questions and follow-up questions on topics could not be calculated and varied between 
interviewees. All the interviewees expressed interest to continue the interview and 
where in no hurry to conclude and after no questions were asked any more, all the inter-
viewees provided topics of their own and offered their insights on the theme in question. 
Furthermore, in most cases the discussion was continued on personal level and 
through friendly chatter after the interview situation was concluded. In one case, the 
interview was suspended for a bathroom break and another interview was put on hold 
for a seminar dinner when the seating was not suitable for the unceasing continuation of 
the interview. All the interviewees where given a choice to as to the time and place of 
the interview (Eskola and Suoranta 1998), and many interviews were conducted from 
their explicit request either at their office or in social settings, such as a cafe or a restau-
rant. 
3.4.5 Directing the Content 
The validity and reliability of the obtained data was further increased by conducting 
deep interview in a sense that some of the interviewees where contacted more than once 
and follow up questions where presented (Eskola and Suoranta 1998). The validity and 
reliability are further increased as well as the notion of deep interview readily achieved, 
through the compact subject and theme of the research (Kortteinen 1982, 296). As part 
of good interview etiquette, the purpose and the organizations involved in the research 
where disclosed (Pitkäranta 2010). 
Besides asking formal questions, interviewer strongly encouraged the interviewees to 
describe their feelings, observations and personal views on the subject as well as to pro-
vide related examples from their daily business, including current projects. The infor-
mation obtained in this way was crosschecked with secondary data. This kind of trian-
gulation allowed the author to minimize the bias of personal perspective and enhance 
the validity of the information. 
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3.4.6 Collection of Secondary Data 
In addition to the primary data, secondary data from several sources have been collected 
for this study. The main reason of collecting secondary data was to increase the reliabil-
ity of the complete data set. Secondary data collected for this study were fitting with the 
primary interview data, and both the data sets complemented each other perfectly. 
The first source of the secondary data was the official websites of the firms with, 
which the interviewees are associated. The company web-sites often contained valuable 
information, including press releases over the years regarding the internationalization of 
R&D activities of the firms. In addition, information regarding the firms’ goals, objec-
tives and future expansion plans also helped to provide important insights. 
The second source of complementary data was articles and pieces published in mag-
azines as well as managerial oriented journals in China. The author chiefly relied on 
English language publications such as Xinghua and China daily but through a help of a 
translator and a moderate knowledge of Chinese was able to access Chinese language 
publications as well.  
Another source of complementary data were Chinese government publications such 
as the 2005 and 2009 Chinese pharmacopoeia’s published by the Chinese pharmacopoe-
ia commission as well as white papers published by for example, China CDC (centre for 
disease control), Chinese health statistical digest in 2012. Similarly, those papers and 
guidelines published by other relevant government agencies, for instance SHPMCC 
(SHPMCC, 2012) along with GMP rules and additional publications by CFDA (CFDA, 
2012). 
3.5 Data Analysis 
3.5.1 Use of Content Analysis 
After the data collection has been complete, the researcher moved to the data analysis 
phase of this study. To analyze the collected data, the researcher used content analysis 
method. As objective of the researcher is to describe the views of key pharmaceutical 
industry personnel on globalization of R&D, content analysis was deemed appropriate 
to discover the opinions or the interviewees regarding the phenomena.  
Content analysis is a scientific method, which achieves to reach conclusions from 
verbal, symbolic or communicative data. Its objective is to analyze documents, which 
can be books, articles, diaries, letters, speech, discussions, reports or interviews that 
have been rendered to a written form. According to Stemler (2001), content analysis is: 
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 “a systematic, replicable technique for compressing many words of text into fewer con-
tent categories based on explicit rules of coding.”  
Another broad definition of content analysis was provided by Holsti (1969), who ar-
gued that content analysis can be defined as “any technique for making inferences by 
objectively and systematically identifying specified characteristics of messages.” To test 
the theory presented on academic literature on the globalization of R&D processes the 
author have chosen a theory-guiding content analysis method. In theory-guiding content 
analysis the classification of the analysis is based on afore described conceptual frame-
work, which can be a theory or a system of concepts. In theory-guiding content analysis 
the concepts come ready prepared as something known from the phenomenon already.  
Another reason for using content analysis in this study is that as a a scientific meth-
od, it enables to reach conclusions from verbal, symbolic or communicative data. As  
objective of the method is to analyze documents, which can be books, articles, diaries, 
letters, speech, discussions, reports or interviews that have been rendered to a written 
form. In addition, the method is suitable for analysis of unstructured as well as struc-
tured material, is extremely sensitive to context and is used to search for meanings. 
(Grönfors 1982; Krippendorff 1989; Kyngäs and Vanhanen 1999; Tuomi and Sarajärvi 
2004) 
3.5.2 Analysis Frame 
With qualitative research interview the author seek to describe and find the meanings of 
central themes in the view of the subjects. Thus the central requirement for interviewing 
is to understand the meaning of what the interviewees say (Kvale 1996). In theory-
guided conceptual analysis this is done by firstly forming the analysis frame, which can 
be extremely loose or structured (Pitkäranta 2010). To facilitate a simpler data collec-
tion and interpretation, taking into consideration the inexperience of the interviewer, the 
author have chosen to use a structured analysis frame. The structured analysis frame the 
author has used is depicted in figure 3. 
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Figure 3: Structured analysis frame for theory-guiding content analysis of qualitative 
interviews of key personnel employed in pharmaceutical industry on the 
globalization of R&D to PCR 
3.6 Generalization of research findings and trustworthiness 
The great challenge in qualitative research is the assurance of scientific eminence and 
dependability of the study (Hägerström 2010). The research has to ascertain the associa-
tion between the results and reality (Hirsjärvi et al. 2001, 128). The transparency of the 
research can be increased by implementing different evaluation criteria, thus providing 
opportunities to identify its strengths and limitations. The naturalist view of trustworthi-
ness presented by Lincoln and Guba (1985) proposes the implementation of naturalistic 
trustworthiness criteria that includes four concepts: credibility, transferability, reliabil-
ity and dependability (Marshall and Rossman 1989; Lincoln and Guba 1985). In this 
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study the author partly ensured credibility by provably identifying and describing the 
subject accurately (cf. Lemmetyinen 2010, 65). As mentioned in the data collection part, 
the interviewees for this research were selected with careful consideration of their ex-
pertise in China, the pharmaceutical industry and pharmaceutical R&D. To further en-
sure its credibility the interviewee's responses are documented extensively throughout 
this study together with their expertise and possible intrinsic biases.  
The strength of qualitative research lays in the flexible and direct interaction between 
the interviewer and the respondent, which ensures the good transferability of infor-
mation and knowledge (Sykes 1990). For the purposes of increasing transferability, 
Ödman (1979, 78) proposes the usage of multiple sources and studying secondary mate-
rial (Bergum 2009). Transferability was achieved in this research by selecting and col-
lecting empirical data from many interviewees with diverse backgrounds, expertise and 
positions but similar in their extensive knowledge of some part of the phenomenon. 
Hence it is expected that the findings of this study can be beneficial and useful to re-
searchers, managers and other practitioners in the pharmaceutical industry. Reliability 
of a study is a strong measurement of the study's scientific standing. As the researcher 
can influence the results of an empirical study, the researcher himself is an important 
factor in data collection and analysis (Bergum 2009, 70) The researcher can either influ-
ence the data collection by affecting interviewee's responses or impact their interpreta-
tion and thus influence data analysis, which is another central part of the researcher’s 
work (Bergum 2009, 70). Marshall and Rossman (1989) argue that researchers can re-
spond to the demand for replicability in qualitative research by keeping carefully pre-
pared and comprehensive notes and records that provide an audit trail and illustrate the 
rationale behind researcher’s results and interpretations. The main research question and 
the subquestions are operationalized in detail to establish the reliability of this study. 
The raw data from all interviews, together with general analysis, are kept as computer-
ized audio files and transcripts for future records. The reliability of results was further 
increased my taking into account the concept of constructed reality and potential bias of 
interviewees by coding the answers of each interviewee randomly with mathematical 
variables t, z, a, b, c, d, x, y while simultaneously providing anonymity for interviewees. 
The last part of the naturalistic trustworthiness criteria is Dependability. Dependabil-
ity refers to the extent that changing settings are standardized or randomized in the phe-
nomenon being studied, so as to minimal affect the results (Lemmetyinen 2010, 67). 
Hence reliability was increased in this study with adoption of the theme interview 
method and semi-structured questions, which enabled the respondent to freely ponder 
the phenomenon and explicitly express their thinking rather than being influenced by 
the researchers questions an opinions or being limited by options provided by the inter-
viewer. Similarly the interviewees were not limited by time constrains as all the inter-
views were held at a time of their choosing, majority in an environment of their choos-
ing or other vice considered positive. Also the timing of the study need to be taken into 
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account as all the interview were taken between November 2011 and February 2012, 
well after the Twelfth Five-Year Guideline and its emphasis on high technology indus-
tries such as pharmaceuticals and biotechnology. Thus the results should already take 
into account the changed environment. Similarly the interviews took place well before 
the pharmaceutical bribery scandals around Big Pharma in 2013, which might have af-
fected the interviewees’ responses and willingness to share information. 
Based on the nature of qualitative research it is evident that limitations are unavoida-
ble. Qualitative research deals with subjective knowledge and concentrates on questions 
concerned with dimensions of the social worlds. Thus a good qualitative research focus-
es on accurately displaying the respondents’ conceptualized subjective meanings, activi-
ties and social interactions (Fossey, Harvey, McDermott and Davidson 2002, 717). As 
the research on the phenomenon was based on opinions and understandings, the author 
recognizes that in this context the research has some limitations. Primarily the research 
has focused on one specific industry pharmaceutical industry, with an emphasis on Big 
Pharma. Subsequently, the results are not fully applicable to adjacent industries, such as 
biotechnology (cf. Yin 2003). Nor are the results completely transferable to different 
size companies in the pharmaceutical industry, although this was an issue discussed in 
the interviews and researched in the supporting secondary data (cf. Yin 2003). Second-
ly, the data collection is based on a limited sample on interviewees on a single data col-
lection periods. A greater number of responses during a longer time frame could have 
provided a more reliable result and a better understanding of the phenomena. The above 
mentioned limitations were controlled with the careful selection of the interviewees, 
together with selection of the geographical and industry specific representativeness of 
the research. As the area spanning from Beijing to Tianjin and Shanghai holds 89% of 
all R&D operations by foreign companies and Shanghai in practice host all of those by 
pharmaceutical companies this research can be generalized to represent all pharmaceuti-
cal R&D by international pharmaceutical companies in PRC. In those aspects were the 
influencing factors are derived from the conditions, institutions or characteristics of 
PRC, the research findings only apply to it. In those aspects were they stem from low 
salaries or substantial ready supply of college graduates, they can be seen to apply to 
some extent on other Newly Industrialized Countries (NICs) if they are carefully evalu-
ated keeping in mind the conditions of PRC on institutional,  infrastructure and market 
level. Nevertheless, this study has ascertained the rationality and trustworthiness of the 
research by several means and thus should provide reliable findings within the limita-
tions of this study (cf. Raukko 2009, 346). 
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4 EMPIRICAL RESEARCH 
4.1 Objectives for R&D globalization 
For the purposes of this research, an empirical study was conducted from the perspec-
tive of the pharmaceutical industry in the case of People's Republic of China. The study 
was performed to confirm the factors of R&D globalization and their relations to the 
forms of dispersing R&D activities globally. As described previously in this paper, 
these R&D globalization forms are R&D offshore outsourcing, R&D offshoring and 
R&D internationalization. This research scrutinizes individual factors or sets of factors 
on pharmaceutical R&D globalization that a firm wishes to pursue. The purpose of this 
research is to illustrate the relationship between these influencing factors and the most 
beneficial mode of geographical R&D globalization associated with specific factors.  
4.1.1 Cross country cost differentials and financial incentives  
According to the interviews conducted for this study, the author has reached the follow-
ing conclusions. According to this study, cost considerations are an influencing factor in 
all forms of R&D globalization. In the case of PRC, this includes cross country cost 
differentials together with costs stemming from infrastructure. In essence, costs can 
apply to industries that experience strong cost competition in relation with high R&D 
requirements and costs (Cheng and Bolon 1993). 
 
Interviewee x: “I think that the major emphasis is cost. […] If I look at the pharmaceu-
tical industry in general, it’s R&D that's the major overhead cost, and 
unfortunately this is a risk posing upfront cost, way of addressing it (re-
ducing risks) is by reducing the R&D costs in general […] when I say 
cost, it's also the ability to do more for the same money. […]The competi-
tive advantage of China is purely cost. It’s purely cost. That's really what 
it comes down to.” 
 
In more detail, majority of costs are comprised of personnel cost differences, which 
on average account for two thirds of costs (Beckmann and Fischer 1994). 
 
Interviewee y: “I think the cost is one important part, because the human part for the 
worker or colleague is lower.” 
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Nevertheless, as shown in the latter quotations concerning cost, it is definitely not the 
decisive factor but more of a secondary issue. 
 
Interviewee x: “These decisions that are purely based on cost, then you have to go back 
and say what are the fundamentals supporting that cost structure as the 
fundamentals supporting a low cost supply side globalization will 




Interviewee b: “Cost is a one factor but not only one. Cost is not an issue even though 
it’s very expensive cost economics is secondary issue.” 
 
Interviewee z: “Ah, cost is always a consideration. In our current move, we are not 
driven by cost. Clearly cost is not a negative factor. I mean cost is a con-
tributing factor but cost is not a determining factor.” 
 
Interviewee a: “Now if you talk to someone, it is going to be a number of different fac-
tors and not just a one. Cost has always been there, so now it is men-
tioned, not anymore on the top, now it's going to be one of the factors af-
fecting.” 
 
The difference in the significance of cost differentials and the way it is manifested 
varies between the alternative forms. In R&D offshore outsourcing it is a major push 
factor even though not conclusive.  
 
Interviewee x: “To address this [cost] major pharmaceutical companies are in a sense 
outsourcing their R&D or setting up essentially self-managed offshored-
subsidiaries.”.” 
 
Interviewee d: “Actually outsource is another way to improve cost-effectiveness. […] If 
you outsource, this company hire from China, they will reduce costs so 
why we don't have our own R&D do that.” 
 
In R&D offshoring, cost also plays an important role, which diminishes over time as 
other factors become more important. 
 
Interviewee x: “The other way is reducing R&D costs in general, […] the inconven-
iences and difficulties of long-distance offshoring start to outweigh the 
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financial benefits. […] Cost is also the ability to do more with the same 
money.” 
 
Interviewee d: “China has kind of cheap labor. So they [company] think move some 
high cost center to China.” 
 
In the case of R&D internationalization, cost is also an influencing factor. Neverthe-
less, benefits associated with cost do not justify this type of a long time span, multi-
operational, evolutionary approach to R&D globalization. This is because R&D interna-
tionalization requires a long-term strategy and a step-by-step approach to building net-
works and focus on the overseas local market. 
 
Interviewee d: “There is right now a very large cost factor gap, between, let's say, doing 
your R&D in Europe and doing your R&D in China. […] ultimately the 
cost factors are just standard of living cost that start to go up. […] R&D 
like manufacturing requires large infrastructure investments. There is a 
great big building, lots of equipment, sterilization, high cost and level of 
training.” 
 
Interviewee z: “Number one is whether you consider China is a strategic investment. 
That is the key point, because you don't come here to just save some 
money.” 
 
Another cost economics factor is government incentives, which for a small company 
can be crucial in the early life, especially in the form of infrastructure incentives.  
 
Interviewee x: “Places like China attract in infrastructure incentives, in monetary in-
centives and low cost incentives. […] The provincial government and 
even the city governments are extremely active in providing financial and 
infrastructure incentives, which are offered to folks that establish some-
thing, not just hire a local company to do R&D but establish their own 
R&D operation. […] Initial infrastructure incentives are buildings, 
equipment.” 
 
Interviewee z: “Second reason is investment from the government for the risk invest-
ment; this is the only nation that's R&D investment for the pharmaceuti-
cal industry is growing.” 
 




Interviewee d: “China has a very good investment environment. Government will give 
you some tax free. We have to buy animals, buy some chemicals and also 
import some medical, medicine materials, so the government will give 
you some tax [exemption], maybe interest free loan, maybe also no im-
port duty.” 
 
Interviewee c: “Companies can move a R&D center to China. Well they might be setting 
one up there due to early incentives. […] If you build your R&D center to 
China they [companies] are going to get price incentives to [products] 
being distributed in China, which is a huge market.” 
 
Based on the findings cost could be corroborated as an influencing factor and it is ev-
ident in all governance forms. Nevertheless the finding by (Lewin and Peeters 2006; 
Norwood 2006; Davis 2000; Reddy 1997; Bucley and Casson 1976) of cost as decisive 
or only factor is refuted. Furthermore financial incentives as suggested by (Hu 2007; 
Gassman and Han 2004; Grossman and Helpman 2003; Boddewyn 1985) such as infra-
structure or cash incentives, or tax subsidies are corroborated as an influencing factor. 
4.1.2 Availability of advanced labor pool  
When looking offshoring in more detail the following factors emerge from the litera-
ture. As depicted earlier, a major factor affecting offshoring decisions is the scarcity of 
advanced R&D resources in the home country. At presently, the insufficient R&D labor 
pool in western countries constitutes a scarce R&D resource that can be seen for exam-
ple from the lack of new science and engineering graduates. Also large portion of stu-
dents studying in life sciences or engineering, especially in the United States, are from 
overseas emerging countries like China and India. In contrast, there is a huge R&D la-
bor pool in these countries that is further supplemented by returning students from 
western countries. Beckmann and Fischer (1994) see that in the Western world, espe-
cially in smaller countries there is a scarcity of engineers and researchers. 
 
Interviewee c: “The USA cannot find [enough] good scientists. Americans don't want to 
go into science and engineering and Singapore has the same problem 
too.” 
 
Interviewee z: “I think that the greater concentration of well-trained scientist, students 
is one of the reasons why it is really catching on.” 
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Interviewee z: “The talent pool in China is another reason discussed, it is not superior 
to Western talent pool but China is catching up and in here you can hire 
tomorrow a hundred new scientist or graduates, which is an influencing 
factor.” 
 
Bardhan (2006) says that crucial features for R&D globalization are geographical 
distribution and clustering of talented labor, tradition for commitment by R&D labor as 
knowledge assets, labor market mobility and labor laws as well as contractual labor 
provisions and practices. 
 
Interviewee c: “Why western companies are moving to China and opening shop is 
cheap labor costs, more consistent labor with no unions and the number 
of engineers, an army of engineers and scientists that graduate every 
year. […] The incentive is the labor force with no union.” 
 
Beckmann and Fischer (1994) also state that first and foremost importance for the 
success of the R&D mission is the availability of advanced R&D labor pool and the 
expertise of the personnel. 
 
Interviewee d: “[When a company] setup this R&D center maybe two three years ago 
basically with two or three persons but now normally they have hundreds 
of personnel, they hire a lot of Chinese scientists. So lot of scientists do-
ing testing. […] When they decide to do research, one thing they think is 
that the Chinese have talent to do the tests. In many overseas R&D facili-
ties, they already have Chinese scientists and China has kind of cheap 
labor force.” 
 
Interviewee c: “There are so many engineers and scientists, the reason why I do think, 
is that China cranks up like a million engineers every year, undergradu-
ates or what you would consider university bachelors. They just have the 
numbers. The actual numbers of people who will do the job with little 
money. Quality of the actual employees, I think they are good academi-
cally, they are obedient, studious, diligent.” 
 
Pharmaceutical industry is highly dependent on the availability of academic person-
nel and expertise (Beckmann and Fischer 1994). 
 
Interviewee y: “There are many candidates in China that can work in the pharmaceuti-
cal sector. […] I think the students in China are very good, they are very 
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hard working and diligent. I think this is a huge advantage of China. 
There are a huge number of graduates from universities every year.” 
 
Interviewee z: “Basically in China they produce vast quantities of PhD's and master's 
degrees and clearly there is a huge talent pool in China, and that is an-
other area that is becoming attractive to us. It has lot of well-trained sci-
entists, which are ready to be employed. The Chinese university students, 
they are very good. The CRO company we are using, they have some of 
their bench scientists, they are freshly out of the Chinese education sys-
tem, have a master's degree.” 
 
A specific case of the talent pool that is available in China is the mentioned overseas 
students and researchers who return to China for top research or managerial positions or 
to start companies, which augments the available skill pool. Amongst the input-oriented 
motivations for establishing R&D in China according to Gassmann and Han (2004), is 
the huge human resource reservoir is of great importance, which is augmented by the 
extremely skilled Chinese overseas students returning to China. These returning Chi-
nese form a uniquely qualified additional human resource pool, which brings with it 
global experience and knowledge (Gassmann and Han 2004). 
 
Interviewee x: “One thing China has to offer is returning Chinese from abroad that are 
extremely well trained, […] majority of students studying life sciences 
abroad in US, the training they get when they stay and work in the phar-
maceutical industry is a very high quality and they show up [back in Chi-
na] with greater sophistication and skill set. The concentration of educat-
ed labor in China is greater than in other areas. And I think that this is 
one of the reasons why this seems to be catching on.” 
 
Interviewee c: “Chinese people who are getting educated in the top US universities, 
getting training and work in the US for a few years and then they go back 
to Asia. There is a lot of them, they want to go to the engineering and 
science fields and if they receive the training in the US, that's usually 
pretty good. […] The people who are at the senior level are people who 
have been educated in the US or Europe. There is always someone who 
is doing all the coordinating, that you are completely relying on, like a 
senior scientist.” 
 
Interviewee d: “They are Chinese but education from overseas. At least the senior level, 
they have overseas background. Maybe for some basic roles they can 
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hire locals but little bit senior they hire overseas talent. So I believe our 
Chinese scientist also have an overseas background.” 
 
Leifer and Triscari (1987) argue that there are increased communication require-
ments for research compared to development. They say that as R&D work progresses to 
being an operational reality that is near production approval, internal and external spe-
cial interest groups become more involved and funds are required. At that point external 
influence on the R&D project grows and the project requires more maintainability from 
higher management (Leifer and Triscari 1987) 
 
Interviewee z: “Western companies coming to China, a very important component is 
whoever can communicate with their counterpart in US or Europe, a sci-
entist who has been working in USA or Europe know more about the way 
people communicate in. You really have to have a core scientist trained 
both in China and in the Western country. […] Little bit more senior offi-
cials, this is always happening that this person is the way they call in 
China, these persons are returnees. Basically they are born in China, 
they spend like ten years, twenty years in the United States or in Europe. 
They come back and they are very good in the bridging role.” 
 
Gassmann and Han (2004) highlight that the difficulty of attracting best international 
talent to overseas destinations, forces companies to establish R&D facilities to locations 
where highest expertise and facilities are available. 
 
Interviewee b: “It's true that US educated Chinese are coming back with excellent sci-
ence degrees. This is a trend that lots of people like myself went back to 
China and bring the business and the technology. Even in the university 
if you look at the professor in China like in Fudan [top 5 university in 
China and Shanghai's leading educational institute], most of them have 
been training at least six months, one year in some western country.” 
 
Geographical distribution, clustering and abundance of advanced labor as indicated 
by (Bardhan 2006; Bardhan and Jaffee 2005; Gassman and von Zedtwitz 1999; Geryba-
zhe and Reeger 1999; Beckmann and Fischer 1994; Boddewyn 1985) was corroborated 
according to author's findings, especially the huge R&D labor pool of graduate scientist 
and engineers in China reported by (Gassman and Han 2004).  
Similarly the author can corroborate the insufficient R&D labor pool in western 
countries, which constitutes a scarce R&D resource that is an influencing factor in R&D 
intensive sectors, such as the pharmaceutical industry (Gassman and Han 2004; 
Gassman and von Zedtwitz 1999; Beckmann and Fischer 1994; Boddewyn 1985). Fur-
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thermore the author can corroborate the influence of returning Chinese students from 
western countries, which supplements the Chinese labor pool with advanced capabilities 
as indicated by (Gassmann and Han 2004; von Zedtwitz and Gassman 2002). 
Access to local science and technology could neither be corroborated fully nor refut-
ed, especially in the sense indicated by von Zedtwitz and Gassmann (2002) in their 
technology-driven model or by Gassman and Han (2004) as pull factor from high rate of 
new technology output. Nevertheless, it can be seen to refer to accessing the huge ad-
vanced labor pool in countries like China and thus to be corroborated. 
A labor implication highlighted by Bardhan (2006) on commitment by R&D labor as 
knowledge assets, labor market mobility and labor laws as well as contractual labor 
provisions and practices could not be corroborated or refuted even thou strongly im-
plied, due to the limited focus of the empirical data in this study. 
4.1.3 Centers of excellence 
Another factor affecting R&D globalization decisions are the spill-over effects from 
local investment to science, technology and advanced infrastructure, together with the 
environment they create. These investments are usually done in Science parks, universi-
ties or technology and science clusters that form centers of excellence. These centers of 
excellence attract investment from the industry and both local, overseas and multina-
tional companies.  
 
Interviewee t:“The (R&D) resources are mostly concentrated in Beijing, Guangzhou 
and Shanghai. Some main platforms were used for highly effective re-
searches, such kind of platforms to conduct R&D. [...] In this way we 
make a perfect match. With their help, they [pharmaceutical companie] 
do not have to build their own R&D centers or teams. ” 
 
Interviewee b: “Like [major pharmaceutical company] has a R&D center, you know the 
area Zhangjiang high tech, it’s in Pudong. In Zhangjiang it's a lot of for-
eign companies R&D center there.” 
 
Interviewee z: “The expertise factor is another thing, probably more important than the 
cost factor, because in our business, sometimes time or speed is even 
more important than the cost.” 
 
Beckmann and Fischer (1994) argue that private facilities as well as public institu-
tions, such as research centers and universities, function as local sources of engineerial 
and natural science knowledge along with technical spill-over. 
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Interviewee b: “We have quite a number of collaborations with the Fudan University. In 
the developing countries we can only work with a small number of pro-
fessionals, universities.[Major pharmaceutical company], my department, 
has three contracts with Fudan University, we sponsor the faculties, we 
help the Fudan medical school and twice a year in China we sponsor the 
large scale workshop to develop the next generation of healthcare policy 
and research. Also we have other research projects with Beijing Univer-
sity and Tongji University and some specific projects together with local 
Shanghainese companies. I think the best thing to consider is not to de-
velop a new lab in China, but the best approach or strategy is to partner 
up with the university in China, to collaborate with Chinese universities 
or local companies.” 
 
Interviewee y: “The researching ability of Chinese universities, research centers or 
hospitals differ greatly. It depends on the ability of each site. And if you 
choose carefully a very professional site, with a strong advantage, you 
can get very good results. Some famous universities and research institu-
tions are quite reliable. There are about two or three laboratory compa-
nies that are quite famous with lot of people. […] When choosing the site 
I think more work should be done to lower the risks.” 
 
Another factor corroborated in this study is centers of excellence, which are usually 
in conjunction with science parks, universities or technology and science clusters 
(Gassman and Han 2004; von Zedtwitz and Gassman 2002: Gerybazhe and Reeger 
1999; Beckmann and Fischer 1994; Boddewyn 1985). Centers of excellence benefit 
companies through spill-over effects from local investment to science, technology and 
advanced infrastructure (Beckmann and Fischer 1994). Centers of excellence also often 
host experts and specialists in particular fields who may benefit companies through easy 
access to leading scientific researchers and networks (Boddewyn 1985). 
These specialists and the centers of excellence are usually dependant on public fi-
nancing, thus their focus and research in general is shaped by the national innovation 
system in the country, which is a macro level factor corroborated in this study as out-
lined by (Gerybazhe and Reeger 1999; Boddewyn 1985).  
As said, access to local science and technology could neither be corroborated fully 
nor refuted, especially in the sense indicated by von Zedtwitz and Gassmann (2002) in 
their technology-driven model or by Gassman and Han (2004) as pull factor from high 
rate of new technology output. It can nevertheless refer to expertise present in centers of 
excellence and individual experts and hence corroborated. But in the case of China the 
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cutting edge science, technological breakthroughs and pharmaceutical innovation are 
still lacking.  
4.1.4 Access to markets, local adaptation  
Market considerations seem to weight most when companies seek R&D internationali-
zation. The growing importance of emerging markets such as China pulls more and 
more advanced corporate functions when conditions are appropriate for them in the host 
country. 
Interviewee d: “For the multinational company like Pfizer, Clensay, GSK they have to, 
we have to be in China. Next question is why? Because the growth rate is 
much higher. I think no one can ignore China. So that's why the reason 
we want to do R&D in the developing country [China]. […] Everyone is 
waiting on the market. […] The reason is the market trend, not the cost 
of development. There are other countries that can do very cheap but 
there is no market. In China there is an economic boom. Right that's in 
China, a huge market that no big company can ignore. […] A lot of for-
eign companies establish R&D centers for the reason because they want 
to get in to the Asia [Chinese market], establish a lab in. That's the trend. 
This is why a number of R&D centers have been established.” 
 
Interviewee t: “Some companies only concentrate on sales. They buy product lines and 
licenses from other companies and produce and sell the products through 
their own sales channels and networks. In this way they make profits. 
From the viewpoint of the Chinese market, the goal of R&D is to make 
profit. Even though some companies concentrate on developing medicine 
for certain kind of diseases, they would evaluate the market for the medi-
cine at first. This is to say, that R&D in China is market oriented.” 
 
 
One of the main reasons for constructing technical research abroad is the difficulties 
in receiving permits from local institutions. 
 
Interviewee c: “Automatically company still need to get to the market in China, there-
fore they need to have a presence there, so move over an R&D center.” 
 
Market potential, i.e. market size and growth, is especially paramount in regards to 
company's interest in placing R&D opposed to lower value operations to that specific 
country (Beckmann and Fischer 1994). To gain long term competitive edge companies 
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have to make strategic investments and attain market share in tomorrow’s biggest mar-
kets. 
 
Interviewee z: “Reason one, is that China becomes the next pharmaceutical market. For 
pharmaceutical industry, research R&D is co-parallel with the commer-
cial development. […] Yes, because China is the next pharmaceutical 
market, so R&D has to follow up. […] I would say that the market poten-
tial is bigger than the cost. […] You consider China is a strategic in-
vestment. […] The discussions are centered on the potentials because 
China will be the second largest pharmaceutical market.” 
 
Interviewee d: “We are informed from our headquarters they want to invest in this R&D 
center and they think that China is very high potential. […] Our Compa-
ny always say we want to invest in China. We look at China's good po-
tential, so we move some R&D center to China. So this is our long term 
strategy.” 
 
Interviewee y: “Decisions on expanding may be dependent on marketing and marketing 
department. It is their decision, because China is a really huge market 
for the drug companies and maybe quite many decisions on research is 
depending on sales and marketing.” 
 
Interviewee t:“market analysis, market development, sales including  presales, during 
sales and after sales services [...] We collect information for R&D de-
partment and market department. And they do analysis and developments 
based on our information.” 
 
In the pharmaceutical industry market access basically requires the conduct of for-
eign R&D in the target market, chiefly the replication of studies for pharmaceutical reg-
istration (Granstrand, Håkanson and Sjölander 1993). Beckmann and Fischer (1994) 
also state that a pre-requirement for introduction of pharma products is their applicabil-
ity to local legal requirements and pharmacopoeia standards (China pharmacopoeia 
commission 2005).  
 
Interviewee y: “So that the product can be on the market in China is based on the legal 
requirements of SFDA, which is the overseeing authority in China. You 
need to hand over the necessary documents to apply to market in China. 
That is the most important document.” 
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Interviewee d: “To get an approval of China food and drug administration (CFDA, 
SFDA) for the more multinational company like Pfizer, Clensay, GSK 
have to, we have to be in China.” 
 
Interviewee t: “the R&D procedure in China is different from that in foreign countries. 
In foreign countries they develop new medicines according to their crite-
ria. When the products are mature [...] they adapt the equipment accord-
ing to characteristics of local people. And these adaptations could be 
conducted in China.” 
 
The decisive influencing factor corroborated in this study is access to markets as re-
ported by (Grossman and Hansberg 2006;2008; Bardhan 2006; von Zedtwitz and 
Gassman 2002; Gerybazhe and Reeger 1999; Beckmann and Fischer 1994). Especially 
the size of the Chinese market and growth rate is an influencing factor, most empha-
sized on a long term strategy of Big Pharma companies but also of importance to small 
and medium sized companies.  The growing importance of emerging markets such as 
China pulls more and more value-added corporate functions to the target country. 
4.1.5 Local requirements and government regulations 
Government regulations and requirements are a direct way to guide market interest. In 
the sense of R&D, governments capitalize on markets interest through requirements for 
locating R&D to the country in question. Thus in exchange for a marketing permission, 
governments require research to be conducted in the country and according to local 
standards and requirements. On top of boosting the local industry and creating jobs, 
locally conducted R&D may also involve involuntary one way technology transfer. In 
the pharmaceutical industry, importance of government regulations and requirements 
are highly pronounced even though they are dependent on markets in many accounts.  
 
Interviewee d: “If we want to sell product in China we have to do some deals with the 
government. The Government, what they want to do is to develop China. 
If we are very focused on our patenting we don't care business in China.” 
 
Interviewee c: “For exporters China wants to do compulsory licensing.” 
 
Interviewee a: “They [the pharmaceutical industry] is late in internationalization of 
R&D because they are very IP sensitive. Generally speaking, the whole 
IP [intellectual property], medical research and development, drugs, 
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hospitals, hospital services, medical services is extremely regulated in 
China so it is very difficult to do what they need to do.” 
 
Beckmann and Fischer (1994) explain that acquiring permits from local institutions 
is one of the biggest obstacles for conducting technical research abroad and the applica-
tion times can total several years. Furthermore especially in China the process requires 
wide open disclosure and cooperation with stakeholders. 
 
Interviewee y: “I think the Chinese government regulations is the weak area. I mean 
SFDA, like Sino food and drug administration, they really don't have the 
experience to approve like first in class drug, I mean in China, I think 
they normally do like, the drug has been marketed in the Western world 
and they launch in China. So they have a lot of precedent to look for. […] 
So the drug has been approved in the Western world and then come to 
China. […] In China I think that the regulatory is much stricter than in 
Western world. It takes much longer time. […] This is because the agen-
cy does not have the experience, so they basically very cautions. I mean 
they basically use the model ‘do no wrong’.” 
 
Interviewee y: “Benefits [from pharmaceutical R&D] in China maybe is that the appli-
cation for the active compound maybe a little easier for the Chinese 
overseeing authority to audit. […] Compared to doing it in another coun-
try maybe no more extra work is needed. Maybe the laboratory work is 
carried out in US and material submitted to SFDA, they may ask the 
companies to carry out similar laboratory work in China to observe the 
results and procedures.” 
 
Interviewee d: “A specific government regulation issue on vaccination is the CDC. CDC 
is owned by the government, so when they have some health problem to 
vaccinate, the whole CDC maybe will focus on this vaccination and not 
on others. There is no continuation, that will impact our sales, that's not 
stable and it’s a very hard to get a forecast and then our production will 
have difficult to do the production.” 
 
Due to historic reasons the Chinese regulatory environment is extremely nervous 
when it comes to medicines not previously approved in other parts of the world (Shah 
2003). For this reason two different approval channels for drugs exist, one for those 
already tested according to FDA or EMA specifications and another one for those drugs 
that see their first clinical trials in China. 
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Interviewee b: “In China FDA or EMA approval is a good start. If a product is totally 
new, it has not been approved in any other country in the world, then 
they have to go through the rougher parts. Most of the product is always 
developed in the western world first and then move to China. The regula-
tory approval, ADN approval right now the process in China is much 
longer, about six months longer than in other countries.” 
 
Safety measures and standards are sometimes used both in the developed countries 
but even more so in developing countries like China to facilitate technology transfer and 
increase investment to the target country. Identically as reported by (Boddewyn 1985) 
companies were pressured to participate in developing European Community (EC) 
standards, which increased investment by U.S. and non-European multinationals to Eu-
ropean subsidiaries. 
 
Interviewee d: “In China the registration environment is important for a pharmaceuti-
cal company to exist. […] Pharmacopeia was updated from last year and 
they improved many standards and these standards are for GSK, Pas-
teur, for this kind of multinational company these standards are very 
hard to meet, but our local company claims that they can do that so, kind 
of protection, government protection, the issue they updated the pharma-
copeia.” 
 
Interviewee t: “[Government policy influences medicine] currently very much. That is 
the current system in China. For example in 2009, [major pharmaceuti-
cal company] as one of the biggest foreign companies in China in terms 
of baby vaccine lost its whole production line because of government in-
tervention to protect domestic producers.” 
 
Interviewee d: “So we have several products affected which cannot meet these stand-
ards. Our team should register products accordingly and sometimes have 
to change our core production biotechnology to meet the standards. 
[…]The standard is ridiculous, because US and EU they all accept our 
[company's] very high standard, so China ask kind of higher standard. 
[…] So this kind of product can never be sold in China.”  
 
Interviewee d: “If your product cannot meet [government] standards, but if you want to 
license your product in China, bring your technology to China, maybe 
you can discuss with the government in that five years if your product 
still exist in China. So after five years we already put our technology to 
China to produce locally so you can produce. During this five years, this 
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transmission period you can give you some temporary import license and 
you can sell the imported product but you have to quarantine you take 
technologies into China. […] There are some dangers to this but have to 
discuss with the government but if you want to continue sell this kind of 
product in China you have to do some deals with the government. Gov-
ernment use these kind of ways to persuade multinational company to 
work with them.” 
 
According to this study the author corroborates the importance of receiving permits 
from local institutions and the difficulties in fulfilling local requirements and standards 
as an influencing factor  as reported by (Grossman and Hansberg 2006;2008; Gassman 
and Han  2004; von Zedtwitz and Gassman 2002; Beckmann and Fischer 1994). Access 
to local science and technology could neither be corroborated fully nor refuted, espe-
cially in the sense indicated by von Zedtwitz and Gassmann (2002) in their technology-
driven model or by Gassman and Han (2004) as pull factor from high rate of new tech-
nology output. Nevertheless, it can be corroborated in a wider sense through the im-
portance of corresponding to local technology standards and requirements, most notably 
the Chinese pharmacopoeia standards. 
4.1.6 Risk factors 
Issues dealing with intellectual property rights (IP) present a challenging case in China. 
IP issues seem to have been an influencing factor in earlier research on R&D globaliza-
tion. However, due to improvements in international IP standards, the nature of IP and 
the problems associated with it, seem to have changed. Also surprising and contrary to 
layman's view of IP protection in China is the improved state of patent protection and 
formal codified IP protection.  
 
Interviewee a: “This is also a matter of IP, how IP has developed, because you don't 
outsource unless you have some legal safety net behind it. For China [in 
the past] this has not been the case” 
 
Interviewee c: “Even though, people think that China is Weak on their patent law and 
IP, which they sort of are and sort of are not depending on how you bias 
it. […]What you need to see is companies need to get into China and one 
of the reasons is to protect their IP. […] Kind of weird that they do it by 
setting an R&D center in there [China]with Chinese people like their em-
ployees but that is a one way for them to set their IP instead of just piling 
it from home country with having no connection with China." 
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Von Zedtwitz (2004) admits that in China intellectual property issues are under-
standably of concern particularly for non-public-domain innovation activities. 
Interviewee x: “So you have to be very careful when you operate in a system like this, if 
you establish your company under the influence that you can go to court 
and enforce your right you better make sure that you can, because if 
someone walks out of the door with your technology you may not be able 
to do anything about it. That's always a risk but in China you have an 
added risk that the court system does not follow the rules that you under-
stand. Even if you are told of your rights or ownership you won’t learn it 
until you try to enforce it in court.” 
 
However, due to improvements in international IP standards, the state of patent pro-
tection and formal codified IP protection has improved substantially. 
 
Interviewee z: “I think IP protection is fine. Because like five years ago everyone was 
after IP but right now nobody talks about IP. Because basically every-
body knows, what everybody else is doing. And because right now what 
will be the best topic to work on, so you know, I mean right now IP is not 
that issue because get IP[a patent] though everybody knows what you 
are doing it will not be easy to mimic you. In pharmaceutical research 
even you know what other people are doing, you want to come up with a 
different compound, slightly better and that's a huge investment. […] 
Even though you would tell me, I might be skeptical and that way you 
have no incentive to hide from me. […] In pharmaceuticals even though 
you know what people are doing you many not just want to copy because 
you don't know if that is the right process and they are common 
knowledge. Nobody have a patent on the processes. […]So basically that 
cancels out everything that doesn't need to be super classified or patent-
ed knowledge.” 
 
According to Li and Zhong (2003) a credible and effective intellectual property pro-
tection regime is one of the most important conditions for international and domestic 
R&D investment. A system that has seen some progress after China’s entry into the 
WTO but still suffers from a cultural contradiction.  
 
Interviewee c: “They [Chinese] really are not into intellectual property that much, be-
cause they are not developing drugs themselves. […] I don't think they 
can do IP, because of their culture they just won’t report any crimes, no 
one will take blame. […] Sometimes they are hiding something because 
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they are steeling it [IP] from other people. […] I have had some instanc-
es where the work they supposedly patented was published by somebody 
else like a year earlier and we found it in our search. That's a problem, 
it's a cultural thing.” 
 
There is insufficient understanding of the Chinese legal environment and business 
practices, such as suitable composition of senior management and distribution of deci-
sion making power. Although some issues on IP have improved, China's legal protec-
tion on uncodified IP, such as on trade secrets and proprietary technology still presents a 
challenge to both small and large companies. 
 
Interviewee x: “The IP risk you are running in China really depends on how much of 
your senior research management structure you put in China. You take 
example [major pharmaceutical company], they are putting their entire 
research division in China, that's a much higher risk. If your senior re-
search makers are still back in your home country you have a much low-
er risk.” 
 
Interviewee x: “The major pharmaceutical companies when they first showed up in 
China, they did what typical foreign firm would do and that is they hired 
locally very sophisticated business development people to do deals. […] 
You hire a local that's well connected and sophisticated to do your deals 
[with company resources], well those people did deals that benefited 
themselves but didn't necessary benefit the corporation. […] Corpora-
tions like [major pharmaceutical company] swap out Chinese decisions 
makers every few years and replace [businessmen] with little less sophis-
ticated, little more technical management, and all the decision making 
and the ability to approve and negotiate deals was taken back to HQ.” 
 
Interviewee y: “Physicians in China are very responsible and the results should be 
trusted, should be real and reliable. […] I think the procedures are very 
established and professional.” 
 
Another IP concern in China is the potential for unintended technology transfer that 
can foster a new competitor as reported by Boddewyn (1985). 
 
Interviewee x: “[Chinese] are very interested in manufacturing technology. […] Actual-
ly the knowledge left behind in R&D, especially manufacturing develop-
ment, they could try to produce a competing company depending on the 
level of sophistication of management you left behind. […] Any time you 
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let it [R&D] go offshore you run a risk of technology walking out of the 
back door. […] If you keep your key decision makers out of China and 
you don't train on the D part of R&D you are in a much safer position.” 
 
Interviewee x: “When […] approaching smaller pharmaceutical companies on licensing 
to China. They are extremely reluctant because of the risks, and yet you 
see the bigger pharmaceutical companies just marching in and they don't 
see it, it's interesting the bigger pharmaceutical companies don't see Ya-
hoo [internet search engine] and Alibaba [Chinese B2B online market-
place] as danger, because they are doing the same kind of deals, and they 
are walking right into the same situation, you can call it a trap.” 
 
Interviewee d: “Multinational companies they don't trust in China because the patenting 
issue. If you got a patent, you know Chinese sometimes [infringe] copy-
right [IP], maybe they leak to other competitor and then the local manu-
facturer will copy these medicines and sell to the hospitals. All multina-
tional companies spend lot of money to protect IP in China.” 
 
Safeguarding core technologies, such as production processes is extremely important 
but at the same time very challenging in China.  
 
Interviewee x: “Everyone gets trained that patents and intellectual property is how you 
maintain control of your product. In China that is somewhat but not real-
ly true. The true control of your product is the knowhow how to manufac-
ture it. So if you want to control your product, you'll got to control the 
ability to manufacture it. […] What you find with Chinese companies is 
that they are somewhat interested in patent licenses, but they are very in-
terested in manufacturing technology.” 
 
Interviewee d: “Production technology is very special, which is not maybe patentable 
but is knowledge how to produce. […] We focus on the technical, this 
type of technology has many hundreds of processes. […] Local Chinese 
technology is not that good. […] So they are very interested. […] Differ-
ent products have different technology. The not technical product, we buy 
a local company or bring the production technology into China. […] But 
the product is very popular and not technical.” 
 
Some factors could not be given confirmation in this study, but are either partially 
corroborated or refuted. IP risks seem to have been an influencing factor in earlier re-
search on R&D globalization. However, due to improvements in international IP stand-
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ards the state of patent protection and formal codified IP protection has improved sub-
stantially. Similarly the author can corroborate a cultural IP find by Li and Zhong 
(2003), which points to a cultural contradiction between the concept of intellectual 
property and the Chinese society. The nature of IP and the problems associated with it 
seem to have changed, especially important is the safeguarding of manufacturing tech-
nology and trade secrets. Irrevocably IP risk as an affecting factor reported by (von 
Zedtwitz 2004; Lewin and Peeters 2006) is refuted, nevertheless IP as an conditional 
factor as reported by Boddewyn 1985 can be corroborated. 
 
 
4.1.7 Basic conditions for R&D 
When looking at the IP issues, we can see that, with the improvements in international 
patenting laws, the codified IP can be reasonably well protected and investment in it as 
well as on other security practices can be considered as necessary infrastructure for do-
ing business in China. In the literature infrastructure is presented as a requirement for 
R&D globalization (Beckmann and Fischer 1994; Boddewyn 1985). 
 
Interviewee z: “We have some outsourcing in India but right now we set up the Asia 
research center in China, because we can see that China has like the 
basic thing, a much better infrastructure.[…] China is pretty good in cer-
tain infrastructures. And they can do certain like, right now they are do-
ing some components work.” 
 
Interviewee x: “They have the fundamentals of technology, the basics of infrastructure. 
But your problems are going to be purely the infrastructure of the coun-
try. Are you getting electricity? You know, the fundamentals of the coun-
try are going to collapse. You already have a huge electrical problem 
here. Blackouts rolling through the industrial sector costing tremendous 
amounts of money, because they can't simply produce enough electrici-
ty.” 
 
Interviewee d: “[The infrastructure] is very difficult for the supply chain.” 
 
Interviewee b: “The challenge compared to the Western countries is that we have much 
less expertise in China and much less data sources like FDA database, 
DMA electronic medical record database, patient registry. In the devel-
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oping country we have tons of [official] data and lots of CRO's and other 
firms to help us, in China we don't have any of those.” 
 
From the interviews conducted the author has gained an understanding that well-
functioning infrastructure is a necessity for R&D globalization but instead of a pull fac-
tor it can be corroborated as conditional factor as described by Boddewyn (1985).  
 
4.2 Pharmaceutical Drug Discovery  
An unexpected factor in the case of pharmaceutical industry, a one not covered in aca-
demic literature on R&D globalization, which emerged from the research was the effect 
of the phase of drug development pipeline in pharmaceutical R&D.  
 
Interviewee b: “Talking about the pharmaceutical and medical research and develop-
ment. Because there is so many different types of R&D, it could be medi-
cal clinical, pharmacokinetics as well as the post marketing research 
[post-marketing clinical research, phase 4].” 
 
Interviewee y: “In terms of operations that is, something you do in US, something Eu-
rope, something in China. We want to do as our quest speaker said, to 
find the natural thing in that country. […] Identify like where ever they 
have strengths. […] We try to do the natural thing, which is the best 
thing we can do in China and then I want to find out what is the best 
thing to do in US and everywhere else and then assemble a global team. 
That will be the winning formula.” 
 
It is evident that pharmaceutical R&D has to be scrutinized as a continuum of differ-
ent R&D processes, which all have unique requirements and benefit from different fac-
tors. Thus it is of extreme importance that the phase of pharmaceutical R&D is consid-
ered when making decisions on globalization of R&D and the factor derived benefits 
are weighted in the light of R&D requirements. From the research the author was able 
to decipher how the phase dependent actual R&D operations affect the way pharmaceu-
tical R&D could be beneficial to conduct in PRC and how different factors on R&D 
globalization can be capitalized on, when taking into account the phase in question. 
 
Interviewee x: “It's difficult to get an R&D system in China to be to be certified by the 
regulatory authorities in Europe and in America. Now that means that 
the R&D becomes much more early stage and it’s a cheap way to decide 
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which molecules you want to take back to your own country and start 
running them through the approved, certified locations. [Also the risks 
are lower] if you are just doing screening of molecules [leads, hit to lead], 
producing data and shipping that data over the internet to Europe and 
reviewing that data for research candidates for mowing forward [lead 
development or pre-clinical]. […] Few years ago it was difficult to find a 
certified preclinical development so it was very basic R&D that was be-
ing offered. In the last three years that's changed. A lot more firms in the 
bigger cities like Shanghai and Beijing are getting FDA, EMA certifica-
tions.” 
Interviewee b: “Normally multinational company they will have some R&D center in 
China. But as far as I'm concerned, knowing their opinions, they will do 
some basic research on chemistry [pre-discovery, hit to lead]. They are 
doing pharmaceutical tests but it is really beginning stage. […] Phase 
one, mean pre-discovery and discovery. It should be very first part, they 
are doing really big research and when they find out some good results 
they send them to overseas labs where they will think if these results are 
useful for the development. […] Like in China you just focus on the basic 
work, maybe England phase two, maybe this country phase three. […] 
We have number of R&D center around the world but we in China take 
responsibility of some of this basic work.” 
 
Interviewee c: “In the development there are certain times when you have to do the 
same process over and over. I mean tasting phase. […] Discovery and 
testing. […] Asian scientist: They are the ones doing just the testing. […] 
They certainly have the knowhow but they don't have the inventiveness, 
the creativity. […] When it comes to creating things I have a hard time 
dealing with inventors in Asia. They are just not very good at interpreting 
their results.” 
 
Interviewee z: “For example like the chemical synthesis, like the chemistry. […] It is the 
chemistry, the making of compounds that's a potential drug. And in Chi-
na they do that well. […] It's before hit-to-lead. Well hit to lead is part of 
the compound finding. So hit-to-lead is also a part of it. […] Hit-to-lead 
is part of the compound finding, you have some hit, those are what we 
call scaffolds. They may not be potent enough as clinical drug so you 
want to make some changes. Hit is normally referred to that you have 
done screening, where you see lots of scaffolds and this is potential. Then 
you have to refine to make that hit into a lead compound. This area they 
do really well in China, but hit to lead is not just chemistry because you 
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need biological agent for screening and in that [part, they do not excel in 
China] in chemistry part they excel. […] China has strengths in the hit-
to-lead and we try to capitalize in those strengths. […] The lead devel-
opment part is also fine, basically even you identify a lead, there is still a 
lot of chemistry involved. […] In terms of chemistry, most of the pharma-
ceutical companies have a presence in China doing the chemistry part.” 
 
Interviewee z: “Most of time pharmaceutical company doing the chemistry part in Chi-
na and once it has reached the late stage like preclinical or clinical they 
often move back to the US or Europe. […] Biology and toxicology, I 
think that combination is still little bit lacking. […] But our company 
come to China and says we want to do the more innovative side. I mean 
that's an area we want to expand.” 
 
Interviewee y: “I think it [pharmaceutical R&D in China] includes some like office 
work, maybe something like data mining. […] Work people can do in of-
fice can also be transferred to China.” 
 
Interviewee x: “In China it’s more of a preclinical and the reason is that Chinese are 
very rightfully quite concerned, about clinical development of molecules 
that have not experienced clinical development outside of China. […] 
The Chinese were treated like guinea pigs for clinical trials for a period 
of time and they are discouraging for clinical trials for foreign firms 
where there is no clinical experience outside China.” 
 
Interviewee x: “Approval in China is independent from other countries but if you have it 
[FDA or EMA approval], if the drug has not experienced approval out-
side of China you will get much more slow and cumbersome process.” 
 
Interviewee y: “Conducting clinical trials in China has real benefits. Procedures are 
very professional and very established. […] Clinical trials maybe 1, 2, 3 
can be transferred to China. […] Any part of clinical trials could be ben-
eficial to be held in China. […] Clinical trials can involve hospitals in 
China, establish a few sites in a big country to enroll patients with [rare] 
specific conditions, for example China has big population. […] I think 
that China has quite a large number of patients to can be enrolled to 
specific research in China, I think these are important aspects. […] The 
patients in China are a huge amount and to the disease that is hard to 
enroll patients in other countries maybe is ok in China.” 
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Interviewee d: “Basically we have some phase 1, 2, 3 medicine, doing clinical reporting 
in China. China have a very big pool, many different patients ad they can 
take these clinical tests and we get results. […] Clinical test we should 
do in China, if we have some clinical test in overseas it takes a long time 
and very complicated just to receive license. […] So when we have a new 
product to launch in China, the very big barrier is just this clinical. We 
may take five or six years to finish this phase. […] If we have an approv-
al from overseas then [in China] we need to do [only] phase three or [af-
ter market approval] phase 4.” 
 
Interviewee b: “I think that in the past patients [in clinical trials] is thirty percent of the 
cost but now is like forty to fifty percent. The reason we like to include 
the patient for the clinical research in developing countries, for example 
in China is that it's much cheaper. The difference is getting smaller and 
right now when we include the patients in China is it’s getting more and 
more expensive although it’s still cheaper than in the US. […] [The clini-
cal trials] in China have been more and more formalized and they require 
at least two hundred patients for each product and each indication. […] 
More and more companies do international trials, we call it a global tri-
al. We will recruit patients from many countries, not just one country. 
China is a hurdle because it takes much more time to get an approval in 
China, so the whole study time is getting longer. And the US FDA still 
has concerns about the research project conducted in a country like Chi-
na.” 
 
As expressed by the author as part of the initial framework that different phases of 
drug development require different competencies and have distinctive benefits, this 
view was confirmed in the empirical research conducted for this paper. The cost empha-
sis plays a part in the earlier phases as personnel costs make up the bulk, a case which is 
almost synonymous with offshoring to China. It is also on these early phases where IP 
risks are most negligible and the IP structure of PRC is less of a concern. Another factor 
speaking on the behalf of this, is the insurmountable amount of advanced labor re-
sources in PRC. This would suggest that early R&D on drug development can be bene-
ficial to conduct in PRC through offshoring or outsourcing. Similarly as a home to thou-
sands of engineers and scientists, China has a patient population, which is greater than 
in any other country in the world and relatively native to wide medicine usage contrary 
to West. This taken together, with the emphasis on the market and strict enforcement of 
the Chinese pharmacopoeia standard, suggest that clinical trials of drugs that target the 
Chinese market or global trials would be beneficial to conduct in the PRC. Aiming for 
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the market, especially for the bigger pharmaceutical companies requires an extensive 
and long term strategic investment best achieved through R&D internationalization. 
4.3 Different Governance Forms for Globalization of R&D   
To answer the questions posted in this study, the clout of each individual mode of glob-
al R&D globalization and the relationships between them on the whole pharmaceutical 
R&D globalization was examined.  
 
Interviewee d: “This is very new in China. […] [Pharmaceutical R&D on this scale has 
been going on] just two or three years in China. I heard they [company] 
have hundreds of projects in China. […] It’s a long term [strategy], I 
don't think in these years our R&D centers do not get perfect, because it 
takes lot of time.” 
 
Interviewee x: “The biggest pharmaceutical companies are offshoring and the smaller 
pharmaceutical companies are outsourcing. […] I think the vast majority 
of it is offshoring.” 
 
Interviewee t:“[Company] doesn’t outsource its R&D. We do R&D on our own. [Com-
pany] has bought a domestic [Chinese] pharmaceutical company whole 
line of R&D, production and sales and it’s R&D is mainly domestic 
[Chinese] based.” 
 
Interviewee b: “For the pharmaceutical industry, any large companies like Jonhson and 
Johnson GSK, Pfizer, AstraZenega, Merc, Eli Lilly, you can see they all 
developed a R&D center in China.” 
 
 
The interviews would suggest that R&D globalization has first been cost driven 
manufacturing development that has expanded and begun to service the Chinese market. 
The focus on the Chinese market seen in the interviews below and the importance 
placed on accessing the market as a factor on R&D globalization would suggest that for 
many companies this is an evolutionary process of the firms overall internationalization 
and continued presence in the Chinese market. 
 
Interviewee y: “Now the functions in our R&D center are expanding, this means that 
more work will be transferred to China. […] Some back office work is es-
tablished as a first step and maybe further steps can then be conducted in 
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China." Further decisions on expanding maybe dependent on marketing 
and the marketing department.” 
 
Interviewee a: “First it has been cost-driven offshoring, now they [companies] are get-
ting more and more to [offshore outsourcing]. […] This really is also the 
continuation of the overall internationalization of the firm. […] I think 
that China has been production, then sales and then R&D. And I think 
the theory would say that it is first sales, then production so that's what I 
think.” 
 
Interviewee b: “The decisions will be made on different levels, it could be the CEO, we 
have a senior leadership team, it's called a board of trust, in every meet-
ing, I think about eighty percent of time they are discussing about [the 
market in]China. […] More and more technology has been transferred to 
China from Western Europe and US. Because of the more and more in-
ternationalized R&D, more research and the technology can be found [in 
China] and the research capability can be in the developing country.” 
 
In the case of China, this internationalization can be said to be the result of the invis-
ible hand of the markets, where the decades spend as the world’s factory and the wealth 
created have transformed China into a lucrative market, increasingly attracting higher 
value chain activities due to its market potential. 
Lately pharmaceutical R&D has started to rely on Chinese outsourcing companies 
and begun to service the Chinese market instead of improving the manufacturing or 
augmenting the products sold at home market.  
 
Interviewee a: “I think initially it has been cost-driven offshoring of R&D, in-house off-
shoring. Only now that local Chinese firms are getting better and better, 
I think that foreign firms are getting more and more towards working 
with the Chinese companies. […] I think India has been quicker doing 
this, industry is basically offering themselves as outsourced services, not 
offshored services. […] Two things [IP and culture] have held back Chi-
na, so China has been late in offshore outsourcing” 
 
Interviewee y: “Cooperation with CRO companies that means transferring some work 
to them. […] This kind of transfer can save money and a lot of energy. 
[…] This kind of work is temporary, which means company doesn't need 
to recruit more scientist for a temporary work.” 
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Interviewee x: “Chinese have a number of things to offer to folks who think that out-
sourcing R&D is a good idea […] I would say that outsourcing in any 
specific sector works pretty decently in the beginning.”  
 
Interviewee d: “Some, not that big company, pharmaceutical company, they will work 
with outsourcing companies. […] Or they will work together [with a 
Chinese company] to make some R&D research. […] [A good] outsource 
company is also very hard to find. We have to do lot of research to iden-
tify if they are qualified.” 
 
Interviewee b: “For our company that is, we started the subsidiary because there is a 
lot of Chinese CRO [contract research organizations] companies and they 
can provide a very efficient service for us.” 
 
Access to local science and technology could neither be corroborated fully nor re-
futed, especially in the sense indicated by von Zedtwitz and Gassmann (2002) in their 
technology-driven model or by Gassman and Han (2004) as pull factor from high rate of 
new technology output. Concerning small or medium sized pharmaceutical companies, 
access to local science and technology can also refer to the flexible access to local CRO 
and CMO companies, their expertise and capabilities, an empirically corroborated find-
ing. Taken together with the flexible access to Chinese CROs and CMOs and their gov-
ernment approved processes, these factors present a convincing argument for smaller 
pharmaceutical companies to engage in a multitude of different sourcing and co-
operation activities with these Chinese service providers. 
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5 DISCUSSION AND CONCLUSIONS 
5.1 Theoretical Contributions 
Multiple reasons for globalization of R&D exist and firms seek to capitalize on those 
factors that further their competitive advantages (Kuemmerle 1999). As companies have 
different reasons and pursue different benefits from the globalization of R&D 
(Kuemmerle 1999), they also use different methods to capitalize on these influencing 
factors. Companies can be divided into different types and sizes based on what they 
seek from the globalization of R&D and through what means (von Zedtwitz and 
Gassmann 2002; Gerybadze and Reger 1999; Ronstadt 1978). Kuemmerle's (1999) divi-
sion on company's overseas R&D operations to either home-base-augmenting (HBA) or 
home-base-exploiting (HBE) draws a clear distinction, whether company’s R&D and 
products are meant for their home and conventional market or meant for a new market 
in the target country.  
The author has shown in this paper that companies can be divided based on the gov-
ernance forms utilized in R&D globalization. These governance forms for R&D global-
ization according to Boehe (2008) are: offshoring of R&D, offshore outsourcing of 
R&D and internationalization of R&D (cf. Ronstadt 1977).  Similarly the author has 
highlighted how distinct influencing factor derived benefits can be capitalized on de-
pending, which governance form company utilizes in R&D globalization.  Furthermore 
in this paper the author has argued that the distinction to home-base-augmenting (HBA) 
or home-base-exploiting (HBE) firms to be fundamental in any decisions regarding 
R&D globalization and has shown the distinction to be an important determinant in 
choosing between strategic long term commitment to target market though R&D inter-
nationalization and between other R&D globalization governance forms.  
The growing importance of emerging markets such as China pulls more and more 
advanced corporate functions when conditions are appropriate for them in the host 
country. Market considerations seem to weight most when companies seek R&D inter-
nationalization, with market potential, i.e. market size and growth being especially par-
amount in regards to company's interest in placing R&D opposed to lower value opera-
tions to a specific country (Beckmann and Fischer 1994). To gain long term competitive 
edge companies have to make strategic investments and attain market share in tomor-
row’s biggest markets.  The author has shown that focusing on the pharmaceutical mar-
ket and following government regulations in PRC requires a long term strategic com-
mitment, multiple business functions from logistics and marketing to local R&D, with 
especially important the conduct of clinical trials according to the Chinese pharmaco-
poeia (China Pharmacopoeia Committee 2005). 
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Market access was also important determinant in von Zedtwitz and Gassmann (2002) 
classification of company's involvement in foreign R&D, which divided factors as those 
related to access to markets and customers or those related to access to local science and 
technology. According to the empirical findings in the case of China, access to local 
science and technology has less to do with accessing cutting edge science, technological 
breakthroughs or pharmaceutical innovation and more to do with the importance of cor-
responding to local technology standards and requirements, accessing the huge ad-
vanced labor pool and expertise present in centers of excellence and individual experts, 
which are all factors mostly influencing offshoring of R&D. Previously offshored pro-
duction or acquisition of local production technology has shown to be a pull factor and 
influencing R&D offshoring as the preferred governance form. Another factor influenc-
ing R&D offshoring are government incentives on infrastructure, technology or as fi-
nancial benefits, which by themselves cannot validate wider involvement in the market 
but are out of reach if offshore outsourcing is preferred. 
Although cost considerations are shown to be a factor in all governance forms, based 
on this study it is evident that they aren't and shouldn't be a decisive factor. This except 
when dealing with operations that can be securely and beneficially offshore outsourced 
to gain access to local service providers, to gain country intelligence and to support ini-
tial market entry through collaboration, which are all factors influencing offshore out-
sourcing decisions. Indeed lately the Chinese CMO, CRO industry has become more 
formidable and pharmaceutical R&D, which either services the Chinese or overseas US 
or European markets has started to rely on Chinese outsourcing companies. Thusly cost 
consideration can be a major factor for offshore outsourcing if it is determined that all 
other factor derived benefits of interest can be capitalized by the firm this way and fur-
ther significant influencing factor derived benefits cannot be gained with the establish-
ment of in-house operations through R&D offshoring. 
Cost can play a factor in more IP sensitive parts of drug discovery if offshoring is 
advisable due to insurmountable labor costs even thou in-house involvement would not 
be required for market, labor or technology access reasons.  
Furthermore cost together with other macroeconomic factors can also influence R&D 
internationalization when weighted against the market potential. Although other factors 
have greater influence as R&D internationalization requires a long-term strategy and a 
step-by-step approach to building networks and focus on the overseas local market and 
thusly any cost advantages could only be capitalized after a period of time and after an 
upfront financial risk. Generally speaking when establishing permanent facilities and 
operations that target the host country cost factor should be overruled as secondary issue 
in favor of market considerations, labor considerations or access to science or technolo-
gy through centers of excellence.  
In the light of author's empirical findings and literature review some factors could be 
corroborated, others partially corroborated while some were refuted on a theoretical 
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level, within the limitations of this study following the theories of Popper (1972) on 
knowledge accumulation by conjectures and refutations.  
Theoretical contributions were achieved by corroborating literature findings on: con-
ditional factors, regional market requirements, local legal requirements, centers of ex-
cellence, national innovation system, cross-country cost differentials, financial incen-
tives, access to advanced labor pool, scarce R&D resources at home and access to mar-
kets. The corroborated factors provide theoretical meaning together with author partially 
supporting literature findings on: convergence of patent standards, IP protection, data 
security, cultural IP issues, access to local technology, while refuting findings on: high 
rate of new technology output, communication risk and institutional or codified IP risk. 
The theoretical contributions presented by the author are that majority of literature de-
rived factors could be supported or partially given conformation in the light of the em-
pirical findings, which is an indication on the theories based on these factors and their 
application to both pharmaceutical industry and China. Thus these findings also apply to 
both the pharmaceutical industry as well as China. Similarly by refuting some factors on 
the grounds of expiration brought on by changes in the world the author can provide 
suggestions on further research not to delve on these issues.  
As the theoretical basis for factors was sound the author was also able to support 
some of the factor frameworks presented in the literature and thus contribute to the theo-
retical understanding. By corroborating the importance of Boddewyn's (1985) frame-
work, which clearly lays out the basic conditions for R&D, the author contributes the 
basic requirements on R&D globalization for a country or location to theoretical under-
standing. Furthermore Boddewyn's (1985) framework presents the decision process and 
the most important motivations for globalization of R&D. By supporting these findings 
the author increases theoretical understanding by presenting the framework as a thought 
experiment on whether a company should consider R&D globalization and as the first 
part on the decision process presented in this paper on how to choose an appropriate 
governance form. By pointing out the lack of market considerations as motivations in-
stead of precipitating circumstances in Boddewyn's (1985) framework the study also 
contributes to the theoretical understanding of company's motivations. 
These frameworks also included Kuemmerle's (1998) division on whether to contin-
ue catering to its home market, utilizing resources available in the offshore location by 
thus furthering its competitive position and introducing new products, or whether it 
wants to access the host market by capitalizing on the existing capabilities at home. The 
study makes a theoretical contribution by drawing similarities between choosing a 
home-base-exploiting (HBE) and home-base-augmenting (HBA) strategy and choosing 
between R&D internationalization and R&D offshoring as governance forms. Similar 
contribution is the exclusion of R&D offshore outsourcing from Kuemmerle's (1998) 
framework, based on his hypothesis of company's own capabilities. 
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A framework by Granstrand et al. (1993) presents an evolutionary view of operations 
supported by Ronstadt (1977) that illustrates how the operations and their part in the 
value chain evolve once the company has attained a certain position in the local market, 
leading to setting up local adaptive R&D when the inducements become pressing, high-
lighting the case for market dependent R&D internationalization. They also provide a 
strong case for environmental factors and evaluation of both micro and macro factors 
(Granstrand et al. 1992).  
The author contributes to theoretical understanding by including this process and en-
vironmental factors in the decision framework presented (1.as part of the initial frame-
work/ 2. in chapter 2.2 as derived from previous frameworks presented in literature). 
The author presents the findings of Granstrand, et al. (1993; 1992) as a step to evaluate 
whether environmental factors support market exploitation with multiple locally situat-
ed business functions by transforming existing operations or with multiple completely 
novel operations that favor demand driven home-country exploiting through R&D in-
ternationalization versus lesser involvement through supply driven offshoring. 
A framework by Beckmann and Fischer (1994) illustrate how company's underlying 
input-driven or output-driven motivations can be superseded in importance by external, 
efficiency and socio-cultural drivers. Furthermore they show how with lack of market, 
labor or technology motivations the only motivations can be external, efficiency and 
socio-cultural drivers together with cost considerations, financial incentives, legal re-
quirements or political considerations such as trade barriers. By protracting these find-
ings the author contributes to the theoretical understanding on the legitimacy for R&D 
offshore outsourcing as a governance form in relation to R&D offshoring and interna-
tionalization of R&D including their findings to author's decision framework. 
The above mentioned influencing factors and frameworks are all derived from previ-
ous literature and empirically scrutinized in this study. From the interviews the author 
was also able to discern further influences to R&D globalization not handled in the lit-
erature. Von Zedtwitz and Gassmann (2002) have notified the inherent difference of 
research in comparison to development and its effect on the R&D globalization process. 
As development varies from research, the different development tasks can vary from 
one another and different research tasks such as basic research may differ from i.e. from 
applied research to the same degree (Iansiti 1993; Lall 1979).  
Building upon this research the author contributes to theoretical understanding by il-
lustrating that the actual R&D function to be globalized should also be taken into con-
sideration on the level of different parts of the drug discovery process, which influences 
what factor derived benefits can be exploited. This is especially true for R&D in indus-
tries such as pharmaceutical industry, whose R&D process covers many fields of sci-
ence, moves up the value chain and has very different requirements for its distinct parts 
(Cooke 2005. Hence all stages of the earlier drug discovery as well as all the phases of 
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clinical trials need to be considered separately when making decision on R&D globali-
zation. 
The initial framework presented by the author takes into account the pharmaceutical 
drug discovery process and scrutinizes governance forms together with the drug discov-
ery process on a continuum, which as whole is influenced by factors. This type of con-
tinuum has not been covered in the academic literature beyond the distinction to re-
search compared to development or basic in relation to applied. The drug discovery pro-
cess was grouped to four major parts: prediscovery, discovery, preclinical and clinical. 
There exist very differing requirements for all these parts, which are thusly influenced 
by distinct factors and separate governance forms on a continuum based on the influenc-
ing factors.  
Here we acknowledge that this is a crude division as all these parts contain both de-
velopment and research tasks, are divided to multiple subparts that all include a variety 
of different scientific disciples and experiments. Nevertheless, the influencing factors 
most strongly associated with prediscovery are the effect of national innovation sys-
tems, centers of excellence and financial incentives. The influencing factors that play 
the greatest part in discovery are: cross-country cost differentials and availability of 
labor, although basic infrastructure requirements are seen as a conditional factor. The 
influencing factors chiefly involved in preclinical stage are: local science and technolo-
gy, new technology output, local requirements and quality control risks. Market access, 
local and market requirements, customer information as well as the local advantage of 
sizeable patient pool and operating efficiency are factors influencing clinical phase drug 
discovery with greatest risk stemming from inadequate healthcare, hospital or other in-
frastructure. 
5.2 Managerial Implications 
Chronological examination would suggest that R&D globalization has first been cost 
driven manufacturing development that has expanded to higher value added R&D activ-
ities while chiefly servicing the Chinese market instead of improving manufacturing of 
products sold at home market. The focus on the Chinese market was evident in the in-
terviews and came out as a decisive factor.  
China is on trajectory to become the second biggest market for pharmaceuticals. The 
industry is experiencing annual double digit growth rate, the highest in the world and 
above average percentage for spending on medicines of total healthcare spending. All 
these economic realities make it the most attractive pharmaceutical market in the world. 
As market access was found to be the major determining factor in this study, the mana-
gerial implications of this finding according to the author is that for Big Pharma to sus-
tain profitability, involvement in the Chinese pharmaceutical market is a must and most 
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efficiently achieved by placing R&D and other higher value added operations to China 
via the process of R&D internationalization. From the clinical trial point of view China 
has the world's greatest patient population, which is relatively untouched by wide usage 
of chronic medication. In drug discovery sense the managerial implication is that con-
duct of local R&D, chiefly the replication of clinical trials for pharmaceutical registra-
tion is basically a requirement for market access in China for pharmaceutical industry. 
The managerial implication of the Chinese market to the R&D of small and medium 
sized companies is that although it is not a decisive factor, its importance is evident 
when acquiring finance or attempting to license products or attracting larger pharmaceu-
tical companies as a M&A target. The market potential, availability of patients for clini-
cal trials together with the government’s strict enforcement of the Chinese pharmaco-
poeia standard as a condition for any market approval suggests that clinical trials of 
drugs that target the Chinese market or global trials would be beneficial to be conducted 
in the PRC, and best achieved through R&D internationalization.  
One of the main reasons for conducting technical research abroad is the difficulties in 
receiving permits from local institutions. In the pharmaceutical industry, importance of 
government regulations and requirements are highly pronounced and application times 
can total several years. This is the case in China as well, if not even more pronounced 
for two reasons. Firstly, in exchange for a marketing permission, the government re-
quires research to be conducted in the country and according to local standards and re-
quirements. Thus the acquisition of permits is tightly linked to capitalizing on the Chi-
nese market potential and is a direct way the government guides market interest. The 
second reason is that the Chinese government and the relevant institutions are extremely 
cautious in approving medicines that have not been approved outside of China, with 
more rigorous demands on safety and efficacy leading ultimately to longer application 
times that can even hinder international trials. For these historical reason two different 
regulatory drug approval channels exist, one to already tested according to FDA or 
EMA specifications and another for drugs with preliminary first clinical trials in China. 
The most notable permits under the Drug Administration Law of the People's Repub-
lic of China are production permission and/or marketing approval following a success-
ful drug registration application to Provincial Drug Administration Authorization 
(PDAA), which is similar to NDA application in the US. The application is ultimately 
approved by The State Food and Drug Administration (SFDA). An earlier permit, espe-
cially of importance to smaller pharmaceutical companies is clinical trial application 
filled to Therapeutic Goods Administration of SFDA.  
There exist clear cross-country cost differentials between China and the western 
countries, which can be taken advantage of through pharmaceutical R&D globalization. 
This is especially in R&D functions where majority of costs are comprised of personnel 
cost differences.  
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In certain parts of China there is a lack of basic infrastructure from clean water to re-
liable electricity supply but also a deficiency of governmental and institutional data and 
support such as hospital and patient information, sales and market figures and lack of 
certain technologies. Similar infrastructure constrain are deficiencies in supply chain, 
pharmacies and hospital practices.  
Government incentives, especially infrastructure or cash incentives, in the case of 
smaller pharmaceutical companies should be taken into consideration when making 
decisions on R&D globalization based on fiscal factors. In the case of Big Parma or 
blockbuster drugs in general, when selecting a host market-driven model tax incentives 
can be second in importance to the market potential and size. 
Although potential savings on labor cost would be substantial, infrastructure costs 
can surmount to sizeable sums and the case is complicated by government incentives 
that can be a make or break form of soft money for early stage companies, while in cer-
tain cases tax subsidies can hugely increase profitability regardless of all other factors. 
When determining the actual fiscal situation around firms R&D globalization, all these 
cost considerations and incentives should be carefully evaluated and taken into account 
in order to reach an informed decision. In the drug discovery sense according to the au-
thor and based on the empirical research presented in this paper the managerial implica-
tion of this is that cost emphasis plays a part in the earlier phases where personnel costs 
make up the bulk, a case which is almost synonymous with offshoring manufacturing to 
China. According to the author in prediscovery stage the risk posed by infrastructure 
failings are also minuscule and should be considered when evaluating centers of excel-
lence. 
An historical shift in thinking that changes the paradigm of China as the factory of 
the world to the second biggest market coincides with a general improvement in both 
basic and advanced infrastructure in the country together with the unification of interna-
tional patenting standards and stronger enforcement of IP rights in China, which have 
created the basic conditions required for R&D globalization as presented by Boddewyn 
(1985). Contrary to layman's view of IP protection in China, the state of patent and for-
mal codified IP protection has improved substantially since China's ascension to WTO 
on 11 December 2001.  
Nevertheless issues dealing with intellectual property rights present a challenging 
case in China. Most vocally this has to do with protecting uncodified IP, such as safe-
guarding core technologies, production processes, trade secrets and proprietary technol-
ogy. This is extremely important but at the same time very challenging in China. Safety 
measures and standards are sometimes used both in the developed countries and even 
more so in developing countries like China to facilitate technology transfer and increase 
FDI to the target country. Furthermore in China especially applying for production per-
mission, marketing approval and clinical trial approval requires wide open disclosure 
and cooperation with stakeholders, which makes it extremely difficult to safeguard un-
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codified IP. Although surprising, a common practice to protect such uncodified IP on 
global markets has been to establish operations to China with strong legal emphasis. 
Another IP concern in China is the potential for unintended technology transfer or 
theft that can result in a leak of core competencies to a local competitor or fostering a 
new competitor inside the company. This issue of technology walking out of the front 
door is present in any country but due to cultural, institutional and legal differences with 
West a more of a pressing issue. Generally speaking there is an insufficient understand-
ing of the Chinese legal environment and business practices, such as suitable composi-
tion of senior management and distribution of decision making power.  
Although some issues on IP have improved, China's legal protection on uncodified 
IP still presents a challenge to both small and large companies, with Yahoo and Alibaba 
as an example. With China's convergence to international patenting laws, the codified 
IP can be reasonably well protected and investment in it as well as on rigorous security 
practices to protect uncodified IP together with management rotation and retention of 
decision making overseas can be considered as necessary infrastructure for doing busi-
ness in China. In the early phases of drug discovery the IP risks are most negligible and 
the IP structure of PRC is less of a concern and thus prediscovery and discovery are 
beneficial stages for R&D globalization if simultaneously capitalizing on other factors. 
The value of networks and personal connections in China can not be overstated, thus 
it is extremely important that both larger and smaller pharmaceutical companies are in 
cooperation with public institutions, such as research centers, science parks and univer-
sities that provide a trustworthy, influential and ready platform for building networks on 
institutional, governmental and industry level.  
For larger pharmaceutical companies this is most efficiently achieved by supporting 
university faculties, renowned professors and promising graduates, which also provides 
them with steady stream of advanced labor. On top of the networks in these centers of 
excellence, small and middle sized pharmaceutical companies can utilize the facilities 
and infrastructure such as laboratories and offices readily available instead of building 
their own. These type of centers of excellence are dependent on public funding, when 
making location decision it should be verified that the content and emphasis of national 
or local innovation systems applicable are aligned to company's needs.  
Centers of excellence can also exist in industry clusters or as individual companies 
operating in science parks and special economic zones, expertise that can be most effi-
ciently accessed through supplier relationships or CRO, CMO service provider agree-
ments. In the pharmaceutical industry the area spanning from Shanghai through Tianjin 
all the way to begin host the highest excellence, with Shanghai as the centre of Chinese 
pharmaceutical, biotechnology and healthcare sector. In drug discovery sense predis-
covery stage R&D can be seen as dependent on centers of excellence and a global net-
work of R&D cooperation with renowned specialist, which are dependent on public 
funding and thus the content and emphasis of national or local innovation systems 
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should be taken into account when making location decision on prediscovery stage 
pharmaceutical R&D. 
The insurmountable amount of cheap advanced labor resources in PRC can be a 
source of cost advantage, but chiefly it is a way to supplement scarce resources at home, 
achieve minimum critical mass and economies of scale through R&D globalization. It is 
further augmented by the expertise of returning Chinese, who are an extremely im-
portant labor resource in China. Ultimately it is a way to do more with the same re-
sources and in the drug discovery sense it is most visible in chemical or component pro-
duction, API formulation and discovery stage R&D, in which the huge R&D labor pool 
of graduate scientist and engineers in China strongly support R&D globalization to 
PRC.  
The sizeable advanced labor resources in PRC speak on behalf of conducting labor 
intensive fairly standardized early drug discovery R&D(Paul et al. 2010), such as hit-to-
lead, lead prioritization, lead optimization in PRC through offshoring or through off-
shore outsourcing in the case of smaller companies, which may lack said competencies. 
The decision framework the author presented in chapter 2.2 as derived from previous 
frameworks presented in literature provides managers with a clear roadmap to make 
decisions on R&D globalization. The author contributes to managerial decision making 
by combining these frameworks to a governance form flowchart presented in picture 4.  
 
Figure 4. Flowchart on governance form decision framework 
The first step is to determine if the necessary basic infrastructure is available in the 
target country to reach a "go" or "no go" -decision. If a "go"-decision is awarded, the 
second step is to determine the target market in question, reflecting the importance of 
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market as an influencing factor and thus choose between demand driven R&D interna-
tionalization or supply driven R&D offshoring.  
The third step is to evaluate the effects of macroeconomic factors to decide on the 
overall attractiveness of the country and thus choose the magnitude of involvement, 
time span of strategy and resources committed. If the macroeconomic conditions are not 
supporting the decision for R&D internationalization, then the market potential must be 
weighted against these factors to re-evaluate the magnitude of involvement and whether 
conditions are more suitable for other governance forms.  
The fourth step is to determine if the environmental infrastructure and risk factors, 
mainly external, efficiency and socio-cultural drivers support in-house operations in the 
target country or whether all benefits derived from influencing factors can be achieved 
by offshore outsourcing. This step also involves a company's culture on risk taking and 
risk management, whether it is more acceptable to be exposed to uncertainty and risk 
than wager on losing a potential benefit or business opportunity, or whether it is more 
acceptable to loose on a business opportunity than be exposed to risks and uncertainty. 
The last and fifth step is to decide whether it is development, research or both that is 
intended to be globalized, with determining the actual operation in question at least to 
the resolution of drug discovery part and its individual requirements. The pros and cons 
of chosen operation and its necessary requirements are then subjected to review through 





Firm's survival and success, which are dependent on its ability to innovate, to create 
knowledge and to capitalize on inventions and know-how, is in essence directly linked 
to its R&D process. Especially in technology driven industries, such as the pharmaceu-
ticals, there are significant positive returns to R&D investments through introduction of 
new or improved products and services. Technological lead and its transformation to 
innovative products as fruits of corporate R&D can be seen as monopolistic advantage 
that helps enterprises to compete in today’s market. This competitive advantage can be 
derived from corporation's ability to integrate its activities across geographic locations. 
Globalization of R&D is intervened with the changes in global economy of the 21st 
century. Some studies argue for the driving forces to be access to vast skilled labor 
pools and centers of excellence. Other studies indicate the R&D cost differentials be-
tween countries to be the major expected benefit. Related factors like financial incen-
tives have also been said to play a part. 
 Access to markets has been seen as an important factor along with other market-
driven factors, such as product adaptation and legal requirements. Similarly some stud-
ies have found risk and conditional factors that influence R&D globalization. As many 
of the studies have been inconsistent and none of the influencing factors alone have 
been sufficient to illustrate this phenomenon, researchers have grouped influencing fac-
tors into frameworks based on multiple factors that has been able to more fully explain 
parts of the phenomenon and portray it as one covering multiple variations of the same 
phenomenon.  
This study proposes that especially in industries such as the pharmaceutical industry 
distinct benefits can be capitalized based on the R&D globalization governance form the 
company utilizes. These governance forms for R&D globalization are: offshoring of 
R&D, offshore outsourcing of R&D and internationalization of R&D. Studies have noti-
fied the inherent difference of research in comparison to development and its effect on 
the R&D globalization process. Further studies have shown how development varies 
from research, the different development tasks can vary from one another and different 
research tasks such as basic research may differ from i.e. from applied research to the 
same degree. Building upon this research the author illustrates that the actual R&D 
function to be globalized should also be taken into consideration on the level of differ-
ent parts of the drug discovery process, which influences what factor derived benefits 
can be exploited. The purpose of this research is to identify factors influencing the glob-
alization of pharmaceutical R&D in PRC and how these factors affect the different gov-
ernance forms on a continuum of pharmaceutical drug discovery. This research attempts 
to fulfill the above mentioned purpose by answering to the following research question:  
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"How to determine the appropriate governance forms for globalization of pharma-
ceutical R&D for international pharmaceutical companies in the context of PRC based 
on the influencing factors?" 
 
 The research question is divided into the following subquestions with the objective 
that when the subquestions are answered they will provide a complete and coherent an-
swer to the main research question: 
 
“What are the different factors influencing the internationalization of pharmaceuti-
cal R&D to PRC?” 
 
  “What are the different factors influencing the offshore outsourcing of pharmaceu-
tical R&D to PRC?” 
 
“What are the different factors influencing the offshoring of pharmaceutical R&D to 
PRC?” 
“How does the continuum formed of pharmaceutical drug discovery's stages influ-
ence the globalization of pharmaceutical R&D in the context of PRC?” 
 
The research question divides the R&D globalization phenomenon to the different 
governance forms as its subconcepts. Together the different governance forms cover the 
whole R&D globalization phenomenon from different operational points of view. While 
offshoring illustrates the operation of transferring activities across national borders us-
ing internal resources, it is an immediate, short time span strategy designed to augment 
company's existing resources in its home market competition. In contrast, international-
ization has been viewed as a process of increasing involvement in international markets, 
through building on existing activities and the growing tendency of operations to span 
across national boundaries. Furthermore the practice of company entrusting to an exter-
nal entity based in other countries the performance of an activity is commonly referred 
to as offshore outsourcing.  
The three above listed concepts are innately separate, follow different motivations 
and are associated with different factors influencing globalization of R&D. Thus factors 
can be categorized based on the benefits capitalized with the governance forms. Even 
thou factors influencing industrial R&D on an international scale are numerous and var-
ied, their wider implication can be conveniently distinguished from classifications into 
groups that better illustrate their implication. Different approaches have been used to 
classify factors influencing R&D globalization.  
One such classification approach based on Aristotle’s' ideas of condition-motivation-
precipitating circumstances framework lays out the basic conditions for R&D in any 
given country in a world as well as describes the decision process from the basic condi-
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tions to the underlying motivations all the way to the precipitating circumstances that 
ignite the spark for R&D globalization.  
Another framework divided reasons for globalization of R&D into two categories of 
R&D globalization: home-base-exploiting (HBE) and home-base-augmenting (HBA). 
The framework presents firms as entities seeking to exploit specific capabilities present 
in their organization in a foreign environment or building new firm-specific advantages 
from resources present in the foreign environment. Thus it is drawing a distinction be-
tween R&D offshoring and R&D internationalization.  
Another classification approach differentiates between demand-oriented and supply-
oriented drivers for R&D internationalization. While clarifying the distinction between 
R&D offshoring and R&D internationalization based supply/demand concepts it also 
illustrates the micro, macroeconomic duality of factors and how that may have an im-
pact on a company level.  
A more refined classification scheme presents five categories of R&D globalization 
drivers: input-oriented, output-oriented, external, efficiency-oriented and politi-
cal/social-cultural. The framework stresses the importance of external, efficiency and 
socio-cultural drivers as complementary to either the input-driven or output-driven fac-
tors. Furthermore, the framework presents the influence of external, efficiency and so-
cio-cultural drivers, when neither market nor advanced R&D resources are fundamental. 
Thus the framework illustrates the legitimacy of R&D offshore outsourcing as a gov-
ernance form in relation to R&D offshoring and R&D internationalization.  
Based on corresponding classification, a separate framework divided factors affect-
ing globalization of R&D into five corresponding categories: quality of the input at the 
foreign site, quality of expected output, external drivers on R&D globalization and fac-
tors dealing with the general operating efficiency as well as political and socio-cultural 
issues.  
A novel framework dwelling onto R&D reveals the inherent difference of research in 
relation to development. Similarly this work together with complementary studies 
shows the continuum of basic to applied research and difference of diverse development 
tasks. Furthermore an additional framework show how research and development are 
subjective to different location drivers, which they list as access to local markets and 
customers as well as access to local science and technology. This framework also illus-
trates the relation of factors to company's and operation's size. 
A classification within the Chinese context merges the aforementioned output and ef-
ficiency-oriented motivation factors into performance-oriented motivation factors while 
combining the external and political/social-cultural into business-ecological motivation 
factors. Thus the framework presents the implications of different factors and their rela-
tions in the conditions of PRC. 
However despite the numerous advantages that can be capitalized with R&D globali-
zation, managerial practices to evaluate opportunities are scarce, knowledge among 
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practitioners lacking while the research remains fragmented and inconclusive. Existing 
literature identifies numerous influencing factors and illustrates their relationships and 
connection to company features but fails to provide guidelines on how to capitalize on 
them.  
A qualitative research approach has been followed in this research. Multiple in depth 
expert interviews were conducted on par with secondary data collection to understand 
the phenomenon and its implications. Furthermore, the research utilized a combination 
of deductive and inductive reasoning, which is based on testing the existing theories, 
corroboration of the previous findings to a large extent and then constructing a revised 
initial framework to accommodate the unique empirical findings. An initial framework 
was developed based on the existing literature and findings. Operationalization of the 
main research question was constructed on that preliminary framework. Also, when 
conducting interviews the themes of the research were kept in mind. This helped in the 
conduct of the interviews and provided a sound methodology. Hence it can be said that 
along with working as the base for the operationalization of the research question, the 
initial framework has been tested against the business reality of pharmaceutical manag-
ers, directors and experts.  
To corroborate or refute factors and their relations on the governance forms of glob-
alized R&D an empirical study was conducted from the perspective of pharmaceutical 
industry managers in the case of People's Republic of China.In order to answer the 
above mentioned research question an empirical qualitative research was conducted in 
China. The research is based on 8 qualitative expert theme interviews with local phar-
maceutical directors and managers conducted in 2011-2012, utilizing theme interview 
method with few standardized guiding open ended questions and validating findings 
using a semi-structured research questionnaire. 
In the concluding part of the thesis, the theoretical implications of corroborating 
some factors, refuting others and conditionally corroborating some are pondered. Simi-
larly as the factor basis for frameworks is found sound, the frameworks are scrutinized 
through their apparent connection to the R&D globalization governance forms. Fur-
thermore, information derived from the frameworks can be used to select the most suit-
able governance form based on their correlation.  
Additionally, managerial implications of the study are discussed which can be used 
to facilitate understanding on capitalizing different factor derived benefits in the Chi-
nese context. Furthermore a decision framework has been developed, which accommo-
dates the pharmaceutical R&D dependant findings of the study along with including the 
existing knowledge on factor frameworks, which have been confirmed through the em-
pirical investigations.  The decision framework provides a tool for managers to evaluate 
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